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Zusammenfassung 
Die systemische Autoimmunerkrankung Systemischer Lupus Erythematodes 
(SLE) ist durch den Verlust der Toleranz gegenüber Nukleinsäuren charakterisiert, was 
wiederum zu einer Produktion von Antikörpern (AK) gegen nukleare Antigene sowie 
anti-Doppelstrang DNA führen kann. Die Produktion dieser AK führt direkt bzw. via 
Immunkomplexe zu Gewebeschädigungen wie z.B. einer Lupus Nephritis. Aus diesem 
Grund spielen B-Zellen eine zentrale Rolle in der Pathogenese dieser 
Autoimmunerkrankung (1-3). 
Bisher konnten Zusammenhänge zwischen der Entstehung von 
Autoimmunerkrankungen und einer veränderten B-Zellaktivierung hergestellt werden (4-
6). In wie weit jedoch veränderte B-Zellrezeptor (BZR) Signalwege oder Co-Rezeptoren 
in diesem Prozess involviert sind, ist noch nicht ausreichend im humanen SLE untersucht 
worden. 
Aus diesem Grund wurde in der vorliegenden Arbeit eine detaillierte Analyse des 
inhibitorischen Co-Rezeptors CD22, der Tyrosinkinase Syk und der Serinkinase Akt in B-
Zellen des peripheren Blutes von SLE Patienten im Vergleich zu gesunden Kontrollen 
durchgeführt.  
CD27- SLE B-Zellen zeigten eine erhöhte Expression und Aktivierung von CD22. 
Des Weiteren wurde in SLE CD27- als auch in CD27+ B-Zellen eine reduzierte 
Phosphorylierung von Syk und PLC-γ2 sowie ein reduzierter Calcium Influx nach BZR 
Aktivierung gemessen. Diese reduzierte BZR Aktivierung wurde unter anderem durch 
eine erhöhte Tyrosinphosphatase-Aktivität verursacht. Im Gegensatz zu den beiden 
Tyrosinkinasen Syk und PLCγ-2 zeigte die Serinkinase Akt eine erhöhte 
Phosphorylierung nach Stimulation in SLE im Vergleich zu gesunden B-Zellen. Dieses 
führte zu einem Ungleichgewicht zwischen dem Syk- und Akt Signalweg, welches 
wiederum das Überleben der Zelle nach BZR Stimulation in SLE Patienten begünstigte. 
Während einer genaueren Untersuchung bezüglich der Expression von Syk in B-
Zellen von SLE Patienten wurde eine Syk++ exprimierende CD27- B-Zellpopulation 
nachgewiesen. Die Frequenz dieser Population war im Vergleich zu gesunden Kontrollen 
signifikant erhöht, korrelierte jedoch nicht mit der Krankheitsaktivität. CD27-Syk++ B-
Zellen zeigten eine mit CD27+ B-Zellen vergleichbare Syk- und Akt Phosphorylierung 
nach BZR Stimulation. Sie wurden als CD38-, CD19++, CD20++ und überwiegend CD21- 
mit einer reduzierten ABC-B1 Transporter Aktivität charakterisiert. Außerdem konnten 
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somatische Hypermutationen in den V(D)JH Genrearrangements, als auch eine 
Differenzierung zu IgG sekretierenden Plasmazellen nachgewiesen werden. 
Interessanter Weise konnte die in vitro Bildung von CD27-Syk++ B-Zellen durch die 
Stimulation mit INF-γ und TNF-α induziert werden. 
Zusammenfassend zeigen die Daten, dass SLE Patienten eine Dysbalance in BZR 
abhängigen Signalwegen aufweisen, welche eine B-Zellsubpopulationen (CD27+, 
CD27-Syk++, CD27-Syk+) unabhängige Reduktion der p-Syk/p-Akt Ratio versursacht. 
Diese Verschiebung könnte zu einer defekten negativen Selektion und somit zur Bildung 
von autoreaktiven Zellen führen, die wiederum durch Überlebensvorteile persistieren 
könnten. Zusätzlich wurde im peripheren Blut von SLE Patienten eine bislang nicht 
bekannte CD27-Syk++ B-Zellpopulation nachgewiesen. Diese wies, trotz des fehlenden 
Gedächtnismarkers CD27, Gedächtnismerkmale auf und könnte für die bekannte erhöhte 
Plasmazell-induktion in SLE Patienten verantwortlich sein. 
Somit konnte Syk als intrazellulärer Marker einer Gedächtnispopulation identifiziert 
werden. Des Weiteren stellt die Wiederherstellung der Balance von Syk- und Akt 
Phosphorylierung nach BZR Aktivierung einen erfolgsversprechenden Therapieansatz 
bei SLE Patienten dar, um die Entstehung und das Überleben von autoreaktiven B und 
Plasmazellen besser kontrollieren zu können.  
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Abstract 
Systemic lupus erythematosus (SLE) is a severe systemic autoimmune disease in 
which loss of tolerance to nucleic acids results into the production of antibodies (Ab) 
against nuclear antigens (ANA) or double-stranded DNA (anti-dsDNA). This can lead to 
the formation of immune complexes which cause inflammation as well as tissue damages 
(1). Therefore, B cells might play a key role in the pathogenesis of this disease (2, 3). 
Several studies linked the development of autoimmunity to abnormalities of B cell 
receptor (BCR) associated signaling molecules (4-6). However, abnormalities of BCR 
associated co-receptors and downstream kinases with potential implications in selection 
processes are rare for human SLE. Thus, a comprehensive analysis of the inhibitory BCR 
co-receptor CD22, the spleen tyrosine kinase (Syk) and the pro-survival serine kinase Akt 
has been undertaken to gain new insights into potential BCR signaling disturbances in 
this autoimmune disease.   
Here, CD27- SLE B cells showed an enhanced expression and activation of CD22. 
Furthermore, SLE CD27- and CD27+ B cells showed after BCR activation a diminished 
Syk and phospholipase C-γ2 (PLC-γ2) phosphorylation as well as a reduced calcium 
release compared to healthy donors (HD). This was related to an enhanced tyrosine 
phosphatase activity in these patients. In contrast, SLE B cells showed an increased 
phosphorylation of Akt after BCR activation and a disturbed balance between the 
intracellular Syk and Akt signaling pathway closely related to an enhanced survival of 
these cells.  
Interestingly, analysis of the expression of Syk in SLE versus HD B cells revealed 
two different subsets within the CD20+CD27- population according to their expression of 
Syk (Syk++ and Syk+). The frequency of CD27-Syk++ B cells was significantly increased 
in SLE compared to HD; however the disease activity did not correlate with the frequency 
of this subset. Of note, CD27-Syk++ B cells showed a significant increased Syk and basal 
phosphorylated (p)-Syk expression as well as memory phosphorylation kinetics of Syk 
and Akt upon BCR engagement. Furthermore, CD27-Syk++ B cells were characterized 
as CD38, CD19++, CD20++ and mainly CD21- with reduced ABC-B1 transporter activity 
and exhibited somatically mutated IgVH rearrangements. These cells shared 
characteristics of memory B cells and differentiated after in vitro stimulation with IL-10, 
IL-2, CpG and anti-IgM/IgG into IgG secreting plasma cells. Additionally, Syk++ B cells 
were inducible in vitro by the stimulation with IFN-γ, LPS or TNF-α. 
Abstract 
6 
 
This data indicate that B cells from SLE patients display an intrinsically disturbed 
balance of BCR related signaling pathways, resulting in a B cell subset (CD27+, 
CD27-Syk+, CD27-Syk++) independent reduced p-Syk/p-Akt ratio. This may lead to a 
diminished BCR dependent negative selection and enhanced survival of SLE B cells, 
permitting the emergence of autoreactive B and plasma cells. Furthermore, SLE patients 
exhibit an increased frequency of a novel CD27-Syk++ B cell subset with memory 
features, enhanced tonic BCR signaling and the capacity to differentiate in auto-Ab 
secreting cells.  
The current study provides evidence that the use of intracellular markers, such as 
Syk, could permit a more precise delineation of CD27- memory B cell subsets in 
autoimmune diseases since the conventional used memory marker CD27 has some 
limitations. In addition, the balance between the BCR associated kinases Syk and Akt 
might be a promising therapeutic target to reduce the occurrence of autoreactive B and 
plasma cells.  
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Abbreviation 
abbreviation meaning 
%  percentage 
°C  degree centigrade 
Ab antibody 
ABC ATP binding cassette 
ACR  American College of Rheumatology  
AID activation induced cytidine deaminase 
AK Antikörper 
ANA  anti-nuclear antibody  
AP alkaline phosphatase 
APC  allophycocyanin 
APCs antigen presenting cell 
APC-H7 allophycocyanin-H7 
ASC antibody secreting cell 
BAFF  B cell activating factor  
BCAP B cell adaptor protein for PI3K 
Bcl-2 B cell lymphoma 2 
BCR B cell receptor  
BD Becton Dickinson 
BILAG  British Isles Lupus Assessment Group  
BLNK B cell linker 
BLK B lymphocyte kinase 
BM bone marrow 
BSA  bovines serum albumin  
BTK  burton tyrosine kinase  
BZR B Zell Rezeptor 
Ca2+  calcium  
Cbl casitas B-lineage lymphoma 
CD  cluster of differentiation  
CD40L  CD40 Ligand  
CLL chronic lymphatic leukemia 
CO2  carbon dioxide 
CpG ODN  cytosine-phosphate-guanine-oligonucleotide  
CST cytometer setup and tracking 
D diversity 
DAS disease activity score 
DC dendritic cell 
DNA  deoxyribonucleic acid 
ds  double-strand 
EDTA  ethylendiamintetraacetate 
ERK  extracellular signal-regulated kinase  
FACS  fluorescent-activated cell sorting  
FcγRIIb gamma fragment crystallizable region receptor II b 
FCS  fetal calf serum  
FITC  fluorescein Isothiocyanate  
FMO  fluorescence minus one-control 
FO  follicular 
FOXO-1 forkhead protein O-1 
FSC  forward light scatter  
g relative centrifugal force 
GC germinal center 
Grb2 growth factor receptor-bound protein 2 
H  heavy Chain  
h  hour 
HD  healthy donor 
HIV  human immunodeficiency patients 
HRP horseradish peroxidase 
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HSC hematopoietic stem cell 
IFN  interferon 
Ig  immunoglobulin 
IgA, IgD, IgE, IgG, IgM  immunoglobulin isotype A, D, E, G or M  
IL  interleukin  
IP3 inositoltriphosphate 
ITAM  immunoreceptor tyrosine-based activation motif  
ITIM  immunoreceptor tyrosine-based inhibitor motif  
J joining 
kDa kilo Dalton 
L  light chain  
LPS lipopolysaccharide 
MACS  magnetic activated cell sorting  
MFI  mean fluorescence intensity  
MHC  major histocompatibility complex  
min  minutes 
ml  milliliter 
MTO MitoTracker orange 
mTOR mechanistic target of rapamycin 
MZ  marginal zone  
NFAT  nuclear factor of activated T cells  
NFκB  nuclear factor 'kappa-light-chain-enhancer' of activated B cells  
NK  natural killer  
nm  nanometer  
ns  non significant  
p phospho 
PacB  pac blue  
PacO  pacific orange  
PAMPs  pathogen associated molecular pattern  
Pax paired box protein 
PBMCs  peripheral blood mononuclear cells 
PBS  phosphate buffered saline  
PCR polymerase chain reaction 
PE  phycoerythrin  
PE-Cy7  phycoerythrin cyanine 7  
PerCp  peridinin chlorophyll-a protein  
PI propidium iodide 
PI3K phosphoinositide 3-kinase 
PLC-γ2  phospholipase C-γ2  
PMT  photomultiplier  
Pro-B-cell progenitor-B cell  
PRR  pattern-recognition receptor  
PS phosphatidyl serine 
pSS primary Sjögren’s syndrome 
p-value calculated probability 
r  Pearson-correlation coefficient 
RA  rheumatoid Arthritis  
RNA  ribonucleic acid 
RPMI  Rosswell Park Memorial Institute (place of origin)  
RRX rhodamine Red-X 
RT  room temperature 
RT  reverse transcriptase 
S serine 
Sec seconds 
SHM somatic hypermutation 
sCD27 soluble CD27 
SH2-Domänen  src-Homology 2  
SHIP-1  signaling inositol polyphosphate phosphatase-1  
SHP-1  src homology region 2 domain-containing phosphatase-1  
Siglec  sialic acid-binding immunoglobulin-like lectin  
Abbreviation 
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SLE  Systemic Lupus Erythematosus 
SLE  Systemischer Lupus Erythematodes 
SLEDAI  Systemic Lupus Erythematosus Disease Activity Index  
SLAM  Signaling lymphocytic activation molecule 
ss  single stranded  
SSC  sideward light scatter  
Syk  spleen tyrosine kinase  
trans transitional  
TD  T cell dependent  
TGF  transformation growth factor  
TH T helper 
Thr threonine 
TI  T cell independent 
TLR  toll-like receptors  
TMB 3,3’5,5’-tetramethylbenzidine 
TNF  tumor necrosis factor 
Tris tris-aminomethane 
V variable 
Y tyrosine 
μL  microliter 
μM  micromole 
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1. Introduction 
1.1 The immune system 
The immune system is a complex system protecting an organism against diseases 
caused by pathogens, such as bacteria, viruses and parasites and can be divided into 
the innate and adaptive immune system (7). The innate immune system plays a crucial 
role during the first defense against pathogens in an antigen independent manner, 
recognizing different specific pathogen associated molecular patterns (PAMP). PAMPs 
bind pattern-recognition receptors (PRR) and induce a complex signaling cascade 
resulting in the activation of these cells (7). One important subclass of these PRRs are 
toll-like receptors (TLRs) (8). Ten TLRs are known in humans, each of them recognizing 
a specific PAMP. TLR9 for example binds dsDNA whereas RNA is recognized by TLR7 
(8). 
Besides anatomic barriers, including skin and mucous membranes, humoral factors 
like the complements system as well as cellular components (neutrophils, macrophages, 
dendritic cells (DC), and natural killer (NK) cells) are permanent present to immediately 
react within hours against pathogens (7).  
The adaptive immune system (cellular immunity) or antigen specific immune response 
driven by lymphocytes mainly T cells (cell-mediated immunity) and B cells (humoral 
immunity) which derive from hematopoietic stem cells (HSC) in the bone marrow (BM) 
takes places 4-7 days after infection. This immune response leads to the production of 
antigen specific antibody (Ab) by B cells and - based on sufficient T cell help and 
co-stimulation - development of an immunological memory (7). 
In addition to the defense against infections the discrimination between self and 
non-self is a crucial function of the immune system (9, 10). A breakdown of self tolerance 
can lead to the development of autoimmune diseases, such as systemic lupus 
erythematosus (SLE) as a prototypic systemic disorder (11-13). 
 
1.2 B lymphocytes 
B cells are indispensable during an immune response by their generation and 
secretion of highly specific Ab, long-lived immunological memory and their function as 
antigen presenting cells (APCs) as well as the establishment of germinal centers (GC; 
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dynamic microanatomical lymphoid structures), co-stimulation and the production of 
cytokines (7, 9).   
 
1.2.1 B cell development 
Early B cells are generated in the BM from HSC (CD34+CD38-CD10-CD19-). HSCs 
differentiate further either in myeloid or lymphoid stem cells. The myeloid stem cells are 
the progenitors for granulocytes, monocytes, macrophages and DC’s. The lymphoid stem 
cells give rise to B, T and NK cells (14) (Figure 1-1). 
 
Figure 1-1: Schematic representation of the B cell development and their surface marker expression. B cells 
develop in the BM into immature B cells and migrate as transitional (transit) B cells into secondary lymphoid organs 
were they differentiate into marginal zone (MZ) or follicular (FO) B cells and develop further after antigen binding into 
memory and plasmablasts (PB)/plasma cells (15). 
The development, maturation and selection of B cells are tightly regulated by the 
affinity and activation threshold of the B cell receptor (BCR) for self or foreign antigens 
(16, 17). This is controlled by a specialized microenvironment including soluble factors 
(cytokines like interleukin (IL)-7), transcription factors (e.g. paired box protein (Pax)-5) 
and other immune cells (e.g. stromal cells) (18). The differentiation of B cell precursors 
can be identified by the expression of specific genes, cluster of differentiations (CD’s) and 
the rearrangement status of Immunoglobulin (Ig) heavy (H) and light (L) chains. Pro-
B cells (CD34+CD10+CD19+IgM-) develop from early lymphoid progenitors which do not 
Introduction 
16 
 
express any functional Ig genes. The diversity, specificity and affinity of the BCR is 
achieved by a random H (V (variable)H, D (diversity)H, J (joining)H) and L (VL, JL) chain 
rearrangement of the V(D)JH chain locus which is regulated by the expression of the 
lymphocyte specific recombination enzymes RAG1, RAG2 and TdT (14). Pre-B cells 
(CD34-CD10+CD19+IgM-) start to express a pre-BCR (IgH chain and surrogate L 
chains). Signaling events through the pre-BCR induces the rearrangement as well as 
allelic exclusion and leads to the expression of a functional BCR composed by an L chain, 
H chain and Igα/β chain which is expressed on immature B cells (7, 14, 19). Immature 
B cells (CD34-CD10+CD19+IgM+) express membrane IgM, leave the BM as transitional 
B cells (CD34-CD19-CD27-CD24++CD38++) and migrate into secondary lymphoid 
organs (spleen, tonsil, lymph nodes) (14).  
Transitional B cells which reside in the lymphoid tissue differentiate either into follicular 
(FO; CD19+CD20+CD21+CD23+CD24+IgMlowIgD+) or marginal zone (MZ) B cells 
(CD19+CD20+CD23+CD21++IgM+IgDlow) (14). The B cell fate decision is among others 
dependent on phosphoinositide 3-kinase (PI3K)/Akt, nuclear factor 
'kappa-light-chain-enhancer' of activated B cells (NFκ−B), B cell activating factor (BAFF) 
and the BCR affinity (20). It is assumed that CD22 may also be involved in the dichotomic 
decision between FO or MZ B cell differentiation (21). Furthermore, MZ B cells 
differentiate in short-lived IgM secreting plasma cells and are located between the red 
and white pulp of the spleen but has been also found in the peripheral blood (14). FO 
B cells reside in the follicle of the lymph node and spleen, are involved in T dependent 
(TD) immune responses and give rise to IgM and isotype switched memory B and plasma 
cells (14).  
 
1.2.2 B cell activation and memory generation 
The generation of memory B cell and long-lived secreting plasma cells out of naïve  
mature FO or MZ B cells is essential for the long-term humoral immunity, protection 
against pathogens and a rapid recall response against secondary infection (22-25). 
However, how the protective memory is maintained for more than 80 years is still under 
discussion especially how the different half life of IgG can be explained and how reactive 
B cell memory in the absence of the cognate antigens is maintained.   
Mature naïve B cell recirculate through the bloodstream and migrate to secondary 
lymphoid organs where they encounter antigens and get fully activated (26). After antigen 
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encounter naïve B cells develop into memory B or plasma cells. Memory B cell subsets 
originate from distinct GC dependent or independent maturation pathways as well as 
T cell independent (TI) or TD activation and give rise to a heterogeneous memory 
population. The expression of the surface marker CD27, a member of the TNF receptor 
family has been established to identify antigen experienced memory B cells (27). CD27 
is upregulated on antigen activated B cells, interacts with CD70 on activated T and B cells 
during GC reactions (28-31) and is important for B cell expansion, differentiation and Ab 
production. However, in the last years CD27 has been found to have certain limitations 
as universal marker for memory B cells in particular in patients with HIV, chronic infections 
and autoimmune diseases since a number of CD27- isotype-switched B cell population 
were found (32-35). For instance, SLE patients display increased frequencies of 
CD27-IgD-CD95+ (36) memory B cells with somatic hypermutation (SHM) of Ig 
rearrangements. Similar populations were reported in the tonsil and in the blood of human 
immunodeficiency virus (HIV) infected patients as well as in elderly subjects (32, 35, 37).  
The expression of an inactive ATP-binding cassette (ABC)-B1 transporter and SHM 
in the Ig gene as well as a class-switched isotype are important characteristics to identify 
antigen experienced memory B cells in humans (24, 38). Recently, also the expression 
of FcRH4 and CD45RB has been described to be memory restricted (39, 40). However, 
a universal marker for all existing memory B cell subsets independent of their CD27 or 
isotype expression has not been identified yet. 
 
1.2.3 T cell independent immune response 
The antigen itself defines the type of the immune response. In the TD immune 
activation proteins bind to the BCR and require the help of T cells to induce a specific 
immune response. In contrast, large peptides or polysaccharides can stimulate B cells 
directly without additional T cell help. TI immune responses can be subdivided into 
TI-Type 1 (large polysaccharide) and TI-Type 2 (highly repetitious molecules) antigens. 
TI-Typ1 antigens require additional interaction with an innate receptor whereas TI-Type 
2 antigens can directly activate B cells by extensive cross-linking of the BCR and induces 
a rapid early immune response against invading and mainly blood borne pathogens (41-
43). The TI immune response consists largely of IgM Ab with low affinity. These Ab do 
not show significant H chain class-switch or affinity maturation. Only Typ-2 TI immune 
responses can induce an immunological memory (42, 43). Among others, MZ B cells can 
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be activated by blood born pathogens and differentiate via the TI pathway into 
CD27+IgM+IgD+ memory B cells. These cells play an important role during an immune 
response against encapsulated bacteria (44). 
 
1.2.4 T cell dependent immune response 
During the primary immune response antigen activated FO B cells interact with 
specific T cells to differentiate either into short-lived plasma cells, GC independent early 
memory B cells or in a GC dependent reaction into class-switched high affine long-lived 
memory B and plasma cells (45-47) (Figure 1-2).  
Soluble or large particular antigens (greater than 70 kDa) are presented by APCs 
whereas small soluble antigens can directly pass by afferent lymph vessels and are 
independent by a cell-mediated antigen presentation. Internalization and processing of 
the antigen by B cells as well as the presentation on major histocompatibility complex 
(MHC) molecules-class II complexes towards cognate CD4+ T helper (TH) cells is 
essential for the initiation of the GC reaction. To activate antigen specific B cells, three 
signals are necessary. First, the binding of the T cell receptor to the antigen presenting 
B cell. Second, the ligation of CD40 expressed on B cells by the CD40 ligand (co-
stimulation). Third, the secretion of a specific cytokine profile (e.g. IL2, IL4, IL-5) (43, 46).  
After activation, B cells migrate to the B-T cell border and upregulate MHC-class II 
molecules which promote a more efficiently cognate T cell help. They start to proliferate 
and differentiate into short-lived plasmablasts with mainly IgM low affinity Ab 
(extrafollicular reaction) or migrate into the B cell follicle. There they induce GC formation, 
SHM, class-switch (IgM to IgG, IgA, IgA or IgE), affinity maturation and differentiation into 
high affinity Ab producing plasma cells and/or long-lived memory B cells (43, 46). 
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Figure 1-2: Schematic representation of the germinal center (GC) reaction. Activated B cells migrate into the dark 
zone where they undergo somatic hypermutation (SHM) and rapid proliferation. Afterwards they move into the light 
zone to get positive selected by follicular dendritic cells (FDC) and T cells. After positive selection the non autoreactive 
high affinity B cells develop into class-switched memory B or plasma cells whereas the autoreactive B cells undergo 
apoptosis or re-enter the GC reaction (48).  
In the dark zone of the GC activated B cells (centroblasts) undergo proliferation and 
SHM. SHM are point mutations introduced by activating-induced cytidine deaminase 
(AID) in the V(D)J viable region gene segments which can lead to a change of the amino 
acid sequence and eventually to an increase of the BCR affinity against the specific 
pathogen. After this process, B cells migrate as centrocytes into the light zone where they 
undergo a stringent selection process controlled by antigen presenting follicular DCs and 
follicular TH cells. The newly generated Ab mutants are selected dependent on their BCR 
affinity. B cells expressing a high affine BCR upregulate the expression of MHC-class II 
molecules which in turn lead to a stronger T cell activation and a better competition for 
the limited T cell help in the GC light zone. Positively selected cells start to differentiate 
into class-switched memory B cells whereas low affinity B cells undergo another round of 
proliferation and SHM or receive dead signals (43, 46, 49, 50).  
 
1.2.5 Extrafollicular B cell activation 
During an extrafollicular immune reaction, activated FO B cells differentiate into 
short-lived memory and Ab secreting plasma cells without entering the GC reaction. The 
choice of B cells to either differentiate rapidly into extrafollicular plasma cells or to undergo 
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GC reaction (hypermutation and affinity maturation) is dependent on the BCR affinity and 
antigen density. Low affinity or antigen density selectively favors GC reactions, whereas 
higher affinity induces a higher rate of extrafollicular responses (51).  
In addition, it has been shown, that a strong CD40 stimulation can directly induce the 
development of memory B cells, mainly IgM+ but also CD27-IgA+ B cells, via the GC 
independent pathway and therefore favors an early memory B cell formation (45, 47). In 
line with this, B cells displaying large numbers of antigen-specific MHC-class II complexes 
can interact with large amounts of CD40 ligands on helper T cells leading to an 
extrafollicular B cell activation (45). 
 
1.2.6 B cell tolerance  
The SHM of Ig gene segments leads to a high diversity of the Ab repertoire against 
pathogens but may also give rise to self-reactive clones. In addition to GC selection 
process multiple tolerance mechanisms exist to control the emergence of autoreactive 
B cells and the development of autoimmunity (9, 52).  
The first control of self-reactivity is the central tolerance checkpoint in the BM (central 
selection) (10). Deletion, receptor editing and anergy lead to the elimination of 
autoreactive B cells. During this selection processes the strength of the BCR response 
and the tonic or baseline BCR signaling against antigens play a crucial role and regulates 
the development and survival of B cells (16). In fact, an increased spleen tyrosine kinase 
(Syk) activity which leads to a hyperactive BCR response was sufficient to induce cell 
death of mouse lymphoblastic leukemia B cells indicating the importance of BCR 
associated signaling molecules (53). During the negative selection process, newly 
generated immature B cells that react with self-antigens are eliminated either by deletion 
(apoptosis) or receptor editing which induces an alternative L chain usage (54). Anergy 
is an additional mechanism to in-activate autoreactive B cell clones. It is characterized by 
unresponsiveness against antigens induced by the up regulation of inhibitory BCR co-
receptors which in turns increases the activation threshold (14). Non autoreactive 
immature B cells continue to differentiate and get positively selected before they can 
leave the BM. Immature B cells have to reach a sufficient signaling level to get positive 
selected and to initiate further differentiation into the transitional B cell stage (10, 55). A 
hyperresponsive as well as a non-responsive phenotype against an antigen leads to the 
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elimination of this B cell clone. Thus, an intermediate BCR response is necessary for 
proper selection and differentiation into memory B and plasma cells (10, 55). 
Self-reactive B cells which escapes the central tolerance in the BM and are 
autoreactive against tissue specific antigens which are not present in the BM gets 
selected by additional peripheral tolerance mechanisms. Activated B cells need 
co-stimulatory signals provided by CD4+ TH cells. In addition, intrinsically regulation 
mechanisms which involves kinases and phosphatases to modulate the strength of the 
BCR signal and determines the B cell fate are necessary for proper selection (16, 56). 
During the GC reaction another selection of self-reactive B cell clones occur (peripheral 
tolerance). Low affinity B cells which lack adequate FDC and CD4+ follicular T cell help 
undergo apoptosis or another round of SHM (positive selection). Also in the late memory 
or plasma cell stage different mechanisms exist to circumvent self-reactivity. How this 
mechanisms works is still not clear but the blockade of differentiation into memory and 
plasma cells, the inhibition of Ab production and a limited survival within niches are 
possible mechanisms (9). 
A breakdown of self-tolerance by defects in selection processes can lead to 
autoimmune diseases as it has been described for SLE (11-13). It has been published 
that defects in the BCR signaling may play an essential role during the development, 
selection and maintenance of autoimmunity (11, 53, 57-59). However, to which extend 
BCR associated receptors and its signaling molecules as well as the balance between 
kinases and phosphatases are involved in human autoimmune diseases are still rare. 
 
1.3 B cell receptor structure and signaling 
1.3.1 Organization of the surface BCR complex   
The antigen receptor expressed on B cells is a transmembrane protein complex, the 
membrane-bound form of an Ig. It is assembled of different subunits including an IgH 
chain, covalently linked with disulfide-bridges to an IgL chain. The antigen binding site is 
located in the variable region of the amino-terminal of the IgH and IgL chain. The diversity 
and specificity of the antigen binding site is generated by V(D)J rearrangements and 
subsequently tuned by SHM. The carboxy-terminal region of the BCR determines the 
Isotype (IgM, IgD, IgG, IgA and IgE) (60). Surface IgM and IgD is expressed mainly on 
immature and mature naïve  B cells (pre-switch), whereas IgG+, IgA+ and IgE+ post-
switch B cells are generated after B cell activation and isotype class-switching (60).   
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In contrast to the soluble form of the Ig secreted by terminal differentiated plasma 
cells, the membrane-bound BCR is associated with two heterodimer polypeptides (Igα 
and Igβ). The intracellular part of Igα and Igβ contains immunoreceptor tyrosine-based 
activation motifs (ITAMs) to initiate the B cell response and determine the B cell fate 
decision (60). 
 
1.3.2 B cell signaling 
Binding of antigens to the BCR induces an affinity dependent clustering of certain 
molecules. High affine BCRs show rapid microcluster formation and enhanced 
recruitment of BCR key kinases as well as an enhanced calcium (Ca2+) influx (61). This 
microcluster formation leads to an activation of a signaling cascade with the induction of 
a specific gene expression profile regulating proliferation, survival and apoptosis of 
activated B cells (17, 61). Besides multivalent and soluble antigens, also monovalent 
antigens are sufficient to induce the initiation of BCR capping, internalization of the 
antigen bound BCR and the presentation on MHC-class II molecules to CD4+ TH cells 
(60). 
During the initiation of the BCR clustering, the membrane topology and lipid raft 
composition plays an essential role. In resting B cells the BCR is excluded from the lipid 
rafts. After activation, the BCR moves into the lipid raft areas and is forced to open the 
cytoplasmic domain to get activated by Lyn (56, 62-64). Lyn activates the ITAM motifs 
within the cytoplasmic Igα/β (CD79a/b) tail of the BCR which directly interact with the 
signaling machinery to promote the recruitment of kinases. Lyn plays an essential role as 
negative and positive regulator of BCR activation (65, 66). Phosphorylation of Igα/β by 
Lyn leads to the recruitment of the SH2-containing kinase Syk which is recruited to the 
activated microcluster and translates the extracellular engagement into an intracellular 
signal in an orchestrated manner (63, 67).  
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Figure 1-3: Schematic diagram of the central BCR signaling cascade. After antigen binding, the intracellular tail of 
the BCR becomes activated by Lyn leading to the recruitment of Syk and further downstream to the influx of Ca2+ and 
the activation of the transcription factors NFκ-B and NFAT. Lyn also activates BTK which induces the activation of 
CD19 and the PI3K/Akt survival pathway leading to an inhibition of the transcription factors FOXO-1 and GSK3. 
Negative regulation of the BCR response occurs by the activation of CD22 and FcγRIIb. CD22 activation recruits SHP-
1 which in turn dephosphorylates Syk and dampens the BCR signal [modified according to (56)]. 
Subsequently, signaling molecules such as bruton’s tyrosine kinase (Btk) and 
phospholipase C-γ2 (PLC-γ2) accumulate in a signalosome to initiate internalization, 
antigen processing, 1,4,5-trisphosphate (IP3) generation and Ca2+ release. This lead 
among others to the activation of the transcription factors nuclear factor of activated 
T cells (NF-AT) and nuclear factor 'kappa-light-chain-enhancer' of activated B cells (NFκ-
B) (68-71) inducing a specific gene expression profile. Lyn also activates B cell adaptor 
proteins (BCAP and BLNK) in a CD19-dependent manner resulting in the activation of 
the PI3K/Akt pathway which has been shown to play an important role in cell survival by 
regulating forkhead box protein (FOX) O1 (72-74) (Figure 1-3).  
BCR signaling differs between naïve and memory B cells and is dependent on the 
isotype expressed on the B cell surface. Compared to naïve, memory B cells show a 
stable BCR response, a stronger formation of BCR oligomers, microcluster formation and 
a more effective recruitment of kinases. Memory B cells also show higher phosphorylation 
kinetics compared to naïve B cells suggesting a lower activation threshold to respond 
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faster during secondary immune responses (75, 76). Intrinsic differences, such as the 
expression of genes involved in activation, co-stimulation and survival are responsible for 
the efficient BCR response in memory B cells (77). 
The BCR isotype has an impact on the signaling outcome since a different BCR 
response has been reported in IgM+ compared to IgG+ memory B cells. The density of 
membrane-bound Ig is similar between IgG+ and IgM+ memory  B cells, the level of p-
Syk, p-PI3K, p-extracellular signal-regulated kinase (ERK) and p-p38 recruited to the 
membrane is significantly higher in IgG+ compared to IgM+ B cells (75). 
The antigen inducing BCR signaling is not the only essential factor during B cell 
development, tonic or basal ligand independent signaling via the BCR is also important 
for the survival and maintenance as well as the selection of B cells. Even without antigen 
binding, BCR oligomers are formed to provide a constant low-level of B cell activation that 
appear to be critical for the overall B cell survival (17, 78).  
Besides the activation and accumulation of intracellular kinases, the recruitment and 
balance of positive (CD19, CD45 and CD21) and inhibitory co-receptors (CD22 and 
FcγRIIb) are important to ensure sufficient BCR signaling and peripheral B cell tolerance 
(40, 79-82). Imbalances between these positive and negative BCR co-receptors can lead 
to autoimmunity as it has been reported for human SLE (83-85). How this dysbalance 
influences the signaling outcome and therefore the B cell fate is still not fully understood.  
 
1.3.2.1 Spleen tyrosine kinase (Syk) and its function in B cells 
The non-receptor cytoplasmic tyrosine kinase Syk which is expressed in all 
hematopoietic- and non-hematopoietic cells like platelets, fibroblasts and endothelial cells 
plays a crucial role during the adaptive immune receptor signaling response. Other 
biological functions are cellular adhesion, innate immune responses and vascular 
development (86, 87). Syk is a 72 kDa enzyme containing two SCR homology 2 (SH2) 
domains separated by a linker and a kinase domain. The kinase domain is inactive in the 
resting state due to an autoinhibitory conformation. The kinase becomes activated by the 
translocation to the plasma membrane and binding of the SH2 domains to the activated 
BCR complex. This activation leads to a change in its conformation which permits the 
phosphorylation of tyrosine (Y) residues within the linker region and the C-terminal tail 
(Y131, Y323, Y348, Y352, and Y629-631). This phosphorylation activates the initiator 
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function of Syk and leads to an amplification of the BCR signal by a rapid phosphorylation 
of the neighboring ITAM sequences (87).  
The residue Y131 is responsible for the dissociation of Syk from the 
phosphorylated ITAMs of the BCR complex and is necessary to switch off Syk activity. 
Binding of the E3 ubiquitin ligase casitas B-lineage lymphoma (Cbl) to Syk is initiated by 
the phosphorylation of Y323 and therefore important for its degradation. The tyrosine 
residues Y348 and Y352 are two early phosphorylation sites of Syk that lead to the 
recruitment and initiation of further downstream signaling cascades and signalosome 
formation (88). Syk activates CD19, the adapter protein BCAP as well as the PI3K 
pathway, B cell linker protein (BLNK), B lymphocyte kinase (BLK), Vav and PLC-γ2 
leading to an intracellular Ca2+ release, proliferation, survival and differentiation. 
However, a Syk independent CD19/PI3K/Akt activation pathway has been identified 
leading to B cell survival even in the absence of this kinase (89). Syk plays an 
indispensable role during BCR signaling, maintenance of mature B cells, ITAM mediated 
tonic signaling and B cell development in the BM (17, 53, 87). 
One negative regulator of Syk is the phosphatase Src homology region 2 domain-
containing phosphatase-1 (SHP-1). It becomes activated after BCR engagement by the 
inhibitory co-receptor CD22 to prevent chronic- or hyperactivation (90). A second negative 
regulator of Syk is Cbl. Cbl leads to the ubiquitylation and hereafter to the degradation of 
Syk (91-93). Deficiency of Syk leads to a complete absence of mature B cells and is 
important during the B cell transition of pro- into pre-B cells and FO into GC B cells as 
well as during positive selection processes of immature B cells (59, 94). Abnormalities of 
Syk have been described to be involved in several forms of leukemia’s (95, 96), T cell 
lymphoma (97) and autoimmune diseases like SLE (98, 99). Thus, the regulation of Syk 
by specific inhibitors, such as R406, seems to be an attractive therapeutic possibility (100, 
101). 
Nevertheless, human studies on the expression of Syk in B cells and its possible 
relation to SLE immunopathogenesis are rare (102) and need to be further evaluated. 
 
1.3.2.2 Functional role of the serine kinase Akt in B cells   
The serine (S)/threonine (Thr) kinase Akt is known to be involved in B cell survival 
and cell cycle progression. The activation of Akt is initiated in a Lyn dependent manner 
by PI3K after BCR and CD19 activation (74). Three isoforms of Akt are expressed in 
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B cells and are constituted of an N-terminal pleckstrin homology containing domain, a 
threonine residue (Thr308) in the activation loop and a hydrophobic motif (S473). Both 
activation sites need to be phosphorylated to fully activate Akt. One important target of 
Akt is the transcription factor FOXO-1. Its phosphorylation leads to the nuclear export and 
degradation and therefore suppression of its transcriptional activity (74).  
The activation of Akt by CD19/PI3K and the capability of Akt to inactivate FOXO-1 
factors regulate the development of mature into MZ B cells. Mice lacking CD19 show a 
loss of MZ B cells (103, 104). This data indicate that the PI3K/Akt signaling pathway 
induces the formation of short-lived, mainly IgM+ plasma cells generated during TI 
immune responses. The choice between rapid extrafollicular plasma cell differentiation 
and GC reaction seem to be dependent on the strength of the PI3K/Akt signaling pathway 
and therefore by the activity of FOXO-1 (103, 105). Loss of the phosphatase and Tensin 
homolog (PTEN) led to an increased differentiation into Ab secreting plasma cells and a 
reduction in GC dependent class-switch recombination by elevated PI3K/Akt activation 
(74).   
However, detailed studies on the activation kinetics of Akt and the interaction of 
Akt and Syk dependent signaling pathways in human SLE B cells are scarce. 
 
1.3.2.3 BCR co-receptor assembly and functional consequences 
BCR associated co-receptors modulate the signaling threshold and are crucial 
during B cell development and cellular selection processes (16, 17).  
On the one hand, an important negative regulator of the BCR signaling is the sialic 
acid-binding lectin CD22 which is exclusively expressed on B cells (79). During B cell 
development CD22 is upregulated and reaches its maximum at the naïve B cell stage. 
After B cell activation CD22 is downregulated on memory B cells and absence on plasma 
cells (106). CD22 negatively regulates the BCR signaling by recruiting several signaling 
molecules to the cell membrane after BCR activation, including Lyn, Syk, growth factor 
receptor-bound protein (Grb) 2, signaling inositol polyphosphate phosphatase (SHIP), 
PI3K and PLC-γ2 (107-110). Key molecules of this downstream signaling cascade are 
the tyrosine phosphatase SHP-1 and Syk. Due to the wide range of CD22 ligands, the 
exact mechanism of the inhibitory activity of CD22 has not been fully revealed yet (79, 
107). Recent studies indicate that CD22 can bind specific to α2-6-sialylated glycoproteins 
on the cell surface in cis (same cell) and trans (other cell), which seems to play an 
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important role for its inhibitory properties. Furthermore, CD22 regulates cell adhesion and 
migration of B cells (106). After BCR activation Lyn initiates Syk recruitment as well as 
the phosphorylation of the immunoreceptor tyrosine-based inhibitory motifs (ITIMs) within 
the cytoplasmic tail of CD22. One important phosphorylation site is Y822 which is 
responsible for the recruitment and activation of the phosphatase SHP-1 leading to a 
dephosphorylation of Syk as it has been shown for human SLE B cells pre-treated with 
the monoclonal anti-CD22 Ab epratuzumab (111). CD22 deficient mice show a 
hyperresponsive Ca2+ response as well as increased levels of auto-Ab (112).   
On the other hand, positive regulators like the co-receptor CD19 influence the 
strength of signals transduced through the BCR by lowering the signaling threshold. CD19 
does not only function as a BCR co-receptor, it can also be used as a lineage marker for 
B cells and is expressed in conjunction with CD21 and CD81 (80, 113). Upon antigen 
binding to the BCR, the cytoplasmic tail of CD19 gets activated and induces the activation 
of the PI3K/Akt survival pathway. Indeed CD19/CD21 co-receptor signaling has been 
implicated to regulate B cell survival during primary immune responses (72, 80). Mice 
lacking CD19 show defects in Ab secretion, GC formation and affinity maturation during 
TD immune responses (114).  
Thus, modulating the BCR response is more complex. To fine tune the BCR signal 
and prevent autoimmunity, an equilibrium of positive and negative regulating co-receptors 
and their associated kinases and phosphatases is required (84, 85, 115, 116). 
1.4 Autoimmune diseases and loss of B cell tolerance  
The breakdown of tolerance against self-antigens and therefore the generation of 
autoreactive B and plasma cells lead to the development of autoimmunity. Autoimmune 
diseases can be organ-specific, such as multiple sclerosis (nerve cells), diabetes mellitus 
Type 1 (insulin-producing cells) or systemic, such as vasculitides, SLE or various other 
diseases (60). 
 
1.4.1 Systemic lupus erythematosus  
SLE is a prototypic autoimmune disease in which loss of B cell tolerance is 
reflected by the production of anti-nuclear antibodies (ANA) including Ab against double 
stranded DNA (dsDNA) due to defects in the clearance of dying cells (117-119). The 
subsequent formation of immune complexes can result in inflammation and tissue 
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damage as well as an aberrant production of cytokines by cells of the adaptive and innate 
immune system including IL-6, IL-10, tumor necrosis factor-α (TNF-α), Interferon-γ (INF-
γ), IL-21, IL-2, IL-4 and BAFF (1, 57, 120-130). T cells for example are the major source 
of IL-4, IL-17 and INF- γ but strikingly reduced IL-2 in the peripheral blood of SLE patients, 
whereas IL-6 and IL-10 was mainly produced by monocytes (131). B cell lymphopenia 
and alteration in peripheral B cell subsets are another common feature of SLE patients 
(3). Several studies reported dysregulation of B cell homeostasis in these patients, 
including an increased frequency of transitional type 1 (T1) and pre-naïve B cells (132, 
133), CD27high or HLA-DRhighCD27high plasmablasts (134, 135), CD27+/-CD19high (136, 
137) and CD27+/-CD21low/neg (138, 139) as well as CD27-IgD- (32) and CD27-IgD-CD95+ 
(36) B cells. A central role in the pathogenesis of SLE plays B cell hyperactivity shown by 
an increased number of circulating plasma cells (135, 140), spontaneous auto-Ab 
production in vitro (141, 142), global increased tyrosine phosphorylation after BCR 
stimulation (143) and the occurrence of hypergammaglobulinemia (144). The disease 
activity of SLE patients is assessed by using clinical and laboratory markers and is 
represented by the systemic lupus erythematosus disease activity index (SLEDAI) or the 
British Isles lupus assessment grouped (BILAG) score (145). However, this ranking 
system has limitations and does not represent the clinical complexity of this disease.  
The development of SLE is still not fully clarified but genetic predispositions (146-
148), increased expression of IFN-related genes (149, 150) as well as intrinsic 
abnormalities related to signaling disturbances (4-6, 98, 151-154) have been found to 
play a mature role in B and T cells.  
 
1.4.2 B cell tolerance and signaling in SLE 
So far, there is no clear understanding to which extent defects in central (mainly 
related to autoreactive naïve B cells) or peripheral (mainly related to autoreactive memory 
B cells) tolerance are involved in the emergence of lupus autoimmunity. Defects in early 
tolerance checkpoints in SLE B cells (13) and the persistence of autoreactive naïve 
B cells even during SLE remission (155) have been described consistent with intrinsic 
disturbances of central selection (11, 12). In the study of Cappione et al., human SLE 
patients fail to exclude autoreactive B cells from GC reactions. The same study showed, 
that autoreactive B cell display a reduced Ca2+ influx after IgM activation (156). 
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Another body of evidence mainly based on the detection of mutated BCR 
rearrangements and phenotypic analyses suggests that most autoreactive B cells in SLE 
carry antigen-experienced BCR gene rearrangements as a result of T cell activation (57, 
134, 157) suggesting defects of peripheral selection. However, central and peripheral 
tolerance mechanisms are strongly dependent on the strength of the BCR signal (53-55). 
Aberration in BCR induced signaling events can lead to the loss of tolerance, the 
development as well as maintenance of autoreactive B cells. Confirming this assumption, 
Lyn deficiency (158), Lynup/up (159), Btk transgenic mice (58) as well as B cell specific 
insufficiency of SHIP-1 and PTEN (160, 161) led to an lupus-like phenotype in mice. A 
multi-signaling analysis of different BCR related signaling molecules revealed in different 
lupus mice models an hyperexpression and activation of the PI3K/Akt/mTOR, the 
MEK1/Erk1/2 signaling pathway together with p38, NFκ-B, multiple Bcl-2 members and 
cell-cycle molecules (162). Abnormalities of BCR signaling in human SLE have been 
described, such as a decreased Lyn (163), aberrant SHP-1 and CD45 expression leading 
to a disturbed lipid raft formation in B cells (5, 164). A reduced expression of PTEN which 
results in enhanced Akt activation (165) and a globally increased tyrosine phosphorylation 
(143) as well as an hyperresponsive BCR activation after IgM stimulation in naïve B cells 
(6) were also linked to B cell abnormalities in SLE patients. Additionally, two genetic 
polymorphisms in the transmembrane domain of the inhibitory co-receptor FcγRIIb have 
been associated with SLE. This polymorphisms led to reduced lipid raft localization and 
inhibition of the BCR signaling (166, 167). Other groups showed a reduced inhibitory 
effect of FcγRIIb on the BCR signaling which was due to an decreased expression of the 
phosphatase SHIP-1 (151) and a reduced expression level of FcγRIIb on CD27+ SLE 
B cells (168).  
Nevertheless, also a diminished BCR response has been associated with SLE and 
other diseases. Especially gene mutations or overexpression as shown for chronic 
lymphatic leukemia (CLL) B cells of the protein tyrosine phosphatase, non-receptor type 
22 (PTPN22) which participates in the BCR signaling has been associated to an 
increased frequency of autoreactive immature B cells. These aberrations led to a block 
of BCR related signaling pathways that regulate apoptosis but induced enhanced BCR 
signaling that activates the pro-survival kinase Akt. These disturbances can lead to the 
circumvention of negative selection processes and the survival of autoreactive B cells 
(147, 169-171). Similar observations were made for SLE (172, 173). Evidence for a 
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diminished BCR response in autoimmunity was also provided by a genetic defect in the 
BCR related kinase BLK which led to a reduced BCR response and enhanced frequency 
of autoreactive naïve  B cells (174). Also in mice models a rather diminished BCR 
response was predicted to be involved in SLE (175). In humans, SLE associated 
abnormalities of the BCR complex were found, including reduced levels of CD21 on 
certain SLE B cell subsets (138). B cells lacking CD21 are enriched in autoreactive and 
unresponsive B cell clones (176).  
Thus, analyzing the expression and function of the BCR-related kinases could 
provide new insights to which extent signaling molecules contributes to SLE 
immunopathogenesis and the maintenance of autoreactivity.   
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2. Research aim 
The strength of the B cell response plays a crucial role during B cell development, 
tolerance and cell fate decision. Defects in BCR related signaling pathways have been 
connected with the breakdown of self tolerance and the development of autoreactive 
memory B and antibody secreting plasma cells. Especially the balance between positive 
and negative co-receptors as well as phosphatases and kinases is crucial for proper 
antigen induced BCR signaling to prevent the emergence and maintenance of 
autoimmunity. Besides intrinsic abnormalities, SLE has been associated with an aberrant 
B cell homeostasis leading to the occurrence of abnormal B cell subsets. Especially within 
the memory B cell compartment abnormalities participating in the development and 
maintenance of this disease has been observed. 
The aim of this study was to gain new insights into potential aberrations of intracellular 
BCR signaling disturbances that could lead to the development and maintenance of 
autoreactive B and plasma cells and the circumvention of tolerance checkpoints in 
patients with SLE. Analyzing SLE B cells more in detail will improve the understanding of 
SLE specific memory subsets regarding their contribution during pathogenic immune 
responses.  
Two main questions were placed: 
1.) How is B cell tolerance in SLE patients disturbed and how can autoreactive 
clones survive and maintain in the repertoire of this disease? 
2.) To which extent are abnormalities of B cell subsets, intracellular BCR 
signaling pathways and the BCR complex organization involved in this 
process? 
A comprehensive analysis in SLE patients versus controls regarding their expression, 
activation and localization of the BCR and its inhibitory co-receptor CD22 as well as its 
downstream kinases with a main focus on Syk versus Akt was performed.  
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3. Material and methods 
3.1 Material 
3.1.2 Chemicals and reagents 
Table 3-1: Reagents 
Reagents Manufacturer  
0.4% Trypan blue solution Sigma-Aldrich, Saint Louis, USA 
1-Step Turbo TMB-ELISA Thermo Fisher Scientific Inc., Rockford, USA 
Tris (C4H11NO3) Carl Roth, Karlsruhe, Germany 
3-Amino-9-Ethylcarbazole (AEC) tablets Sigma-Aldrich, Saint Louis, USA 
4',6-diamidino-2-phenylindole (DAPI)  Roche, Basel, Switzerland  
Acetic acid  (CH3COOH) Carl Roth, Karlsruhe, Germany  
Avian Myeloblastosis Virus RT Sanquin Reagents, Amsterdam, Netherlands 
Boric acid (H3BO3) Merck KGaA, Darmstadt, Germany 
BSA Biomol, Hamburg, Germany 
Cytometer setup and tracking beads BD Biosciences GmbH, Plymouth, USA 
Deoxynucleotides (dNTPs) Sigma-Aldrich, Saint Louis, USA 
Dimethyl sulfoxide (DMSO)  SERVA, Heidelberg, Germany 
Dithiothreitol (DTT) Sanquin Reagents, Amsterdam, Netherlands 
Electrophoresis marker ml-100kbp+ DNA Metabion international AG, Planegg, Germany 
Ethanol 96% Merck KGaA, Darmstadt, Germany 
Ethanolamine Merck KGaA, Darmstadt, Germany 
EDTA 0.5 mM Invitrogen Corporation., Camarillo, USA 
FCS  DRFZ, Berlin, Germany 
GelPilot DNA Loading Dye, 5x Qiagen, Hilden, Germany 
GelRed Nucleic Acid Gel Stain, 10,000X in water Biotium, Hayward, CA, USA 
Glycerol Sigma-Aldrich, Saint Louis, USA 
hydrochloric acid (HCl) Merck, Darmstadt, Germany 
hydrogen peroxide (H2O2) Sigma-Aldrich, Saint Louis, USA 
Indo-1 acetoxymethyl (AM) dye  Invitrogen Corporation., Camarillo, USA 
LE Agarose Biozym, Hessisch Oldendorf, Germany 
Lymphocyte Separation Medium LSM 1077  PAA Laboratories, Paschin, Austria 
Lyse/Fix-Puffer 5x PhosphoFlow BD Biosciences GmbH, Plymouth, USA 
Mito Tracker Orange CMTMRos Life Technologies, Carlsbad, USA 
p(dT)15 Primer Roche Diagnostics GmbH, Berlin, Germany 
PBS 1x  Biochrom, Berlin, Germany 
PBS/BSA 0.5%  DRFZ, Berlin, Germany 
Perm Buffer II  PhosphoFlow BD Biosciences GmbH, Plymouth, USA 
Perm Buffer III  PhosphoFlow BD Biosciences GmbH, Plymouth, USA 
Pierce Lysis IP buffer Thermo Fisher Scientific Inc., Rockford, USA 
p-nitrophenyl phosphate (p-NPP) tablets Sigma-Aldrich, Saint Louis, USA 
Protease inhibitor cocktail Cell signaling technology, Cambridge, England 
RNasin Plus RNase inhibitor Promega Corporation, WI, USA 
RPMI 1640 + GlutaMAX  Invitrogen Corporation., Camarillo, USA 
RPMI 1640 + GlutaMAX+10 % FCS, 2-
Mercaptoethanol (0.05 mM), Penicillin (100 U/ml) and 
Streptomycin (100 g/ml)  
DRFZ, Berlin, Germany 
Sodium acetate trihydrate (NaOOC-CH3 * 3 H2O) Sigma-Aldrich, Saint Louis, USA 
Sodium carbonate (Na2CO3)  Sigma-Aldrich, Saint Louis, USA 
Sodium chloride (NaCl)   Merck KGaA, Darmstadt, Germany 
Sodium fluoride (NaF) Sigma-Aldrich, Saint Louis, USA 
Sodium hydrogen carbonate (NaHCO3)  Sigma-Aldrich, Saint Louis, USA 
Sodium hydroxide (NaOH) Merck, Darmstadt, Germany 
Sodium orthovanadate (Na3VO4) Sigma-Aldrich, Saint Louis, USA 
Spermidin DRFZ, Berlin, Germany 
Sphero Rainbow calibration particles 8 peaks BD Biosciences GmbH, Plymouth, USA 
β-Mercapthoethanol Sigma-Aldrich, Saint Louis, USA 
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Sulfuric acid (H2SO4) Carl Roth, Karlsruhe, Germany 
Tetanus/diphtheria toxoid Sanofi Pasteur, MSD GmbH, Leimen, Germany 
TruCount-Lysis buffer 10x BD Biosciences GmbH, Plymouth, USA 
Tween 20 Sigma-Aldrich, Saint Louis, USA 
Ultra pure Water  Biochrom, Berlin, Germany 
Vectashield Hard set mounting medium with DAPI Vector Laboratories, Burlingame, CA, USA 
Goat F(ab`)2 anti human IgM/IgG (H+L)  Jackson ImmunoResearch, Suffolk, UK  
Human recombinant BAFF Proptech, Hamburg, Germany 
Human recombinant IFN-γ Proptech, Hamburg, Germany 
Human recombinant IL-10 Proptech, Hamburg, Germany 
Human recombinant IL-2 Proptech, Hamburg, Germany 
Human recombinant IL-21 Proptech, Hamburg, Germany 
Human recombinant IL-6 Proptech, Hamburg, Germany 
Human recombinant TNF-α Proptech, Hamburg, Germany 
CpG-B oligodeoxynucleotides 2006  Invitrogen Corporation., Camarillo, USA  
LPS from Escherichia coli 055:B5 InvivoGen, San Diego, USA 
3.1.2 Consumables 
Table 3-2: Consumables 
Consumables  Manufacturer 
1.5 ml reaction tubes Eppendorf AG, Hamburg, Germany  
2.0 ml reaction tubes Eppendorf AG, Hamburg, Germany 
10 ml EDTA-tubes BD Biosciences GmbH, Plymouth, USA  
2 ml heparin-tubes BD Biosciences GmbH, Plymouth, USA  
5 ml FACS tubes 75x12mm Sarstedt, Nümbrecht, Germany  
CellStar 96-well culture plate, U-bottom  Greiner Bio-one, Frickenhausen, Germany  
Falcon tube 15 and 50 ml  Sarstedt, Nümbrecht, Germany  
Filter Pipette tips (1250 µl, 0.1-10 µl and 2-200 µl) Sarstedt, Nümbrecht, Germany 
MACS® cell separation columns  Miltenyi Biotec GmbH, Gladbach, Germany  
Microscope cover glasses 24x50mm VWR International, Radnor, USA 
Microscope slides superfrost plus 25x75x1mm Thermo Fisher Scientific Inc., Rockford, USA 
MSIPN4550 Multiscreen-IP, 0,45 µm 96-well plates Millipore, Billerica, USA 
PCR plate strip caps Thermo Fisher Scientific Inc., Rockford, USA 
PCR plates, deep well cycler iQ Biorad, CA, USA  
Pipette tips (1250 µl, 0.1-10 µl and 2-200 µl) Sarstedt, Nümbrecht, Germany  
TruCount tubes BD Biosciences GmbH, Plymouth, USA 
Nunc™ MicroWell™ 96-Well Microplates Thermo Fisher Scientific Inc., Rockford, USA 
3.1.3 Equipment 
Table 3-3: Equipment 
Equipment Manufacturer 
ABX Micros60 Axonlab AG, Baden, Germany 
BD FACSCanto II Flow cytometry BD Biosciences GmbH, Plymouth, USA 
Block Heating System For Micro tubes Grant, Essex, England 
Clean bench Herasafe KS  Thermo Fisher Scientific, Waltham, USA  
Counting chamber „Neubauer“  Brand, Wertheim, Germany 
Elispot reader + fluorescent lamp  AID GmbH, Straßberg, Germany 
FACSDivaTM Flow Cytometry & Cell sorter BD Biosciences GmbH, Plymouth, USA 
Grant water bath GD100 Grand, Shepreth, UK 
Heidolph Titramax x10000 neo-Lab, Heidelberg, Germany 
Heraeus Fresco 17 centrifuge Thermo Fisher Scientific Inc., Rockford, USA 
Incubator Heracell 240i  Thermo Fisher Scientific, Waltham, USA  
Labor centrifuge 5415D Eppendorf AG, Hamburg, Deutschland 
Laboratory shaker Neolab, Heidelberg, Germany 
MACS LS Columns Miltenyi Biotec GmbH, Gladbach, Germany 
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MACS MultiStand Miltenyi Biotec GmbH, Gladbach, Germany 
Megafuge 1.0  Heraeus Instruments, Hanau, Germany 
MidiMACS Separator LS Miltenyi Biotec GmbH, Gladbach, Germany 
Multichannel Pipette Biohit, Rosbach, Germany 
Multifuge X3R  Thermo Fisher Scientific, Waltham, USA  
Multistep pipette  Brand, Wertheim, Deutschland 
Optical microscope Olympus, Hamburg, Germany 
pH-meter Schott Instruments BDL Czech Republic, Trutnov, Czechia 
Pipetboy  IBS Integra Biosciences, Fernwald, Germany 
Pipettes (1000 µl, 200 µl, 100 µl, 20 µl, 10 µl) Eppendorf AG, Hamburg, Germany 
Refrigerators and freezer (4°C, -20°C, -80°C)  Liebherr Heraeus Instruments, Hanau, Germany 
Shaker Titramax 1000r  Heidolph, Schwabach, Germany 
Shandon CytoSpin III Cytocentrifuge GMI, Minnesota, USA 
SpectraMax190 microplate reader  molecular devices, Sunnyvale, CA, USA 
T100 Thermo Cycler Biorad, CA, USA 
Zeiss LSM 710 confocal microscope Carl Zeiss, Jena Germany 
3.1.4 Buffer and solutions  
Developer 
Solution A 
- 10 ml CH3COOH 0.2 M 
- 14.1 ml NaOOC-CH3 * 3 H2O 0.2M 
- 20 ml dest. water 
Solution B 
- 1 tablet AEC in 2 ml DMSO  
add 1 ml AEC-DMF stepwise to the solution A and 
after filtration add 12 µl H2O2 (30%) to the solution 
 
Coating Buffer: in 500 ml dest. water pH 9.6 
- 1.46 g NaHCO3  
- 4.5 g NaCl  
- 0.8 g  Na2CO3  
 
Loading Buffer electrophoresis: in 11 ml dest. 
water 
- 1.8 ml Loading dye  
- 1 ml Glycerin 
- 5 µl GelRed 
 
Phosphatase storage buffer 
- 25 mM Tris-HCl (pH 7.4) 
- 2 mM EDTA  
- 10 mM β-Mercaptoethanol 
 
Removal buffer: in PBS 
- 1% BSA 
- 0.05% Tween 
 
20xTBS: in 500ml dest. water pH 7.4 
- 121 g Tris 
- 90 g NaCl 
 
10x TBE electrophoresis buffer: in 1 l dest. water 
- 121.1 g Tris 
- 61.8 g Boric acid 
- 7.4 g EDTA 
 
3.1.5 Antibodies 
Table 3-4: Antibodies. If not otherwise indicated, all antibodies listed below are from mouse against 
human. 
antibody conjugate clone company Application field dilution 
CD3 PacB UCHT1 BD FC, cell sorting 1:50 
CD14 PacB M5E2 BD FC, cell sorting 1:50 
CD19 PE Cy7, 
APC-H7 
SJ25C1 BD FC, cell sorting 1:15, 
1:12 
CD20 PerCP-Cy5.5, 
PacO 
H1 (FB1), 
HI47 
BD, 
Invitrogen 
(intracellular) FC, 
cell sorting 
1:12, 
1:50 
CD21 PE B-ly4  FC 1:25 
CD22 PE S-HCL-1 BD FC 1:20 
CD27 APC HIT2 BD FC 1:30 
CD38 PE HIT2 BD FC, cell sorting 1:20 
CD80 FITC B7-1 BD FC 1:20 
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CD86 FITC 2331 (FUN-1) BD FC 1:50 
CD95 PE DX2 BD FC 1:50 
CD138 PE B-B4 Miltenyi FC 1:25 
donkey 
anti-goat IgG 
FITC  Jackson Research CM 1:100 
donkey  
anti-mouse IgG 
RRX  Jackson Research CM 1:200 
donkey  
anti-rabbit IgG 
RRX  Jackson Research CM 1:200 
Epratuzumab  
(anti-CD22) 
Bio  UCB 
 
CM 1:10 
F(ab’)2 goat  
anti-IgM/ IgG 
  Jackson Research CM, stimulation 1:25, 
1:100 
goat anti-IgG 
(γ-chain specific) 
unlabeled  Sigma-Aldrich ELISA, ELISPOT 1:200 
IgD PE-Cy7 IA6-2 BD FC 1:50 
IgA FITC M24A Chemicon FC 1:50 
IgG PE-Cy7 G18-145 BD FC 1:50 
IgM PerCp5.5 G20-127 BD FC 1:50 
IgG Bio  Sigma-Aldrich ELISPOT 1:200 
IgG AP  Sigma-Aldrich ELISA 1:3000 
Ki67 PE-Cy7 B56 BD (intracellular) FC 1:50 
p-Akt (S473) PE M89-61 BD (intracellular) FC 1:16 
p-CD22(Y822) PE 12A/CD22 BD (intracellular) FC 1:6 
p-Syk(Y352) PE 17A/P-ZAP70 BD (intracellular) FC 1:6 
p-Syk (Y348) PE II20-722 BD (intracellular) FC 1:6 
p-PLC-γ2 (Y759) FITC K86-689.37 BD (intracellular) FC 1:6 
rabbit 
anti-IgM 
unlabeled  DAKO CM 1:200 
SHP-1 unlabeled 52/PTP1C BD CM 1:200 
Streptavidin Alexa633  Jackson Research CM 1:200 
Streptavidin HRP  Sigma-Aldrich ELISPOT 1:3000 
Syk FITC 4D10 BD (intracellular) FC, 
CM, cell sorting 
1:100 
 
 
FC= flow cytometry; CM= confocal Microscopy; BD= Becton Dickinson Biosciences GmbH, Plymouth, USA 
3.1.6 Primers 
Table 3-5: Primers used for single cell PCR 
 Sequence 
external PCR  
VH1 LC 5’ CC ATG GAC TGG ACC TGG A 3’ 
VH2 LC 5’ ATG GAC ACA CTT TGC T(AC)C AC 3’ 
VH3 LC 5’ CC ATG GAG TTT GGG CTG AGC 3’ 
VH4 LC 5’ ATG AAA CAC CTG TGG TTC TT 3’ 
VH5 LC 5’ ATG GGG TCA ACC GCC ATC CT 3’ 
VH6 LC 5’ ATG TCT GTC TCC TTC CTC AT 3’ 
for IgA:IgVH-cα 5’ GGA AGA AGC CCT GGA CCA GGC 3’ 
for IgG: Ecγ 5’ AC GCC GCT GGT CAG GGC GC 3’ 
for IgM: Ecµ 5’ TCA GGA CTG ATG GGA AGC CC 3’ 
interne PCR  
VH1 FM 5’ CAG GTG CAG CTG GTG CAG TCT GG 3’ 
VH2 FM 5’ CAG GTC ACC TTG AAG GAG TCT GG 3’ 
VH3 FM 5’ GAG GTG CAG CTG GTG GAG TCT GG3’ 
VH4 FM 5’ CAG GTG CAG CTG CAG GAG TCG GG3’ 
VH5 FM 5’ GAG GTG CAG CTG GTG CAG TCT GG3’ 
VH6 FM 5’ CAG GTA CAG CTG CAG CAG TCA GG3’ 
IgA 5’ ACC AGG CAG GCG ATG ACC AC 3’ 
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IgG 5’ AAG TAG TCC TTG ACC AGG CAG C 3’ 
IgM 5’ AGG AGA CGA GGG GGA AAA GGG TTG 3’ 
 
OD= optical density; MW= molecular weight 
3.1.7 Kits 
Table 3-6: Kits 
Kit Manufacturer 
Tyrosine and serine/threonine Phosphatase assay  Promega, Madison, WI, USA 
AnnexinV, PI staining kit Miltenyi Biotec GmbH, Gladbach, Germany Stem  
Rosette Sep(R) depletion kit for CD3 and CD36 Roche Diagnostics GmbH, Mannheim, Germany 
Titan One tube RT-PCR System Sanquin Reagents, Amsterdam, Netherlands 
PeliKine CompactTM human soluble CD27 ELISA  Qiagen, Hilden, Germany 
QIAquick gel extraction  Roche Diagnostics GmbH 
AmpliTaq DNA Polymerase kit components Generic Assay, Berlin, Germany 
Hep-2 immunofluorescence assay Miltenyi Biotec GmbH, Gladbach, Germany 
B cell isolation Kit II (human) Miltenyi Biotec GmbH, Gladbach, Germany 
3.1.8 Software 
Table 3-7: Software 
Software Manufacturer 
FlowJoTM 7.6.5 software  Tree Star, Ashland, CR, USA Miltenyi 
Zen 2011 light edition software  Carl Zeiss, Jena Germany 
GraphPad Prism4 software GraphPad, San Diego, CA  
Chromas 2.33 sequence viewer Chromas Technelysim, Helensvale, Australia; link: 
http://joinsolver.niaid.nih.gov/ 
Joinsolver® software Tree Star, Ashland, CR, USA Miltenyi 
3.2 Patients and Methods 
3.2.1 Patients 
The study was approved by the local ethics committee of the Charité University Hospital 
Berlin and written consent was obtained by all patients and controls. EDTA or heparin 
anti-coagulated peripheral blood was taken from 50 healthy donors (HD) (40 females/10 
males) with a mean age of 35 years (range 25-58 years) and 82 patients suffering from 
SLE (76 females/6 males) with a mean age of 43 (range 22-79 years). The disease activity 
of the latter was assessed by the SLEDAI and was 7.7 (Range 1-32) which was calculated 
based on 25 different clinical and medical domains. All patients received 
immunosuppressive drugs; methotrexate, prednisone, azathioprine and mycophenolate 
mofetil. In addition, 15 rheumatoid arthritis (RA) patients (13 women, 2 men) mean age 
of 49, range 27-71 years) with a mean disease activity score (DAS 28) of 3.2 (range 1.8-
4.9) and 20 female primary Sjögren’s syndrome (pSS) patients (all anti-Ro/La Ab positive; 
mean age of 56, range 31-76 years) served as controls. For each blood sample the 
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differential cell count (measured by Micros60 Table 3-3) and the total B cell count (3.2.4) 
were determined.  
 
3.2.2 Cell isolation 
3.2.2.1 Peripheral blood mononuclear cell (PBMC) isolation 
PBMC were isolated by Ficoll density-gradient centrifugation. According to their specific 
density, lymphocytes and monocytes will be concentrated at the interphase between the 
plasma phase and the Ficoll layer. Erythrocytes and granulocytes will form a pellet 
because of their higher density. EDTA anti-coagulated whole blood or buffy coat was 
diluted 1:2 with PBS. 30 ml blood-PBS suspension was layered on 15 ml lymphocyte 
separation medium and centrifuged for 20 min at RT at 840xg w/o brake. The PBMC 
concentrated in the interphase, were collected in a fresh 50 ml tube and washed two 
times with 50 ml cold PBS/0.5% BSA using a centrifuge at 400xg for 10 min. After cell 
counting with a counting chamber (Neubauer), cells were resuspended either in pre-
warmed RPMI for stimulation assays, in RPMI/10% FCS for in vitro cultures or in cold 
PBS/0.5% BSA for FACS analysis and B cell purification. Trypan blue was used to 
exclude dead cell during the counting process. 
 
3.2.2.2 B cell purification  
B cells isolated from PBMC were purified using the human B cell isolation Kit II according 
to the manufacture’s protocol (Table 3-6).  
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Figure 3-1: Gating strategy and flow cytometric analysis of PBMC before and after B cell purification. A, PBMC 
were isolated from whole blood. After duplet exclusion lymphocytes were gated regarding their expression of CD3, 
CD14 and CD20, to identify the frequency of total CD20+ B cells (2.29%). Non-B cells were labeled with biotin 
conjugated Ab and anti-biotin magnetic beads. B, Magnetic labeled non-B cells bound to the magnetic column (positive 
fraction) whereas negative target B cell population runs through with a B cell purity of 92.90%. C, The positive fraction 
bound to the magnetic column contained only a small fraction of remaining B cells (0.88%).  
The B cell isolation Kit II labels non-B cells with magnetic beads and untouched B cells 
can be purified. Non-B cells (T cells, NK cells, monocytes, DCs, granulocytes and elytroid 
cells) were labeled with biotin conjugated Ab and afterwards by anti-biotin MicroBeads. 
These magnetic labeled cells bound to a magnetic MACS column and the negative target 
population (B cells) will remain untouched and appeared in the efflux fraction. Afterwards, 
the cells were washed (8 min at 250xg) with PBS/0.5% BSA/2 mM EDTA and 
resuspended in PBS. B cells were counted and an aliquot was used for the purity check 
by FACS analyses (3.2.6). Trypan blue was used to exclude dead cell during the counting 
process. A total B cell purity over 90% (Figure 3-1) was revealed as pure and was used 
for further B cell specific analysis. Cells were kept on ice for further assays. 
3.2.3 Flow Cytometry (FC) 
Flow cytometry, a fluidic-and laser-based method, was used to perform multi-parameter 
analysis on single cells. Besides the cell size and granularity, the expression of various 
surface and intracellular markers were determined by labeling cells with fluorochrome-
conjugated Ab specific for the marker of interest. Specific conjugated monoclonal Ab 
(Table 3-4) were used in a final staining volume of 50 µl. The staining time was depending 
on the Ab used. As a quality control, CST beads and rainbow beads according to the 
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manufacture’s instructions were measured before each FC analysis to ensure stable MFI 
values for the expression of surface markers and intracellular kinases over time.  
 
3.2.4 Determination of the total B cell count (TruCount) 
For the determination of the absolute B cell number, a specialized TruCount FACS tube 
was used which contains a pellet with a defined number of fluorescent beads. 20 µl 
TruCount Ab Mix (Table 3-8) and 50 µl anti-coagulated whole blood was pipetted in the 
TruCount tube and incubated at RT for 15 min. Afterwards, 450 µl TruCount Lysis solution 
was added incubated for additional 15 min at RT and cells were analyzed by FC using 
Canto II flow cytometer.   
 
Table 3-8: TruCount Ab Mix  
antibody conjugate clone company Volume [µl] 
CD14 PacB MT1 BD 1 
CD19 PE-Cy7 SJ25C1 BD 2 
CD20 FITC H147 BD 2 
CD45 PerCp 2D1 BD 3,5 
dest. water    11,5 
 
3.2.5 Intracellular staining 
For the analysis of different receptors and intracellular kinases regarding their 
phosphorylation and expression profile, 500 µl EDTA anti-coagulated whole blood or 
1x106 stimulated PBMC were immediately fixed with pre-warmed 1x Lyse/Fix Buffer for 
10 min at 37°C and subsequently washed with 4 ml ice cold PBS for 8 min at 600xg. 
Afterwards, cells were permeabilized with Perm Buffer II or III over night at -20°C or 30 
min on ice. After washing two times with 4 ml cold PBS/1% FCS for 8 min at 600xg cells 
were resuspended in 50 µl PBS/1% FCS and stained for 1h at RT (CD3-PacB, CD14-
PacB, CD19-APH-H7, CD20-PacO, CD27-APC and CD38-PE or CD22-PE, p-CD22-PE, 
p-Syk-PE, Syk-FITC, CD80-FITC, CD86-FITC, CD95-PE, Ki67-PE-Cy7, IgD-PE-Cy7 or 
CD21-PE, respectively), subsequently washed with 2 ml PBS/1% FCS and analyzed by 
FC using Canto II flow cytometer. Data were analyzed using FlowJo™ 7.6.5. software    
(Figure 3-2A). 
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3.2.6 Surface staining/purity check  
Cells were resuspended in 50 µl PBS/0.5% BSA and stained for 15 min at 4°C (purity 
check: CD3-PacB, CD14-PacB, CD19-APC-H7, CD20-PacO and CD27-APC). After 
washing 5 min at 350xg once with PBS/0.5 % BSA, 1µl DAPI was added and cells were 
analyzed by FC using Canto II flow cytometer (Figure 3-2B).  
 
Figure 3-2: Gating strategy and flow cytometric analysis. A, Whole blood was fixed, lysed, permeabilized and 
duplets were excluded. Lymphocytes were gated on their expression of CD3, CD14 and CD20, to identify the 
expression of different markers or intracellular kinases within CD20+CD27+ and CD20+CD27- B cells. B, After Ficoll, 
single lymphocytes were gated based on their expression of CD3, CD14 and CD19 to identify the expression of different 
markers in total CD20+CD27+ and CD20+CD27- B cells. 
 
3.2.7 Flow cytometric analysis of apoptosis by AnnexinV 
For the analysis of viable, apoptotic and necrotic B cells after BCR stimulation, an 
AnnexinV and propidium iodide (PI) staining was performed. AnnexinV binds to 
phosphatidylserine (PS) which is located on the cytoplasmic surface of the cell membrane 
in viable cells. In cells undergoing apoptosis PS translocate, to the outer leaflet of the 
membrane, and accessible for AnnexinV binding. Apoptotic but not necrotic cells are PI 
negative, since only necrotic cells with a permeable cell membrane leak PI. Therefore, 
viable cells (AnnexinV and PI double negative) can be distinguished from apoptotic 
(AnnexinV positive, PI negative) and necrotic (AnnexinV and PI double positive) cells. 
1x106 PBMC from SLE patients and HD were pre-incubated for 1h at 37°C in RPMI and 
subsequently stimulated with 12 µg/ml anti-IgM/IgG for 5 or 60 min at 37°C. As an 
AnnexinV negative control unstimulated cells were used. For a positive AnnexinV control 
cells were stimulated for 5 min with 3% H2O2. PBMC were immediately put on ice and 
washed with AnnexinV binding buffer. Afterwards cells were stained for 30 min on ice in 
the dark (CD3-PacB, CD14-PacB, CD19-PE-Cy7, CD20-PacO, CD27-APC and 
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AnnexinV). Stained cells were washed again with AnnexinV binding buffer and prior to 
analysis PI was added to the cells. The frequency of AnnexinV/PI double negative cells 
represented the proportion of viable cells. 
 
3.2.8 Intracellular phosphorylation kinetics 
PBMC were isolated from SLE patients and HD and resuspended in RPMI (10x106 
PBMCs/ml). 1x106 cells were pre-incubated in a water bath for 1h at 37°C and 
subsequently stimulated with 12 µg/ml anti-IgM/IgG for different time points. PBMCs were 
immediately fixed after stimulation with 1 ml pre-warmed 1x Lyse/Fix Buffer and 
permeabilized with 200 µl Perm buffer II or III (3.2.5). Cells were afterwards stained at RT 
for 1 h (CD3-PacB, CD14-PacB, CD19-PE-Cy7, CD20-PerCp5.5, CD27-APC, Syk-FITC 
or p-PLC-γ2(Y759)-FITC and p-Syk(Y352)-PE or p-Syk(Y348)-PE, p-CD22(Y822)-PE, 
p-Akt(S473)-PE, respectively).  
 
3.2.8.1 After in vitro culture (resting)  
1x106 PBMC from SLE patients and HD were incubated for 24 h and 48 h at 37°C/5% 
CO2 in RPMI/10% FCS medium and subsequently stimulated at 37 °C with 12 µg/ml 
anti-IgM/IgG for 5 min. PBMC were immediately fixed and permeabilized after stimulation 
(3.2.5) and stained 1h at RT (CD3-PacB, CD14-PacB, CD20-PerCp5.5, CD27-APC, 
p-Syk(Y352)-PE and Syk-FITC). 
3.2.9 Confocal microscopy 
3.2.9.1 Whole blood analysis 
For analysis of the cellular distribution of intracellular Syk, 10 ml EDTA anti-coagulated 
whole blood from patients with SLE was fixed, lysed and permeabilized in 50 ml Lyse/Fix 
and 5 ml Perm II Buffer as described before (3.2.5). Cells were stained at RT for 1 h 
(CD3-PacB, CD20-PerCp5.5, CD27-APC and Syk-FITC). Three CD20+ B cell 
populations were sorted: CD27-Syk+, CD27-Syk++ and CD27+ by using the FACSAria™ 
cell sorter. 0.15x105 sorted B cells were incubated with the primary Ab rabbit anti-human 
IgM at 5 µg/ml for 40 min at RT. Subsequently, cells were washed once with 3 ml PBS/1% 
FCS and stained with the secondary Ab donkey anti-rabbit IgG Rhodamine Red X (RRX) 
for 40 min at RT. Cells were centrifuged at 250xg for 1 min and covered with Vectashield 
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Hard set mounting medium with DAPI. Afterwards, the cells were measured using Zeiss 
LSM 710 confocal microscopy (magnification: 630x). For quantitative determination, the 
subcellular distribution by single cells was analyzed with Zen 2011 light edition software.
  
  
3.2.9.2 BCR stimulation analysis 
B cells were enriched from whole blood before sorting using RosetteSep® Human CD3 
and CD36 depletion Cocktail according to the manufacturer’s protocol. Briefly, 20 µl 
anti-CD3 and 20 µl anti-CD36 tetrameric Ab complexes were added to 10 ml EDTA whole 
blood and incubated at RT for 20 min. CD3+ T cells and CD36+ monocytes were 
cross-linked to red blood cells by the tetrameric Ab complexes recognizing simultaneously 
CD3 or CD36 and the red blood cell specific marker glycophorin A. After separation by 
Ficoll density-gradient centrifugation the labeled CD3+ and CD36+ cells together with the 
red blood cells formed a pellet because of their higher density. B cell enriched 
lymphocytes will be concentrated at the interphase between plasma and Ficoll. 0.5x106 
B cell enriched PBMC were incubated at 37°C for 1 h and subsequently stimulated with 
12 µg/ml goat anti-human IgM/IgG for 5 min. Afterwards cells were fixed and 
permeabilized as recorded previously (3.2.5). For analyzing the capping and recruitment 
of SHP-1 to CD22 and CD22 to the BCR, cells were stained at RT for 40 min with 
epratuzumab-biotin (bio, UCB), goat anti-human IgM/IgG (unstimulated control only) and 
mouse anti-human SHP-1. Cells were washed once with 3 ml PBS/1% FCS and stained 
at RT for 40 min with the secondary Ab donkey anti-goat FITC, Streptavidin-Alexa 633 
and donkey anti-mouse RRX. Fixed, permeabilized and stained cells were centrifuged at 
250 g for 1 min on a slide and covered with Vectashield Hard set mounting medium with 
DAPI. Afterwards, the cells were measured using Zeiss LSM 710 confocal microscopy 
(original magnification: 630x). For quantitative determination, the co-localization 
coefficient by single cells (CD22+, IgM+/IgG+ B cells) were analyzed with Zen 2011 light 
edition software.  
 
3.2.10 Calcium flux assessment 
B cells were purified by using human B cell isolation Kit II (3.2.2.2). 0.5x106 B cells were 
washed in RPMI/10% FCS and loaded with Indo-1 acetoxymethyl (AM) dye at 0.2 µM at 
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37°C for 30 min. B cells were washed with PBS/0.5% BSA and stored on ice. 
Measurements were performed by using a LSR II flow cytometer. Before stimulation 
B cells were pre-incubated at 37°C for 5 min and afterwards the baseline was recorded 
for 40 sec, then 12 µg/ml anti-IgM/IgG was added and changes in the intracellular calcium 
(Ca2+) concentration were recorded for 6 min. The intracellular Ca2+ concentration was 
quantified by calculating the ratio of 405 nm/ 475 nm Indo-1 AM emission (bound/unbound 
indo). 
 
3.2.11 Tyrosine and serine/threonine phosphatase activity assay 
B cells isolated from HD and SLE patients were purified using human B cell isolation Kit 
II as indicated above (3.2.2.2). 1x106 purified B cells were lysed in 100 µl Pierce IP Lysis 
buffer supplemented with 1% protease inhibitor cocktail on ice for 30 min and centrifuged 
afterwards 15 min 17.000xg at 4°C. The lysate was diluted 1:4 with phosphatase storage 
buffer (177). Supernatants were analyzed regarding their phosphatase activity by using 
the phosphatase assay system kit according to the manufacture’s instruction (tyrosine 
and serine/threonine phosphatase assay, Table 3-6). Endogenous phosphate was 
removed from the lysate by Sephadex G-25 spin columns supplied with the kit. 
Specialized phosphorylated peptides for tyrosine and serine/threonine phosphatases 
were used as substrate (Tyrosine-1: END(pY)INASL, Tyrosine-2: DADE(pY)LIPQQG, 
Serine/Threonine: RRA(pT)VA). Each lysate was incubated with or without 100 µM 
substrate for 15 min at 37°C and free phosphate which was released during the reaction 
was detected by a molybdate solution at 600 nm by using a SpectraMax190 microplate 
reader. The background (lysate without phosphopeptide) was subtracted. A phosphate 
standard curve was generated and used as reference for the B cell lysates. As control, 
phosphatase inhibitors were used (10 mM sodium fluoride or sodium orthovanadate). 
 
3.2.11.1 Preparation of sodium orthovanadate 
A 100 mM sodium orthovanadate solution at pH of 10 was prepared and boiled until the 
solution was colorless. Afterwards the solution was cooled down on ice and the pH was 
calibrated again (pH 10). If the solution turns yellow/orange again after cooling, boiling 
and cooling process have been repeated as well as pH adjustment until the solution 
appeared to be colorless during the cooling procedure with a final pH of 10. 
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3.2.11.2 Tyrosine phosphatase inhibition for intracellular phosphorylation 
analysis 
1x106 isolated PBMC from SLE patients and HD were pre-incubated for 1h at 37°C in 
RPMI, pre-treated with 10 mM of sodium orthovanadate for 5 min at 37°C and 
subsequently stimulated with 12 µg/ml anti-IgM/IgG for 5 min. PBMC were immediately 
fixed and permeabilized (3.2.5) and stained 1h at RT (CD3-PacB, CD14-PacB, 
CD20-PerCp5.5, CD27-APC, p-Syk(Y352)-PE and Syk-FITC). 
 
3.2.12 Tetanus (TT) vaccination 
During a TT vaccination study 6 HD (3 female and 3 male; average age of 36 with an age 
range of 26-55) underwent secondary immunization against TT/ diphtheria toxoid (20 
immunization units TT and 2 immunization units diphtheria toxoid). Whole blood was 
drawn and analyzed at day 0, 6, 7 and 14 after vaccination with the tetanus/diphtheria 
toxoid to assess the frequency of CD27-Syk++ and CD19+CD27++ B cells. Therefore 
whole blood was fixed and permeabilized as described previously (3.2.5) and stained 1h 
at RT (CD3-PacB, CD14-PacB, CD19-PE-Cy7, CD20-PacO, CD27-APC and Syk-FITC).  
3.2.13 ATP-binding cassette (ABC)-B1 transporter activity 
For the analysis of the ABC-B1 transporter activity a MitoTrackerOrange (MTO) staining 
was performed. MTO is an orange-fluorescent dye that stains mitochondria and 
accumulates in live cells. The ABC-B1 (P-glycoprotein) transporter is an ATP dependent 
drug pump and decreases the accumulation of different drugs including 
MitoTrackerOrange in the cell. If cells express an active ABC-B1 transporter, like naïve 
CD27- B cells, MTO will not accumulate in these cells. Therefore, those cells would be 
negative for MTO. In contrast, memory (CD27+) or transitional (CD27-CD24++CD38++) 
B cells show an inactive ABC-B1 transporter. The MTO dye accumulates in these cells 
(MTO positive). 100 µL EDTA anti-coagulated whole blood was incubated with 1 mM 
MTO CMTMRos for 30 min at 37°C and subsequently fixed, lysed and permeabilized with 
Perm Buffer II 30 min on ice as delineated before (3.2.5). Afterwards cells were stained 
at RT for 1 h (CD3-PacB, CD20-PerCp5.5, CD27-APC, CD38-PE and Syk-FITC). FC 
Material and methods 
45 
 
analysis was performed after one washing step using Canto II flow cytometer. Data were 
then analyzed using FlowJo™ 7.6.5. software. 
 
3.2.14 Real time (RT)-PCR of immunoglobulin mRNA from single cells 
3.2.14.1 Single cell sort and cDNA synthesis 
Fixed and permeabilized PBMC according to the manufacturer’s protocol from BD (3 
patient samples SLE#1-SLE#3) were incubated for 1 h at RT using the following 
anti-human Ab: CD3-PB, CD14-PB, CD19-PECy7, CD27-APC and Syk-FITC. For SLE#4 
isolated PBMC were incubated for 15 min at 4°C using the following anti-human Ab: 
CD3-PacB, CD14-PacB, CD19-PECy7, CD27-APC and CD38-PE. For each of four SLE 
patients, single CD3-CD14-CD19+CD27-Syk+ and CD3-CD14-CD19+CD27-Syk++ cells 
(SLE#1-SLE#3) or CD3-CD14-CD19+CD27-CD38+ and CD3-CD14-CD19+CD27-CD38- 
cells (SLE#4), respectively, were sorted into a 96-well plate (round bottom) using a 
FACSAria cell sorter (BD). Each well was pre-loaded with 30 µl reaction mix containing 
8.3 mM DTT, 0.8 nM Spermidin, 0.5 µg BSA, 20 U RNasin Plus RNase inhibitor and 1.7% 
TritonX. After the FACS sort 20 µl of a second mix containing the Titan One Tube kit’s 
RT-PCR buffer and AMV reverse transcriptase (Table 3-6), prepared according to the 
manufacturer’s instruction, supplemented with the p(dT)15 Primer  and 0.5 mM dNTPs 
was added and cDNA was generated at 50°C for 60 min. 
 
3.2.14.2 Nested PCR and sequence analysis 
To amplify the cDNA of rearranged VHDJHCµ transcripts a nested PCR protocol was 
performed. For the external and internal PCR the final reaction mix consisted of the 
AmpliTaq DNA Polymerase kit components prepared according to the manufacturer’s 
instructions (Table 3-6) and supplemented with 0.2 mM dNTPs and 0.06 µM of each of 
the external and internal primers, respectively. Specific oligonucleotide sequences for the 
external and internal PCR as shown in Table 3-5 a forward primer set for VH1-VH6 regions 
as well as a reverse isotype-specific IgA, IgG and IgM primer set was used. 5 µl of the 
generated cDNA were used as a template for the external PCR. Thermo cycler conditions 
for the external PCR were as followed: 95°C for 2 min, 50 cycles of 95°C for 1 min, 56°C 
annealing temperature for 30 s, and 72°C for 1.5 min, with a final extension at 72°C for 
10 min and a ramping of 2.5°C/s. 5 µl of the external PCR products were used as template 
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for the internal PCR. The internal PCR was performed in an identical manner, except for 
the annealing temperature, which was set to 58°C. PCR products were separated by 
agarose gel electrophoresis, visualized with gelred by exposure to UV light and purified 
by using a QIAquick gel extraction kit according to the manufacturer’s instruction (Table 
3-6). PCR products were sequenced at Eurofins MWG Operon. The sequences were 
analyzed using the Chromas 2.33 sequence viewer and the Joinsolver® software (Table 
3-7). 
 
3.2.15 Plasma cell differentiation in vitro 
PBMC were isolated and stained at 4°C for 15 min against human CD3-PacB, CD14-
PacB, CD19-PE-Cy7, CD27-APC and CD38-PE. Three CD3-CD14-CD19+ B cell 
populations were sorted: CD27+CD38+/-, CD27-CD38+ and CD27-CD38-, respectively 
using a BD FACSAria™ cell sorter. Sort-purified B cell populations were seeded with 
0.5x105 cells per well (96-well round bottom) and cultured for 5 days at 37°C/5% CO2 in 
RPMI/10% FCS in the presence of IL-2 (40 ng/ml), IL-10 (40 ng/ml), anti-human IgM/IgG 
(2 µg/ml) and CpG oligodeoxynucleotides (2.5 µg/ml, ODN 2006). The supernatants were 
collected and subsequently frozen at -70°C until further analyses. The cells were washed 
once with 2 ml PBS/0.5% BSA and stained for 15 min at 4°C (CD3-PacB, CD14-PacB, 
CD20-PacO, CD27-APC and CD138-PE) for FC analysis or cultured for further ELISPOT 
experiments. 
 
3.2.16 Detection of immunoglobulin secretion 
0.5x105 sorted B cells according to their expression of CD27 and CD38 were seeded per 
well and cultured with IL-2 (40 ng/ml), IL-10 (40 ng/ml), anti-human IgG/IgM (2 µg/ml) and 
CpG oligodeoxynucleotides (2.5 µg/ml, ODN 2006) for 5 days at 37°C/ 5% CO2. 
Supernatants were collected and levels of total IgG were measured by an enzyme-linked 
immunoabsorbent assay (ELISA) or the frequency of spontaneous IgG-producing cells 
was determined using ELISPOT.  
 
3.2.17 ELISPOT 
An ELISPOT plate was prepared using 15 µl of 35% ethanol per well. Afterwards the plate 
was washed 3 times with 100 µl PBS and coated with 50 µl anti-human IgG (5µg). The 
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plate was incubated over night at 4°C and washed afterwards 3 times with 100 µl PBS. 
Membranes were blocked with 100 µl TBS/2% BSA and 100µl 1:1 RPMI/10% FCS for 1 
h at 37°C and washed once. Cultured cells were washed two times with 200 µl cold RPMI 
(8 min 350xg) and a cell serial dilution (1:3, 1:9, 1:27, 1:81, 1:243, 1:729 and 1:2187) with 
a total volume of 150 µl was plated. As positive control, 10 µl serum from a HD was used. 
After 3 ½ h incubation at 37°C/ 5% CO2, plate was washed 6 times with cell removal 
buffer. For the detection, 50 µl anti-IgG-bio was added and incubated for 1h at RT. After 
washing with PBS 50 µl Streptavidin-HRP (30 min, RT) and thereafter 100 µl of the 
staining solution were added. The plates were incubation 5 min at RT (dark), washed with 
dest. water and dried over night. Dots were analyzed with an AID UV ELISPOT reader. 
 
3.2.18 ELISA 
96 well plates (NUNC, Germany) were coated (2 h, 37°C) with 50 µl anti-human IgG (5 
µg) in coating buffer. After removing the coating buffer plates were blocked with 200 µl 
TBS/2% BSA (1h, RT). Afterwards, the plates were washed and 50 µl culture supernatant 
or standard was pipetted and incubated on the shaker (2 h, RT, 300 rpm). Plates were 
washed 3 times with 200µl TBS/0.05% Tween and incubated with 100 µl anti-IgG-AP (2 
h, RT). Washing steps were repeated and finally the plates were incubated for 30 min at 
RT with 100 µl substrate (2 pNPP tablets dissolved in 10 ml Ethanolamine). The optical 
density (OD) was measured (405 nm) using a SpectraMax190 microplate reader. 
 
3.2.19 Detection of auto-IgG-Ab by indirect Hep-2 immunofluorescence assay 
The production of auto-Ab against nuclear and cytoplasmic antigens of sorted and 
cultured B cells (3.2.16) was analyzed by using indirect Hep-2 immunofluorescence 
assays    (Table 3-6). 25 µl of supernatant (5 days cell culture), positive and negative 
control (provided with the kit) were incubated for 30 min on immobilized Hep-2 cells. After 
three washing steps with PBS, the slides were incubated for 30 min with FITC labeled 
anti-human IgG Ab (provided with the kit). The cells were afterwards covered with 
Vectashield Hard Set mounting medium with DAPI. Bound auto-Ab were detected using 
Zeiss LSM 710 confocal microscope (x630 magnification) and processed by Zen2011 
light edition software.  
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3.2.20 Whole blood cell culture 
100 µl whole blood (Heparin) per well (96-well round bottom) were cultured at 
37°C/5% CO2 in the presence of BAFF (200 ng/ml), IFN-γ (200 ng/ml), TNF-α (200 ng/ml), 
IL-6 (200 ng/ml), IL-21 (200 ng/ml), LPS from Escherichia coli 055:B5 (2.5 µg/ml) or CpG 
oligodeoxynucleotides (2.5 µg/ml, ODN 2006) for 24 h. Afterwards the blood was fixed 
and permeabilized as described previously (3.2.5). Cells were stained at RT for 1 h (CD3-
PacB, CD14-PacB, CD19-PE-Cy7, CD20-PerCp5.5, CD27-APC and Syk-FITC) and 
analyzed by flow cytometry (FC) using a BD Canto II flow cytometer. Data were 
subsequently analyzed by using FlowJo™ 7.6.5. software. 
 
3.2.21 sCD27 ELISA 
A 96 well plate provided by the PeliKine Compact TM human soluble CD27 ELISA kit 
(Table 3-6) was coated with 100 µl anti-sCD27 in coating buffer at 4°C overnight. After 
removing the coating buffer plates were blocked with 200 µl TBS/2% BSA 1 h at RT. 
Afterwards, plates were washed twice with 100 µl 1x TBS and 100 µl of culture 
supernatant (1:1), serum (1:5) or standard (serial dilution: range 100-3.125 U/ml) were 
diluted in TBS/0.5% BSA, pipetted on the plate and incubated for 2 ½ h at RT on the 
shaker (300 rpm), washed 3 times with 200 µl TBS/0.05% Tween and incubated with 100 
µl anti-sCD27-Bio (1½ h, RT). Washing steps were repeated and the plates were 
incubated for 1 h at RT with 100 µl Streptavidin-HRP. After washing (TBS/0.05% Tween) 
100 µl 1-Step TMB-ELISA solution was added (15 min, RT). Reaction was stopped with 
100 µl 1.8 M H2SO4 and the OD was measured (450 nm) using a SpectraMax190 
microplate reader. 
 
3.2.22 Statistical analysis 
The statistical analysis was performed with GraphPad Prism4 software (GraphPad, San 
Diego, CA). Non-Gaussian distributed sets of paired data were analyzed using Wilcoxon 
signed-rank-test; other non-parametric data were compared using the Mann-Whitney 
test, and Fisher’s exact test was used for binary data analysis (contingency table). P 
values less than 0.05 were considered statistically significant. The data are shown as 
mean±SD if not otherwise indicated.  
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4. Results 
4.1 Dysbalanced BCR signaling in SLE B cells 
4.1.1 Increased expression and activation of the inhibitory BCR co-receptor 
CD22 and disturbed CD19/CD22 balance in CD27- SLE B cells 
The inhibitory co-receptor CD22 which is exclusively expressed on B cells plays a 
pivotal role during B cell differentiation and development (83). The development 
dependent CD22 expression regulates the signaling threshold and plays a crucial role in 
controlling peripheral tolerance (79, 83, 178). To assess the expression and activation of 
the inhibitory co-receptor CD22 in CD27+ and CD27- B cells, whole blood from 30 SLE 
patients and 22 HD was fixed, permeabilized and stained for CD22 and phosphorylated 
(p)-CD22 on tyrosine (Y) 822. Comparing CD27+ and CD27- B cells for their CD22 
expression showed enhanced expression levels of CD22 on CD27- compared to CD27+ 
HD and SLE B cells in their mean fluorescence intensity (MFI; Figure 4-1A). However, 
the expression of CD22 between HD and SLE patients revealed a significant increased 
expression of CD22 on CD27- but not CD27+ SLE B cells (HD: CD27+ 3849±1474, 
CD27- 7018±2486; SLE: CD27+ 4674±1654, CD27- 8546±2571; mean±SD, *p<0.05).  
No differences between whole blood CD27+ and CD27- B cells of HD and SLE 
patients was observed for the phosphorylation of CD22(Y822) which is responsible for 
the recruitment of the phosphatase SHP-1 (107) (Figure 4-1B). 
CD19, another BCR co-receptor, also plays an important role in regulating the BCR 
response. Indeed, disturbances of the balance between CD19 and CD22 (CD19/CD22 
loop) has been considered to be involved in autoimmune diseases (115, 116). Therefore, 
the expression of CD19 and the ratio of CD19 and CD22 in whole blood of SLE patients 
and HD were analyzed (Figure 4-1C). Although SLE and HD B cells express the same 
levels of CD19, the ratio of CD19 and CD22 showed a significant reduced balance of 
these two co-receptors on CD27- SLE B cells with a shift towards the inhibitory co-
receptor CD22 (Figure 4-1D). Here, the ratio of CD19/CD22 in CD27- B cells of HD was 
0.10±0.01 and of SLE patients 0.07±0.1 (mean±SD, ***p<0.001). 
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Figure 4-1: CD27- B cells from SLE patients expressed enhanced levels of CD22 and showed simultaneously 
a disturbed CD19/CD22 balance. Whole blood CD27+ (open square) and CD27- (filled square) B cells obtained from 
systemic lupus erythematosus (SLE) patients and healthy donors (HD) were analyzed regarding their CD22 (A, HD 
n=22; SLE n=30), p-CD22(Y822) (B, HD n=13; SLE n=16) and CD19 (C, HD n=10, SLE n=12) expression as well as 
their ratio of the mean fluorescence intensity (MFI) of CD19 and CD22 (D, HD n=10; SLE n=12) revealing an enhanced 
expression of CD22 and a reduced balance of CD19/CD22 expression in CD27- B cells from SLE patients. Each symbol 
represents an individual subject; horizontal lines show the mean; ***p>0.001, *p<0.05 by Mann-Whitney U test. 
In order to gain insights into potential intrinsic signaling abnormalities in SLE 
B cells and to analyze to which extent the increased expression of CD22 and disturbed 
CD19/CD22 balance influences the activation of CD22, the phosphorylation kinetic of 
CD22(Y822) after BCR stimulation (Figure 4-2) as well as the co-localization of SHP-1 
and the BCR with CD22 (Figure 4-3) were studied in B cells from SLE patients versus 
HD. Here analyses of the phosphorylation kinetic of CD22 after BCR stimulation showed 
a significantly increased phosphorylation level in CD27- SLE B cells compared to HD 
(Figure 4-2). After 15 and 30 min of BCR stimulation, CD27- SLE B cells displayed a 
significantly increased p-CD22 MFI of 913±188 (15 min) and 921±272 (30 min) compared 
to 633±136 (15 min) and 617±133 (30 min) in CD27- HD B cells (mean±SD, **p<0.01). 
Additionally, comparing the phosphorylation of CD22 after BCR activation in CD27+ 
versus CD27- B cells revealed an enhanced activation in CD27+ B cells in HD but not in 
SLE patients. Indeed, SLE CD27- B cells expressed higher levels of p-CD22 after BCR 
activation compared to CD27+ SLE B cells (15 min SLE: CD27+ 880±181, CD27- 
913±188; HD: CD27+ 857±186 CD27- 633±136, mean±SD; Figure 4-2B). This data are 
consistent with the enhanced expression of CD22 and shifted balance towards CD22 in 
CD27- SLE B cells (Figure 4-1). 
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Figure 4-2: Significantly enhanced activation of the inhibitory co-receptor CD22 by CD27- SLE B cells upon 15 
and 30 min of BCR stimulation. PBMC from 7 SLE patients and 7 HD were incubated with anti-IgM/IgG for 0, 2, 5, 
15, 30 and 60 min. CD27+ (open square) and CD27- (filled square) B cells from SLE patients (dotted) compared to HD 
(solid) were analyzed regarding their CD22(Y822) phosphorylation and showed significant enhanced expression of p-
CD22 after 15 and 30 min anti-IgM/IgG activation in CD27- SLE B cells. B cells were gated as CD3-, CD14-, CD20+ 
(data are represented as mean±SD; Mann Whitney U-test; **p<0.01).  
 
4.1.2 Normal recruitment of SHP-1 and CD22 to the activated BCR complex in 
B cells of SLE patients 
After BCR activation several kinases and co-receptors are recruited to the cytosolic 
part of the plasma membrane to form functionally competent signaling domains (lipid 
rafts)/ microclusters which modulate the B cell response by enhancing or in case of CD22 
dampening the signal transduction (62, 64) by influencing the BCR activation threshold 
(79, 83). In order to gain further insights into the functional relevance of CD22 expression 
in SLE B cells, the localization of CD22 and SHP-1 was analyzed upon BCR activation.  
Confocal microscopy studies addressed the co-localization of CD22, SHP-1 and 
the BCR after activation. These studies revealed a strong co-localization (co-localization 
coefficient >0.5) of these molecules after stimulation indicating a recruitment of SHP-1 to 
CD22 and CD22 to the activated BCR complex (Figure 4-3). In controls the co-
localization of CD22 with the BCR was 0.38±0.16 without and 0.61±0.21 with BCR 
activation, in SLE patients 0.37±0.23 without and 0.61±0.17 with BCR stimulation. Similar 
results were obtained for the recruitment of SHP-1 to CD22. Control B cells showed an 
increase of the co-localization coefficient from 0.38±0.14 to 0.53±0.17. In SLE B cells the 
co-localization was 0.40±0.21 before and 0.57±0.19 after BCR engagement. However, 
no significant differences between HD and SLE B cells could be observed (mean±SD; 
Figure 4-3B). 
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Figure 4-3: SLE B cells showed no disturbed co-localization of SHP-1 with CD22 or CD22 with the BCR after 
IgM/IgG activation. Purified B cells from SLE patients and HD were stimulated with RPMI (control) or anti-IgM/IgG for 
5 min and stained (A) for IgM/IgG (red), CD22 (green) and SHP-1 (magenta). DAPI (blue) was used to stain the nucleus 
(original magnification: 630x). B, SLE compared to HD B cells were analyzed regarding their co-localization coefficient 
(merge) of CD22 with the BCR or SHP-1 with CD22 after RPMI (open square) or anti-IgM/IgG stimulation (filled square) 
revealing no differences between HD and SLE patients. Each symbol represents an individual B cell of 3 SLE and 3 
HD; horizontal lines show the mean, Wilcoxon’s signed rank test. Co-localization coefficient over 0.5 (dotted line) 
reflects co-localization between the two molecules analyzed. 
This data indicate that the enhanced activation of CD22 upon BCR engagement 
in CD27- SLE B cells compared to HD is more likely due to a higher expression of CD22 
and reduced ratio of CD19/CD22 in these cells than a disturbed signalosome formation 
and recruitment of CD22 and SHP-1 to the activated BCR complex. 
 
4.1.3 Disturbed BCR response in patients with SLE 
4.1.3.1 Reduced BCR response regarding Syk in B cells of SLE patients 
compared to HD 
After BCR engagement a complex and tightly regulated signaling network 
becomes activated including the kinase Syk and further downstream PLC-γ2 but also Akt, 
a kinase which plays a crucial role in regulating the cell survival. To dissect potential 
implications of the enhanced CD22 phosphorylation of CD27- SLE B cells on the BCR 
Results 
54 
 
signaling, a comprehensive analysis on the phosphorylation of the BCR downstream key 
kinase Syk (Y352 and Y348), PLC-γ2 (Y759) and Akt on serine (S) 473 as well as on the 
intracellular Ca2+ mobilization upon BCR activation was performed (Figure 4-4 and 
Figure 4-6).  
At all-time points studied, total CD20+ B cells from SLE patients showed a reduced 
Syk(Y352) phosphorylation compared to HD (Figure 4-4A, B). After 5 min of anti-IgM/IgG 
stimulation (phosphorylation maximum of Syk(Y352)), CD20+ B cells from HD showed a 
p-Syk MFI of 2890±1636, while the p-Syk MFI of SLE CD20+ B cells was substantially 
lower (1670±402; mean±SD, *p<0.05). This difference was even more substantial when 
the phosphorylation efficiency of Syk in SLE and HD B cells was analyzed. Therefore, the 
ratio of the MFI of p-Syk and Syk was determined (Figure 4-4B). After 5 min BCR 
activation, B cells from HD displayed a MFI ratio of p-Syk(Y352)/Syk of 0.46±0.18 
compared to the ratio of SLE B cells with 0.26±0.07 (mean±SD, **p<0.01, *p<0.05). This 
significantly lower ratio of SLE B cells was found at all-time points consistent with a 
globally reduced Syk phosphorylation efficiency in SLE.  
Further analysis dissected CD20+ B cells into conventional CD27- naïve and 
CD27+ memory B cells. It has been shown that the thresholds of BCR dependent 
activation differs between these two B cell subsets (179) (Figure 4-4C). Interestingly, HD 
but not SLE patients showed stronger p-Syk(Y352) MFI values upon BCR stimulation in 
CD27+ B cells compared to CD27- B cells. CD27+ B cells from HD showed a p-Syk MFI 
of 3556±1744 and CD27- of 2731±1656  after 5 min of BCR stimulation, respectively 
(mean±SD, **p<0.01).   
In contrast, CD27+ B cells from SLE patients showed only a modest increase in 
p-Syk MFI of 1689±600, whereas CD27- B cells developed a p-Syk MFI of 1704±483 
(mean±SD, ns=1.00). The distinct p-Syk response of CD27+ versus CD27- B cells seen 
in controls was not detectable in B cells from SLE patients. 
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Figure 4-4: Diminished Syk and PLC-γ2 phosphorylation as well as a reduced Ca2+ influx upon BCR activation 
is a characteristic of SLE B cells. A, Representative histograms comparing the p-Syk(Y352) expression by CD20+ 
B cells from SLE patients and HD after 5 min RPMI (control) or anti-IgM/IgG stimulation. B, PBMC from SLE patients 
(n=9) and HD (n=10) were stimulated with anti-IgM/IgG for 0, 1, 2, 5, 8, 15 and 30 min. Comparative time kinetics of 
CD20+ B cells from SLE patients (dotted line) and HD (solid line) regarding their Syk phosphorylation (Y352) as well 
as the MFI ratio of p-Syk(Y352)/total Syk are shown (data are represented as mean±SD, *p<0.05 and **p<0.01 by 
Mann Whitney U-test). C, Phosphorylation of Syk was analyzed for CD27+ (open square) and CD27- (filled square) 
B cells, respectively (data are represented as mean±SD, *p<0.05 and **p<0.01 by Mann Whitney U-test). D, PBMC 
from 5 SLE patients and 5 HD were stimulated with anti-IgM/IgG for 0, 1, 2, 5, 8 and 30 min. CD27+ (open square) and 
CD27- (filled square) B cells of SLE patients and controls were analyzed regarding their Syk(Y348) and PLC-γ2(Y759) 
phosphorylation (data are represented as mean). E, Representative time kinetic of the intracellular Ca2+ concentration 
of Indo 1-AM-loaded CD27+ and CD27- B cells after BCR stimulation (SLE patients: CD27+=red; CD27- =light red;  
HD: CD27+=black; CD27-= grey; n=3). This data disclose a disturbed BCR response in SLE B cells and showed 
comparable responses of CD27- and CD27+ SLE B cells compared to HD.    
Interestingly, analyzing another important Syk phosphorylation site (Y348) 
revealed similar results as found for Y352 (Figure 4-4D). CD27+ as well as CD27- SLE 
B cells displayed reduced phosphorylation kinetics regarding Syk(Y348) and diminished 
phosphorylation responses between these two B cell subsets compared to controls. Here, 
p-Syk(Y348) revealed a MFI of 876±433 for CD27+ and 772±381 for CD27- SLE B cells 
Results 
56 
 
after 5 min of BCR stimulation. The mean MFI value for HD was substantially higher 
(CD27+: 1461±381, CD27- 1119±293; mean±SD).  
To analyze disturbed downstream signaling events in SLE patients, the 
phosphorylation of PLC-γ2(Y759) as well as the Ca2+ influx were studied after BCR 
stimulation. Comparable to the phosphorylation response of Syk, PLC-γ2 displayed 
reduced phosphorylation amplitude after stimulation with anti-IgM/IgG (Figure 4-4D). The 
control group showed MFI values of 4933±2734 in CD27+ and of 4152±3051 in CD27- 
B cells compared to SLE patients with a MFI of 1300±453 in CD27+ and of an even higher 
value of 1406±481 in CD27- B cells. In addition, a reduced BCR-induced Ca2+ 
mobilization in both CD27+ and CD27- B cell subsets in patients with SLE was detected 
compared to B cells from HD (Figure 4-4E). Interestingly and consistent with the findings 
for p-Syk and p-PLC-γ2, no differences in BCR-induced Ca2+ mobilization between CD27- 
and CD27+ SLE B cells were observed.  
 
4.1.3.2 Isotype independent reduced Syk activation after BCR stimulation in 
patients with SLE 
A recently published paper investigated different phosphorylation patterns after 
BCR activation in switched (IgG+) versus pre-switch (IgM+) memory B cell showing a 
reduced BCR response in pre-switch IgM+ memory B cells (75). Therefore, the 
distribution of IgM+ and IgG+ memory B cells in SLE patients compared to HD as well as 
the Syk phosphorylation after IgM activation was analyzed. Since no differences between 
the percentage of IgM+ and IgG+ B cells within the CD27+ B cell subset of SLE and HD 
has been found (HD: IgM+ 49.2±8.6%, IgG+ 28.5±12.4%; SLE: IgM+ 58.6±16.3%, IgG+ 
23.6±10.9; mean±SD; Figure 4-5A), the reduced Syk phosphorylation in SLE CD27+ 
B cell is not related to an enhanced occurrence of less responsive IgM+ memory B cells 
in these patients and reflect rather an intrinsic molecular defect. Stimulation with only anti-
IgM revealed a reduced Syk phosphorylation in CD27+IgM+ memory B cells of SLE 
patients compared to controls (Figure 4-5B). CD27+ SLE B cells had p-Syk MFI values 
after 5 min BCR activation of 2957±883 compared to 3941±1075 of healthy controls 
indicating a global reduction of Syk activation after BCR stimulation in CD27+ memory 
B cells of SLE patients independent of their isotype. 
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Figure 4-5: Comparable frequencies of IgM+ and IgG+ memory B cells in SLE and HD but reduced Syk 
phosphorylation kinetics in IgM+ memory B cells of SLE patients after BCR activation. A, The frequency of 
CD27+IgM+ and CD27+IgG+ memory B cells from SLE (filled square) compared to HD (open square), respectively are 
shown demonstrating no differences between HD and SLE patients regarding the occurrence of IgM or IgG memory 
B cells. Each symbol represents an individual subject of 5 SLE and 4 HD; horizontal lines show the mean, Mann 
Whitney U-test. B, PBMC from 5 SLE patients and 6 HD were stimulated with anti-IgM for 0, 5, 10, 15 and 30 min. 
CD27+ B cells (open square) of SLE patients (dotted line) and controls (solid line) were analyzed regarding their 
Syk(Y352) phosphorylation revealing also in CD27+IgM+ SLE B cells a reduced BCR response (data are represented 
as mean). 
 
4.1.3.3 Hyperactive Akt phosphorylation and imbalanced p-Syk/p-Akt ratio on 
B cells of SLE patients 
In contrast, phosphorylation of Akt(S473) after BCR activation unfolded a 
significantly increased Akt activation in SLE B cells compared to HD (Figure 4-6A). After 
5 min BCR activation CD27- B cells from SLE patients showed Akt phosphorylation MFI 
values of 1786±395 compared to 1015±583 in HD (mean±SD, *p<0.05). After 15 min 
anti-IgM/IgG stimulation (phosphorylation maximum of Akt(S473)) an enhanced response 
has been even observed in both CD27 B cell subsets (HD: CD27+ 1382±598 MFI, CD27- 
961±534 MFI; SLE: CD27+ 2151±804 MFI, CD27- 1848±505 MFI; *p<0.05, **p<0.01). 
After 30 min of BCR stimulation CD27- SLE B cells revealed enhanced p-Akt MFI values 
(SLE: 1747±471, HD: 921±523; *p<0.05) demonstrating a higher Akt phosphorylation in 
patients with SLE especially in CD27- B cells. Since an enhanced activation of Akt in SLE 
patients was observed, a global or general unresponsiveness of SLE B cells related to 
chronic in vivo activation, therapeutic interventions or disease activity is rather unlikely. 
In line with this, no correlation between the BCR response regarding p-Syk or p-Akt and 
the treatment or the SLE disease activity index (SLEDAI) of these patients has been 
observed (data not shown). 
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Figure 4-6: Enhanced activation of the pro-survival kinase Akt and disturbed balance between the p-Syk and 
p-Akt pathway in CD27+ and CD27- SLE B cells after BCR activation. A, PBMC from SLE patients (dotted, n=7) 
and HD (solid, n=8) were stimulated with anti-IgM/IgG for 0, 5, 10, 15 and 30 min and the phosphorylation of Akt at 
serine (S) 473 in CD27+ (open square) and CD27- (filled square) B cells were analyzed showing enhanced 
phosphorylation kinetics in CD27+ and CD27- SLE B cells. B cells were gated as CD3-, CD14-, CD20+, CD27+ or 
CD27- (data are represented as mean±SEM, **p<0.01, *p<0.05 by Mann Whitney U-test). B, The ratio shown here of 
p-Syk(Y352) (5 min) and p-Akt(S473) (15 min) was analyzed in CD27+ (open square) and CD27- (filled square) B cells 
from SLE compared to HD demonstrating a disturbed balance between this two kinases analyzed. Each symbol 
represents an individual subject of 10 SLE and 6 HD; horizontal lines show the mean, Mann Whitney U-test; ***p<0.001, 
**p<0.01). 
Subsequent studies addressed the balance of Syk and Akt activation by using the 
ratio of p-Syk/p-Akt, since the B cell fate is determined by the equilibrium of different 
signaling pathways (56). A significant decreased p-Syk/p-Akt ratio in CD27+ and CD27- 
B cells was found in patients with SLE clearly demonstrating a shifted balance towards 
the pro-survival kinase Akt (Figure 4-6B). Here CD27+ B cells of HD showed a p-Syk/p-
Akt ratio of 2.88±0.81 and CD27- B cells of 2.99±1.00. SLE patients had a ratio of 
1.40±0.21 for CD27+ and 1.63±0.49 for CD27- B cells (mean±SD, **p<0.01, ***p<0.001), 
respectively. No significant differences were observed between CD27+ and CD27- B cells 
of HD and SLE patients, exhibiting a comparable balance of Syk and Akt activation in 
these two B cell subsets. Interestingly, in both B cell subsets (CD27+ and CD27- B cells) 
a striking positive correlation between the ratio of CD19/CD22 expression and the ratio 
of p-Syk/p-Akt has been found (CD27+ r=0.6400, CD27- r=0.5742, *p<0.05, **p<0.01;  
Figure 4-7) although the CD19/CD22 ratio was only significantly decreased in SLE CD27- 
B cells. This data indicate that the balance of the BCR co-receptors CD19 and CD22 and 
the balance between Syk and Akt pathways are strongly interdependent.  
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Figure 4-7: The balance of CD19/CD22 expression correlates with the balance of Syk and Akt phosphorylation 
after BCR activation. Pearson’s correlation analysis of the ratio of CD19/CD22 expression and the MFI ratio of p-Syk 
(5 min)/p-Akt (15 min) upon anti-IgM/IgG stimulation in CD27+ (open square, r=0.6400) and CD27- B cells (filled square, 
r=0.5742) is shown. This data indicate that the expression of the BCR co-receptors CD19 and CD22 directly regulates 
the activation strength of the two signaling pathways in CD27+ as well as in CD27- B cells. Each symbol represents an 
individual subject of 10 SLE and 6 HD; **p<0.01, *p<0.05. 
 
4.1.4 Increased tyrosine phosphatase activity in patients with SLE 
It has been shown earlier that a balanced kinase/phosphatase (e.g. Syk/SHP-1) 
equilibrium plays a crucial role for normal B cell signaling, development and function (90). 
Based on the observation, that SLE B cells exhibited a reduced Syk phosphorylation on 
tyrosine 352, tyrosine 348 and on PLC-γ2 tyrosine 759 but enhanced Akt phosphorylation 
on serine 473, the tyrosine and serine/threonine phosphatase activity was analyzed in 
phosphate free B cell lysates. Specific phosphorylated peptides (Tyr-1, Tyr-2 and Ser/Thr) 
were used as substrate to assess the tyrosine and serine/threonine phosphatase 
activities.  
Dephosphorylation of the peptides by phosphatases in the B cell lysates of SLE 
patients and controls including the tyrosine phosphatase SHP-1 led to an increase of free 
phosphate. Therefore, a high concentration of free phosphate is consistent with an 
elevated phosphatase activity in the corresponding B cell lysate. As shown in Figure 4-8A 
a higher phosphate concentration (pMol free phosphate/ 0.5x105 B cells) after incubation 
of the Tyr-1 with the B cell lysate from SLE patients was measured resulting in an 
enhanced tyrosine phosphatase activity in these patients (HD: Tyr-1 1549±198; SLE: Tyr-
1 3140±1550 mean±SD, *p<0.05). For Tyr-2 and Ser/Thr no differences have been seen 
between HD and SLE patients.   
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Figure 4-8: Enhanced tyrosine phosphatases activity which directly influenced the phosphorylation of 
Syk(Y352) after BCR activation in B cells from SLE patients. A, Tyrosine (Tyr-1 and Tyr-2) and serine/threonine 
(Ser/Thr) phosphatase activity was measured in phosphate free B cell lysates from 6 SLE patients (filled bar) and 5 HD 
(open bar) represented by the concentration of cleaved phosphate in pMol/0.5x105 B cells. Background was subtracted. 
Specificity was analyzed by phosphatase inhibitors (sodium orthovanadate (Van)= inhibits tyr phosphatases; sodium 
fluoride (NaF)= inhibits ser/thr phosphatases, grey bar; data are represented as mean±SD, *p<0.05 by Mann Whitney 
U-test. B, Pearson’s correlation between the p-Syk(Y352) or p-Akt(S473) MFI and the free phosphate per 0.5x106 
B cells in pMol in patients with SLE (n=5); Tyr-2 r=-0.8856, Tyr-1+Tyr-2 r=-0.8882, *p<0.05.  
To validate the specificity, the phosphatase inhibitors sodium orthovanadate (Van; 
tyrosine phosphatase inhibitor) or sodium fluoride (NaF; serine/threonine phosphatase 
inhibitor) were added and could demonstrate a specific inhibition of the phosphatase 
activity (Tyr-1+Van 250±32, Tyr-1+NaF 2631±42; Ser/Thr+Van450±30, Ser/Thr+NaF3±4; 
mean±SD; Figure 4-8A). 
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In addition, for the phosphorylated peptide Tyr-2 and the combination of Tyr-1+Tyr-
2 a significant correlation between the concentration of free phosphate and the 
phosphorylation of Syk(Y352) after 5 min BCR activation was determined (Tyr-2 r=-
0.8856, Tyr-1+Tyr-2 r=-0.8882, *p<0.05; Figure 4-8B). This data revealed a negative 
correlation between the tyrosine phosphatase activity and the BCR response regarding 
Syk but not between the serine/threonine tyrosine phosphatase activity and the activation 
of Akt after BCR engagement. Since no differences between SLE and controls regarding 
their phosphatase activity specific for Tyr-2 and Ser/Thr peptides were measured, a 
general abnormality of phosphatase activity in SLE patients can be excluded. 
 
Figure 4-9: Inhibition of tyrosine phosphatase activity led to an enhanced Syk phosphorylation and shifted 
balance of p-Syk/p-Akt towards the tyrosine kinase Syk in SLE B cells. Syk(Y352) and Akt(S473) phosphorylation 
(A) and the ratio of p-Syk/p-Akt (B) was measured in BCR activated B cells with (filled square) and without pre-treatment 
(open square) with 10mM sodium orthovanadate from 6 SLE patients; each symbol represents an individual subject; 
*p<0.05 by Wilcoxon’s signed rank test.  
 
Furthermore, treatment of SLE PBMC with sodium orthovanadate which inhibits 
specific the tyrosine phosphatase activity significantly enhanced the phosphorylation of 
Syk(Y352) after BCR activation and shifted the ratio of p-Syk/p-Akt towards Syk 
phosphorylation (Figure 4-9). The MFI of p-Syk increased from 3623±979 to 5804±2565 
in CD27+ B cells and from 2910±718 to 8624±8144 in CD27- B cells (mean±SD, *p<0.05). 
As a control, no difference between the phosphorylation of Akt(S473) has been observed 
after 15 min anti-IgM/IgG stimulation with or without sodium orthovanadate pre-treatment 
(Figure 4-9A). The ratio of p-Syk/p-Akt shifted in CD27+ B cells from 2.07±0.85 to 
3.49±1.58 and in CD27- B cells from 1.98±0.59 to 5.87±5.6 (mean±SD, *p<0.05; Figure 
4-9B).  
These observations raise the interesting possibility that the disturbed CD22/CD19 
balance of SLE B cells is related to an enhanced activity of tyrosine phosphatases and 
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leads to a reduced Syk and PLC-γ2 phosphorylation with disturbed Ca2+ mobilization after 
BCR activation. Furthermore, it indicates that the disturbed tyrosine phosphatase activity 
in SLE patients controls the balance between the p-Syk and p-Akt signaling pathway. 
 
4.1.5 Imbalanced BCR signaling in SLE patients led to an increased survival of 
SLE B cells 
To investigate the consequences of the dysbalanced p-Syk/p-Akt ratio towards the 
pro-survival kinase Akt, the survival of anti-IgM/IgG stimulated B cells using the frequency 
of viable (AnnexinV and PI double negative) cells was analyzed as a function of the BCR 
response. For this purpose an AnnexinV/PI staining was performed on 60 min anti-
IgM/IgG stimulated compared to unstimulated B cells (Figure 4-10A). The viability of 
CD27+ as well as CD27- B cells after 60 min BCR activation appeared to be significant 
correlated with the ratio of p-Syk/p-Akt observed after 5 min BCR stimulation for p-Syk 
and 15 min BCR stimulation for p-Akt (phosphorylation maximum of both kinases) (Figure 
4-10B). This data showed a direct impact of the shifted balance towards Akt and the 
enhanced survival of CD27+ and CD27- B cells. Therefore, the imbalanced BCR signaling 
towards Akt activation in SLE patients may result in a survival advantage of 
(auto)-reactive B cells.  
 
Figure 4-10: Shifted balance towards Akt phosphorylation enhances the survival of B cells. A, Representative 
dot plots are shown for the gating strategy of viable CD27+ and CD27- B cells (AnnexinV-/PI-) after 5 and 60 min 
anti-IgM/IgG stimulation. H2O2 treated cells were used as AnnexinV/PI positive control. B, Pearson’s correlation 
between the ratio of p-Syk/p-Akt and the frequency of viable cells after 60 min anti-IgM/IgG stimulation in CD27+ (open 
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square) and CD27- (filled square) B cells indicating that enhanced phosphorylation of Akt is related with enhanced 
survival. Each symbol represents an individual subject of 4 SLE and 4 HD; *p<0.05, **p<0.01.  
 
4.1.6 Disturbed BCR response in SLE patients is independent of an in vivo 
pre-activation 
To determine to which extent an in vivo pre-activation could lead to this 
hyporesponsive phenotype in SLE patients regarding Syk, a comprehensive analysis on 
whole blood CD27+ and CD27- B cells from HD and SLE patients regarding their 
expression of CD80 and CD86 was performed (Figure 4-11). The co-stimulatory 
molecules CD80 and CD86 play an important role during immune activation and can be 
used as activation marker for in vivo activation (180).  
As shown in Figure 4-11B, a significant increased frequency of CD27+CD86+, 
CD27-CD86+ as well as CD27-CD80+ B cells in SLE patients compared to HD was 
observed as it has been described previously (181).  
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Figure 4-11: The aberrant BCR response of SLE B cells is independent of an in vivo pre-activation represented 
by the occurrence of CD80+ and CD86+ B cells. A, Representative dot plots and histograms are shown for the gating 
strategy of CD86+ and CD80+ B cells within CD19+CD27+ and CD19+CD27- B cell subsets. B, Whole blood CD27+ 
(open square) and CD27- (filled square) B cells obtained from 14 SLE patients and 9 HD were analyzed regarding their 
frequency of CD86 and CD80 positive cells. Each symbol represents an individual subject; horizontal lines show the 
mean; **p>0.01, *p<0.05 by Mann-Whitney U test. C, Pearson’s correlation between the MFI of p-Syk in CD27+ (open 
square) and CD27- (filled square) SLE B cells after 5 min of anti-IgM/IgG stimulation and the frequency of CD86+ and 
CD80+ B cells showed no correlation between the strength of Syk(Y352) activation and incidence of CD80+ or CD86+ 
B cells. Each symbol represents an individual subject of 10 SLE patients.  
The frequency of CD27+CD86+ B cells of SLE patients was 5.6±3.8% compared to 
2.2±1.5% in CD27+ B cells of HD (mean±SD, *p<0.05). Within the CD27- compartment 
2.8±2.1% in SLE patients but only 0.6±0.5% in HD were CD86+ (mean±SD, **p<0.01). 
Regarding CD80+ B cells, only CD27- SLE B cells showed significant enhanced 
frequencies (SLE: 1.4±0.8%, HD: 0.7±0.5; mean±SD, *p<0.05). This data indicate a 
higher pre-activation of SLE B cells in vivo. However, comparing the frequency of CD86+ 
and CD80+ B cells with the phosphorylation of Syk after BCR activation, no correlation 
has been observed (Figure 4-11C).  
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Figure 4-12: The in vivo environment of SLE patients had no impact on the Syk phosphorylation in response 
to BCR ligation. PBMC from 7 SLE patients were stimulated with anti-IgM/IgG for 5 min immediately ex vivo (0 h) or 
after a 24 h and 48 h in vitro resting phase in RPMI/10% FCS. Syk(Y352) phosphorylation of CD27+ (open bars) and 
CD27- (filled bars) B cells was analyzed; data are represented as box and whiskers min to max. Lines inside the boxes 
represent the median; *p<0.05 by Wilcoxon matched pair test. 
In addition, isolated SLE PBMC were incubated for 24 and 48 h in vitro to analyze if 
removing the in vivo environment could rescue the BCR responsiveness in SLE B cells 
regarding Syk activation. Interestingly, an additional resting phase of 24 h and 48 h did 
not led to a normalization of the Syk phosphorylation after BCR stimulation in SLE CD27+ 
and CD27- B cells. In detail, the MFI of p-Syk(Y352) at day 0 was 1988±1108 for CD27+ 
and 2317±1150 for CD27- B cells compared to 1732±1100 for CD27+ and 1860±1345 for 
CD27- B cells after 24 h and 1918±939 (CD27+ B cells) and 1860±1261 (CD27- B cells) 
after 48 h in vitro resting (median±SD; Figure 4-12).  
This data indicate that the expression of CD86+ and CD80+ B cells and therefore a 
pre-activation in vivo in SLE patients or the in vivo environment with enhanced levels of 
free dsDNA, pro-inflammatory cytokines and auto-Ab levels (120, 182-184) appears to be 
independent from the hyporesponsive BCR reaction regarding Syk and PLC-γ2 activation. 
Therefore, an intrinsic molecular defect in B cells of SLE patients is suggested. 
 
4.2 Enhanced frequency of a unique Syk bright memory B cell subset in 
patients with SLE 
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4.2.1 Whole blood CD27- SLE B cells expressed high levels of Syk 
Further studies compared the basal expression of Syk and p-Syk(Y352) in whole 
blood SLE versus HD B cells to dissect if a disturbed expression of Syk and p-Syk(Y352) 
could be involved in the reduced Syk phosphorylation response after BCR activation. As 
expected CD27+ memory B cells in HD as well as in SLE patients express higher MFI 
levels of Syk and p-Syk(Y352) compared to CD27- B cells (HD: CD27+ 2195±458, CD27- 
1335±301; SLE: CD27+ 1884±355, CD27- 1261±363; mean±SD, ***p<0.001; Figure 
4-13A).  
However, comparing SLE patients with HD B cells showed a significant reduced 
expression of Syk in CD27+ memory SLE B cells (*p<0.05) and p-Syk in CD27- and 
CD27+ B cells (HD: CD27+ 456±132, CD27- 339±103; SLE: CD27+ 366±126, CD27- 
272±113; mean±SD, *p<0.05). Therefore, a reduced basal expression of Syk and 
p-Syk(Y852) could be beside the enhanced tyrosine phosphatase activity and the 
disturbed CD19/CD22 balance responsible for the reduced Syk phosphorylation 
efficiency after BCR activation in SLE. 
Interestingly, analyzing Syk within the CD27- B cell compartment revealed a 
unique Syk high expressing subpopulation in SLE patients. Comparing the frequency of 
CD27-Syk++ B cells between SLE patients, HD and other autoimmune diseases like RA 
and pSS showed a significantly enhanced frequency in patients with SLE (Figure 4-13B). 
In detail, the frequency in HD of CD27-Syk++ was 6.4±4.0% with only 4 of 28 
having a frequency over 10%, by contrast 20 out of 33 patients (*p<0.05 by Fisher`s exact 
test) showed a frequency of CD27-Syk++ B cells with a frequency of 16.1±14.1% 
(mean±SD, **p>0.01). RA patients and pSS patients did not show an increase of this 
population (8.6±4.5% (RA) and 10.1±8.0% (pSS)), except in individual cases, compared 
to HD. Thus, an overrepresented frequency of peripheral CD27-Syk++ B cells was very 
characteristic for patients suffering from SLE. 
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Figure 4-13: Peripheral blood of SLE patients revealed increased frequencies of a unique CD27-Syk++ B cell 
subset. A, The expression of Syk and p-Syk(Y352) in CD27- and CD27+ B cells was analyzed in whole blood from HD 
(n=25) and patients with SLE (n=33); *p<0.05 by Mann-Whitney U test. B, Representative histograms comparing Syk 
expression by CD27- B cells and T cells (negative control) are shown. Dot plot shows enhanced frequencies of 
CD27-Syk++ B cells in patients with SLE (n=33) compared to HD (n=28), rheumatoid arthritis patients (RA; n=13), or 
primary Sjögren’s syndrome patients (pSS; n=20), respectively. Each symbol represents an individual subject; 
horizontal lines show the mean; **p<0.01 by Mann-Whitney U test.  
Interestingly, analyzing the phosphorylation response of Syk and Akt after BCR 
stimulation revealed a memory like BCR response of CD27-Syk++ compared to 
CD27-Syk+ and CD27+ B cells. CD27-Syk++ B cells showed a p-Syk(Y352) MFI value 
of 2351±411 after 5 min of BCR stimulation which was comparable with CD27+ memory 
B cells (2391±595), while the phosphorylation of Syk in CD27-Syk+ B cells was only 
1272±224. Similar results were obtained for p-Akt(S473) after 15 min BCR stimulation 
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(CD27-Syk++: 2849±140, CD27+ 2491±311, CD27-Syk+: 1965±200; mean±SD; Figure 
4-14A, B). 
 
Figure 4-14: CD27-Syk++ B cells from SLE patients showed a memory-like BCR dependent phosphorylation 
kinetics. A, Time kinetics of CD27-Syk+ (filled square), CD27-Syk++ (filled circle), and CD27+ (open square) B cells 
from SLE patients (dotted, n=3) and HD (solid, n=11) are shown as mean. PBMC were stimulated with anti-IgM/IgG for 
0, 1, 2, 5, 8, 15, and 30 min revealing similar phosphorylation kinetics of CD27-Syk++ compared to CD27+ SLE B cells 
but still reduced compared to HD B cells. B, PBMC from SLE patients were stimulated with anti-IgM/IgG for 0, 5, 15 
and 30 min. Comparative time kinetics between CD27-Syk+ (filled square), CD27-Syk++ (filled circle), and CD27+ 
(open square) SLE (dotted line, n=3) and HD (solid line, n=8) B cells of the phosphorylation of Akt(S473) unfolded 
increased activation in CD27-Syk++ B cells. Data are represented as mean. D, The ratio of p-Syk(Y352) and p-
Akt(S473) was analyzed in CD27-Syk+, CD27-Syk++, and CD27+ B cells from SLE patients disclosing no differences 
between the balance of p-Syk and p-Akt between the three B cell subsets analyzed. Each symbol represents an 
individual sample of 5 SLE patients; horizontal lines show the mean. 
However, the phosphorylation kinetics of Syk after BCR stimulation in 
CD27-Syk++, CD27-Syk+ and CD27+ SLE B cells was still diminished compared to 
healthy controls. Noteworthy, comparing the phosphorylation ratio of p-Syk/p-Akt no 
differences between CD27-Syk++, CD27+ and CD27-Syk++ B cells have been seen. This 
data indicate a B cell subset independent dysbalance of p-Syk/p-Akt in patients with SLE 
(Figure 4-14C and Figure 4-6).  
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Figure 4-15: Occurrence of CD27-Syk++ B cells in HD is independent of their age but is significantly enhanced 
in HD suffering from dental root inflammations. A, Spearman’s correlation analysis of the frequency of CD27-Syk++ 
B cells with age (n=22). B, Frequency of CD27-Syk++ B cells was analyzed in HD below the age of 35 (n=11), above 
the age of 35 (n=11), with other diseases including gastro-intestinal disease, sinusitis, gum bleeding/infection (n=4), 
lung inflammation (n=1) and dental root inflammation (n=3). Each symbol represents an individual subject; horizontal 
lines show the mean; *p<0.05 by Mann Whitney U test. 
Further studies analyzed the occurrence of CD27-Syk++ B cells in HD and 
revealed no correlation between the frequency of these cells and their age (Figure 
4-15A). Interestingly, analyzing the frequency of CD27-Syk++ B cells more in detail within 
HD, a significant enhanced frequency was found in HD suffering from dental root 
inflammation compared to HD below 35 years (Figure 4-15B). Here, HD below the age 
of 35 had a frequency of 6.0±1.8% compared to 9.6±0.8% in HD with dental root infections 
(mean±SD, *p<0.05). 
Additionally, comparing the frequencies of CD27-Syk++ B cells between HD below 
and over 35 as well as other inflammatory diseases like gastro-intestinal disease, sinusitis 
or gum bleeding/infection showed no significant differences (<35 years: 6.0±1.8%, >35 
years: 6.4±3.7%, other diseases: 5.0±1.1%). Interestingly, one HD with lung inflammation 
(pneumonia) showed a frequency of 12.7%.   
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Figure 4-16: Occurrence of CD27-Syk++ B cells in SLE patients is independent of the SLE disease activity index 
(SLEDAI) or antinuclear antibodies (ANA) and stays stable over time. Spearman’s correlation analysis of the 
frequency of CD27-Syk++ B cells with (A) the SLEDAI (n=41) and (B) the ANA titer (n=33) did not indicate a functional 
relationship. C, The frequency of CD27-Syk++ B cells were analyzed in 11 SLE patients over a time period of maximal 
two years showing no changes over time in individual patients. The different numbers show the SLEDAI on the time 
point analyzed. Each color represents one SLE patient. 
Of note, no correlation between the SLEDAI or ANA titer has been found. 
Furthermore, analyzing the frequency of CD27-Syk++ B cells over time during various 
follow-ups of several SLE patients remained stable (Figure 4-16). This data indicate, that 
CD27-Syk++ B cells are disease specific and not essentially related to lupus activity.   
In addition, whole blood analysis after secondary tetanus/diphtheria (adjuvant 
alum) vaccinations showed no increased frequency of CD27-Syk++ B cells after 7 or 14 
days post vaccination even though the typical increase in plasmablasts/plasma cells was 
detected indicating that this population is not inducible by tetanus specific in vivo immune 
activation (Figure 4-17). 
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Figure 4-17: Constant frequency of CD27-Syk++ B cells after secondary vaccination with the tetanus/diphtheria 
toxoid (TT) after day 6, 7 and 14. Whole blood of 6 HD (TTI-TTVI) was analyzed at day 0, 6, 7 and 14 after secondary 
vaccination with the TT to assess the frequency of CD27Syk++ B cells. Time kinetic and scatter plot show the frequency 
(A) and the absolute numbers (B) of CD27-Syk++ B cells after vaccination. Each color or symbol represents an 
individual subject; horizontal lines show the mean; Wilcoxon’s signed rank test. C, The absolute number of CD27++ 
plasmablasts/plasma cells per ml whole blood is shown. The occurrence of CD27-Syk++ B cells is not inducible by in 
vivo immune activation even though the typical increase in plasmablasts/plasma cells was detected after day 6/7 
especially in TTI and TTIII. 
In accordance with the findings of the tetanus vaccination study, no correlation 
between the frequency of CD27-Syk++ B cells and the occurrence of CD80+ and CD86+ 
B cells was found (Figure 4-18). 
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Figure 4-18: The appearance of CD27-Syk++ B cells is independent of a recent in vivo immune activation 
represented by the occurrence of CD80+ and CD86+ B cells. Pearson’s correlation between the frequency of 
CD27-Syk++ B cells and the frequency of CD80+ (A) and CD86+ (B) within CD27+ (open square) and CD27- (filled 
square) B cells showed no correlation. Each symbol represents an individual subject of 10 SLE patients.  
 
4.2.2 CD27-Syk++B cells express a distinct phenotype and lack CD38  
Several studies described the presence of certain CD27- B cell memory subsets in 
patients with SLE, such as CD27-IgD-, CD27-IgD-CD95+ or CD21low B cells (36, 138, 
185). Therefore, a detailed phenotypic study of CD27-Syk++ B cells was performed to 
analyze if this subset might share specific characteristics with one of the already known 
subsets mentioned above.  
Interestingly, careful studies of CD27-IgD-, CD27-IgD-CD95+ and CD27-CD21- 
B cells revealed that not all subsets express homogenously Syk++. Here, only 
39.2±24.7% of the CD27-IgD-, 67.4±22.8% of the CD27-IgD-CD95+ and 64.2±20.9% of 
the CD27-CD21- B cell subsets were found to carry Syk++ (median±SD, Figure 4-19A).  
By contrast, 31.9±11.6% of the CD27-Syk++ B cell subset were neither CD27-IgD-, 
CD27-IgD-CD95+ nor CD27-CD21-. Thus, the CD27-Syk++ B cell subsets represents a 
unique B cell subset enhanced in SLE patients and has not been fully described by 
previous studies (Figure 4-19B).  
In addition, CD27-Syk++ B cells were found to uniquely lack the expression of the 
type II transmembrane glycoprotein CD38 (Figure 4-19C). CD38 expression is tightly 
regulated during B cell development and downregulated during the late B cell memory 
phase (186, 187). CD38 has been reported to play an important role as BCR co-receptor 
modulating its threshold (186, 188). However, the exact function of CD38 appears 
contradictory and not well characterized (187).  
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Figure 4-19: CD27-Syk+ B cells from SLE patients lack the expression of CD38 and cover only partially 
previously described B cell abnormalities. A, Box and whisker plots show the frequency of Syk++ cells within the 
CD27-CD21-, CD27-IgD-, and CD27-IgD-CD95+ B cell subsets (n=5–16 samples). B, Composition of CD27-Syk++ 
B cells according to their expression of CD21, IgD, and CD95. Values are the mean±SD of 18 samples. 
C, Representative histograms show the expression of CD38 on CD27-Syk+, CD27-Syk++, and CD27+ B cells. Dot plot 
demonstrates that CD27-Syk++ cells lack CD38 expression. Box and whisker plots show the MFI of CD38 on 
CD27-Syk+, CD27-Syk++, and CD27+ B cells (n=11 samples). Each box represents the 25% and 75% confidence 
limits. Lines inside the boxes represent the median. ***p<0.001 by Wilcoxon’s signed rank test. D, CD27-CD38-, CD27-
CD38+, and CD27+CD38+/- B cells were gated and their corresponding Syk expression is shown in a representative 
histogram.  
Analysis of the MFI values of CD38 of CD27-Syk++ B cells showed a significant 
reduced expression compared to CD27-Syk+ and CD27+ B cells (CD27-Syk++: 777±258, 
CD27-Syk+: 1620±401, CD27+ 1122±361; median±SD, ***p<0.001). Analyzing the 
expression of Syk in sorted CD27-CD38- B cells revealed an enhanced Syk expression, 
confirming that the lack of CD38 as a unique characteristic of CD27-Syk++ B cells    
(Figure 4-19D).  
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Furthermore, analyzing the baseline level of phosphorylated Syk showed 
significantly elevated levels of p-Syk(Y352) in CD27-Syk++ compared to CD27-Syk+ and 
CD27+ B cells reflecting an pre-activated phenotype (CD27-Syk++: 569±211, CD27-
Syk+: 291±115, CD27+ 367±125; mean±SD, ***p<0.001; Figure 4-20A). 
Previously, a comparable cellular distribution of Syk within the cytoplasm and the 
nucleus in unstimulated B cells has been described (189). In order to identify potential 
differences of the cellular localization of Syk within CD27-Syk+, CD27-Syk++ and CD27+ 
B cells, the distribution of Syk together with IgM as membrane and DAPI as nuclear 
staining were determined in freshly obtained blood from SLE patients using confocal 
microscopy.  
The fluorescence intensity of Syk in the cytoplasm and the nucleus was analyzed 
by calculating the mean intensity in these two subcellular areas using a cellular histogram. 
As shown in Figure 4-20B and C, CD27-Syk++ cells expressing IgM showed an overall 
increased Syk intensity in the nucleus as well as in the cytoplasmic region. CD27-
Syk++IgM+ cells had a cytoplasmic mean Syk fluorescence intensity of 8666±4501 
compared to 3796±1780 in CD27-Syk+IgM+ and 4326±2818 in CD27+IgM+ memory 
B cells, respectively (mean±SD, ***p<0.001; Figure 4-20B).  
In the nucleus, the mean Syk fluorescence intensity was 6498±2957 for 
CD27-Syk++IgM+ cells compared to 3386±950 for CD27-Syk+IgM+ and 4299±2134 
within CD27+IgM+ B cells, respectively (mean±SD; Figure 4-20B, C). Further, 
CD27-Syk++IgM+ B cells showed a significantly higher Syk fluorescence intensity in the 
cytoplasm region compared to the nucleus, which has neither been observed for 
CD27-Syk+IgM+ nor for CD27+IgM+ memory B cells (***p<0.001).  
Taken together, the accumulation of Syk at its functional site (membrane IgM and 
cytoplasm) in CD27-Syk++ B cells differs substantially to the classical naïve and memory 
B cells and confirms the pre-activated or recently activated state of these B cell subset. 
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Figure 4-20: CD27-Syk++ B cells from SLE patients showed enhanced expression of basal p-Syk(Y352) and a 
preferential accumulation of Syk in the cytoplasm compared to CD27-Syk+ and CD27+ B cells. A, Whole blood 
analysis of CD27-Syk+, CD27-Syk++, and CD27+ B cells from SLE patients (n=34) according to their basal expression 
of p-Syk(Y352) showed enhanced expression (MFI values) of p-Syk(Y352) in CD27-Syk++ B cells. Each symbol 
represents an individual subject; horizontal lines show the mean; ***p<0.001 by Wilcoxon’s signed rank test. B and C, 
Fixed and permeabilized sorted B cells were stained against IgM (red) and analyzed by confocal microscopy. DAPI 
(blue) was used to stain the nucleus (original magnification: 630x). The Syk fluorescence intensity within CD27-
Syk+IgM+, CD27-Syk++IgM+ and CD27+IgM+ B cells was determined by cellular histograms (DAPI (blue), Syk-FITC 
(green) and IgM-RRX (red)) across an individual cell and analyzed according to their membrane/cytoplasmic (DAPI-; 
filled square) and nuclear (DAPI+; open square) Syk expression. Each symbol represents an individual B cell of 3 SLE 
patients; horizontal lines show the mean; ***p<0.001 by Wilcoxon’s signed rank test (≥15 cells/B cell subset).  
Beyond the lack of CD38, enhanced Syk and p-Syk expression and an 
accumulation of Syk in the cytoplasm compared to the nucleus, a significantly higher 
expression of the B cell lineage markers CD19 and CD20 by CD27-Syk++ B cells were 
observed compared to CD27-Syk+ as well as CD27+ memory B cells (CD27-Syk++: 
CD19 1539±398, CD20 1347±1571; CD27-Syk+: CD19 1138±189, CD20 1228±1140; 
CD27+: CD19 1282±265, CD20 1160±1137; median±SD, **p<0.01, ***p<0.001; Figure 
4-21A, B).  
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Figure 4-21: CD27-Syk++ B cells show a unique phenotype. A, Gating strategy of CD27-Syk+, CD27-Syk++, and 
CD27+ B cells (left). Representative histograms are shown (right) for the expression of CD19, CD20 and CD21. B, MFI 
of CD19 (n =17) and CD20 (n =29) and the frequency of CD21+ (n=14) of CD27-Syk+ (light grey), CD27-Syk++ (strips), 
and CD27+ (dark grey) B cells are shown. Data are represented as box and whisker plots. Each box represents the 
25% and 75% confidence limits. Lines inside the boxes represent the median. Lines outside the boxes represent the 
minimum and maximum values. **p<0.01, ***p<0.001 by Wilcoxon’s signed rank test.   
In addition, comparing the expression of the C2 complement receptor (CD21) 
showed a significantly lower percentage of CD21 expressing B cells within CD27-Syk++ 
(27.0±13.3%) compared to CD27-Syk+ (89.3±13.6%) or CD27+ (73.5±10.3%) B cells, 
respectively (median±SD, ***p<0.001; Figure 4-21A, B). 
To characterize the phenotype of CD27-Syk++ B cells in further detail, the Ig heavy 
chain isotype expression by CD27-Syk+, CD27-Syk++ and CD27+ B cells was examined. 
An increase of pre-switch IgM+ only (CD27-Syk+ 7.9±6.3%, CD27-Syk++ 14.4±13.1%) 
and post-switch IgM-IgD- memory B cells (CD27-Syk+ 6.7±8.5%, CD27-Syk++ 
25.8±21.5%) as well as a decrease of IgM+IgD+ B cells (CD27-Syk+ 78.4±12.5%, CD27-
Syk++ 51.0±18.5%) was observed among CD27-Syk++ compared to CD27-Syk+ B cells 
(mean±SD; Figure 4-22A, B). However, comparing the frequency of IgM+ only, IgM-IgD- 
and IgM+IgD+ B cells showed a distinct distribution between CD27-Syk++ and classical 
CD27+ memory B cells (CD27+: IgM+ 39.5±16.9%, IgM-IgD- 47.9±17.8%, IgM+IgD+ 
10.3±6.4%). Therefore, CD27-Syk++ B cells contain an increased frequency of IgM+ only 
and IgM-IgD- post-switch memory B cells compared to CD27-Syk+ B cells but decreased 
frequency compared to conventional CD27+ memory B cells. 
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Figure 4-22: CD27-Syk++ B cells contained a distinct frequency of IgM+ only and IgM-IgD- post-switch memory 
B cells. A, Representative dot plots are shown for the expression of IgM and IgD by CD27-Syk+, CD27-Syk++ and 
CD27+ B cells. Gating strategy of four different B cell subsets regarding their IgM and IgD expression. B, Stacked bars 
represent the mean frequency of “IgM+ only” pre-switch memory (black), IgM+IgD+ naïve (light grey), IgD+ only naïve 
(white) and IgM-IgD- post-switch memory B cells (dark grey) within CD27-Syk+, CD27-Syk++ and CD27+. Data are 
represented as mean from 18 independent experiments. 
Taking together, the CD27-Syk++ B cells does not completely overlap with the 
previously recorded CD27- memory B cell subsets described in SLE patients. These cells 
lack the expression of CD38, show enhanced levels of p-Syk(Y352) and an accumulation 
of Syk in the cytoplasm as well as an enhanced expression of CD19 and CD20. In 
addition, CD27-Syk++ B cells showed reduced frequencies of CD21+ cells and a 
divergent frequency of IgM+ only and IgM-IgD- post-switched memory B cells.  
 
4.2.3 CD27-Syk++B cells share memory B cell characteristics 
Although CD27 can serve as a reliable surface marker for memory B cells (27), 
CD27-IgD-CD95+ memory-like B cells correlating with SLE activity (36), low mutated and 
isotype-switched CD27-IgD- memory B cells with an increased frequency in SLE patients, 
human immunodeficiency virus (HIV) infections and elderly people have been identified 
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(32, 33, 36, 37, 185). Thus, CD27 has apparently limitations as marker for memory B cells 
in certain immune diseases.  
Therefore, other additional markers are needed to identify memory B cells, such 
as SHM of V(D)J gene rearrangements, Ig class-switching (23, 24, 190) as well as an 
inactive ABC-B1 transporter (38). In this regard, analysis of the ABC-B1 transporter 
activity was measured by the export of the MTO dye. As expected and previously reported 
(38) CD27+ memory B cells failed to exclude the dye and thus remained MTO+ 
(92.1±5.3%). CD27-Syk+ naïve B cells expressed an active ABC-B1 transporter and were 
MTO- (13.7±13.5%). Interestingly, CD27-Syk++ B cells showed a similar ABC-B1 
transporter activity compared to CD27+ memory B cells (MTO+ 86.8±7.5%) consistent 
with the conclusion that these cells do not represent a conventional naïve B cell subset 
and represent rather memory-like B cells (median±SD, *p<0.05, ***p<0.001; Figure 
4-23A, B). 
Furthermore, the frequency of CD95+ B cells, was significant increased in the 
CD27-Syk++ (22.4±14.6%) compartment compared to CD27-Syk+ cells (1.8±1.9%) but 
similar to CD27+ B cells (25.5±12.0%; median±SD, ***p<0.001; Figure 4-23A, B). Neither 
one of the three B cell subsets analyzed contained substantial numbers of Ki67+ B cells, 
which indicates that >99% of CD27-Syk++ cells had not recently proliferated (CD27-
Syk++: 0.94±0.44%, CD27-Syk+: 0.59±0.67%, CD27+ 1.10±3.24; median±SD, **p<0.01;      
Figure 4-23A, B).  
Additionally, analysis of the mutation frequency of CD27-Syk++ and CD27-CD38- 
B cells showed an average mutation frequency of 7.2±5.9% (mean±SD; Figure 4-23C) 
which is consistent with reported mutation frequencies of 4-12% in peripheral memory 
B cells (191), whereas CD27-CD38+ naïve B cells did not express somatic 
hypermutations within V(D)J regions (mutation frequency 0%). Interestingly, also three 
sorted CD27-Syk++(CD38-) clones did not show any mutations within the heavy chain. 
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Figure 4-23: CD27-Syk++ B cells showed a memory-like phenotype. A, Gating strategy of CD27-Syk+, CD27-
Syk++, and CD27+ B cells (left). Representative histograms are shown (right) for the expression of CD95, and Ki-67, 
as well as the activity of the ABC-B1 transporter by MitoTracker Orange [MTO] exclusion. B, Frequency of CD95+ 
(n=16), Ki-67+ (n= 11), and MTO+ (n=19) cells in CD27-Syk+, CD27-Syk++, and CD27+ B cells are shown. Data are 
represented as box and whisker plots. Each box represents the 25% and 75% confidence limits. Lines inside the boxes 
represent the median. Lines outside the boxes represent the minimum and maximum values. *p<0.05, **p<0.01, 
***p<0.001 by Wilcoxon’s signed rank test. C, Sorted single CD27-Syk+(CD38+) and CD27-Syk++(CD38-) B cells were 
analyzed regarding their mutation frequency of B cell receptor gene rearrangements. Included are 5 IgM sequences 
from CD27-CD38+ B cells and 5 IgM, 1 IgG, and 7 IgA sequences from CD27-Syk++ and CD27-CD38- B cells. 
Intracellular staining’s were performed for SLE patients no. 1–3. CD27-Syk+ and CD27-Syk++ B cells were sorted and 
further analyzed for their VHDJH gene rearrangements. Surface staining was performed for cells from SLE patient no. 
4. Subsequently, CD27-CD38+ and CD27-CD38- B cells were sorted and analyzed. Each symbol represents an 
individual sample; horizontal lines show the mean. 
Additionally, analysis of the mutation frequency of CD27-Syk++ and CD27-CD38- 
B cells showed an average mutation frequency of 7.2±5.9% (mean±SD; Figure 4-23C) 
which is consistent with reported mutation frequencies of 4-12% in peripheral memory 
B cells (191), whereas CD27-CD38+ naïve B cells did not express somatic 
hypermutations within V(D)J regions (mutation frequency 0%). Interestingly, also three 
sorted CD27-Syk++(CD38-) clones did not show any mutations within the heavy chain. 
The overall data are consistent with the conclusion that CD27-Syk++ B cells clearly 
differ in their phenotype from conventional CD27-Syk+ naïve cells and express 
phenotypic and especially functional characteristics more typical of memory B cells 
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lacking the memory marker CD27. Thus, these cells are a unique CD27- subset that is 
enhanced in SLE patients and reflects a pre-activated memory-like B cell subset. 
 
4.2.4 Enhanced differentiation of CD27-CD38- into CD27++ and Ab secreting 
B cells 
Subsequent experiments thought to determine whether CD27-Syk++ B cells show 
functional differences compared to classical naïve CD27-Syk+ B cells. Since the 
discrimination of CD27-Syk+ with CD27-Syk++ B cells required fixation and 
permeabilization, CD27-CD38- B cells that were largely Syk++ were used for functional 
analysis (Figure 4-19C). Three B cell subsets regarding their CD27 and CD38 expression 
were sorted: the Syk expression prior to the experiments of CD27-CD38- and 
CD27-CD38+ B cells were verified as shown in Figure 4-19D. CD27-CD38- B cells 
showed an enhanced differentiation into CD27+ and CD27+CD138++ cells in contrast to 
CD27-CD38+ B cells after 5 days of in vitro stimulation (Figure 4-24A).  
In detail, CD27-CD38+ B cells stimulated with IL-2, IL-10, CpG and anti-IgM/IgG 
differentiated into CD27++ B cells at a frequency of 6.2±4.9% and only 0.5±0.4% were 
CD27++CD138++, whereas 20.0±11.8% CD27++ and 1.7±1.3% CD27++CD138++ cells 
were found for CD27-CD38- B cells. Comparable levels of CD27++ and 
CD27++CD138++ B cells were observed in the CD27+CD38+/- B cell memory subset 
(CD27+CD38+/-: 62.5±13.3% CD27++ and 4.1±2.8% CD27++CD138++; mean±SD; 
Figure 4-24B).  
These results were consistent with the concentration of IgG measured by ELISA 
in culture supernatants and the number of Ab secreting cells (ASCs) in the corresponding 
cultures (Figure 4-25): CD27-CD38- cells representing CD27-Syk++ cells produced 
substantially higher IgG in vitro compared to CD27-CD38+ cells (Figure 4-25A). 
Moreover, the secretion of IgG by the different B cell subsets was confirmed by ELISPOT         
(Figure 4-25B) showing increased differentiation into IgG secreting cells by CD27-CD38- 
B cells compared to CD27-CD38+ B cells. 
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Figure 4-24: Enhanced differentiation of CD27-Syk++ into CD27++ B cells compared to CD27-Syk+ cells after 
5 days in vitro stimulation. A, Gating strategy of CD19+CD20+ B cells for sorting CD27+CD38+/- (gate I), CD27-
CD38+ (gate II), and CD27-CD38- (gate III) B cell subsets based on the expression of CD27 and CD38. Dot plots show 
the expression of CD27 and CD138 on CD27+CD38+/- (gate I), CD27-CD38+ (gate II), and CD27-CD38- (gate III) 
B cells after 5 days in vitro culture with IL-2, IL-10, CpG, and anti-IgM/IgG. B, The frequencies of CD27++ and 
CD27++CD138++ B cells were determined in the 3 gated subsets showing enhanced frequencies of CD27++ and 
CD27++CD138++ B cells in CD27-CD38- (gate III) compared to CD27-CD38+ (gate II) B cells. Values are represented 
as mean±SD of 6 independent experiments; *p<0.05 by Wilcoxon’s signed rank test.  
The differentiation of self-reactive B cells into auto-ASCs plays a crucial role in the 
pathogenesis of SLE. Therefore, the differentiation capacity of CD27-CD38- B cells into 
auto-ASCs was analyzed by testing supernatants for the presence of auto-Ab using the 
human epithelial type 2 (Hep-2) cell system as substrate coated on microscopy slides for 
human auto-Ab. Incubating the supernatants on the slides coated with Hep-2 cells, no 
autoreactive IgG obtained from HD was detected, whereas all three SLE patients showed 
auto-Ab production against cellular antigens (mainly cytoplasmic reactivity) from CD27+ 
memory B cells as shown in Figure 4-25C. 
Of note, ASCs derived from CD27-CD38- cells from one out of three SLE patients showed 
staining of Hep-2 cells against cytoplasmic autoantigens. Although IgG has been 
produced by ASCs derived from normal CD27-CD38+ as shown by ELISA and ELISPOT, 
auto-Abs were not detectable in this assay. Together, CD27-CD38-(Syk++) showed an 
enhanced differentiation capacity into IgG secreting PC compared to the 
CD27-CD38+(Syk+) B cell subset. 
IgM/IgG 
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Figure 4-25: CD27-Syk++ B cells differentiated after 5 days in vitro stimulation into IgG secreting (auto)-Ab 
producing B cells. A, Total IgG secreted into supernatants of CD27+CD38+/-, CD27-CD38+, and CD27-CD38- B cells 
stimulated with IL-2, IL-10, CpG, and anti-IgM/IgG after 5 days of in vitro culture from 2 HD and 3 SLE patients. 
B, Enzyme-linked immunospot analyses of 0.5x105 sorted CD27+CD38+/-, CD27-CD38+, and CD27-CD38- B cells 
from 2 SLE patients. Cells were stimulated in vitro for 5 days with IL-2, IL-10, CpG, and anti-IgM/IgG. Spots representing 
IgG Ab-secreting cells were counted. Numbers indicate spots of Ab-forming cells. Representative examples are shown. 
C, Autoreactive IgG in supernatants from the 5 days B cell cultures from CD27+CD38+/-, CD27-CD38+, and 
CD27-CD38- B cells subsets derived from the 2 HD and from the 3 SLE patients shown in A. Autoreactive IgG binding 
to cytoplasmic antigens was determined by confocal microscopy using HEp-2 cells; original magnification x630.  
 
4.2.5 Stimulation with IFN-γ, LPS or TNF-α leads to increased frequencies of 
CD27-Syk++ B cells 
To analyze the nature of CD27-Syk++ B cells, whole blood was stimulated with 
different agents that have been previously described to be involved either in autoimmune 
diseases, such as IFN-γ (125), TNF-α, IL-6 (124), and BAFF (192) or abnormal B cell 
responses, such as LPS and CpG (193).  
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Figure 4-26: Stimulation with IFN-γ, LPS, or TNF-α induced the generation of CD27-Syk++ B cells in vitro. 
A, Median frequencies of CD27-Syk++ B cells after 2 days of stimulation with IFN-γ, TNF-α or LPS, as compared to 
unstimulated whole blood. Representative dot plots are shown. B, Stimulation index (frequency of CD27-Syk++ cells 
among total CD20+ B cells stimulated/unstimulated) after 2 days of in vitro culture with either BAFF, IL-6, IFN-γ, LPS, 
TNF-α, CpG, IL-21, or IFN-α as compared to unstimulated cells (n=12 for each analysis except IL-21 (n =8) and IFN-
α (n=4)). Data are shown as box and whisker plots. Each box represents the 25% and 75% confidence limits. Lines 
inside the boxes represent the median. Lines outside the boxes represent the minimum and maximum values. *p<0.05, 
**p<0.01 by Wilcoxon’s signed rank test. 
After 48 h in vitro stimulation with the typical Th1-cytokines (41) IFN-γ, TNF-α or LPS 
a substantial increase of CD27-Syk++ B cells was observed (Figure 4-26).  
Here the stimulation index (frequency of CD27-Syk++ stimulated/unstimulated) 
increased substantially to 1.4±0.2 after IFN-γ stimulation (**p<0.01), to 1.2±0.2 after TNF-
α treatment (*p<0.05) and to 1.5±0.4% after LPS stimulation (**p<0.01). Stimulation with 
BAFF (1.0±0.2), IL-6 (1.0±0.2), CpG (1.2±0.4), IL-21 (1.3±0.2) or IFN-α (1.1±0.2) showed 
no significant changes in the frequency of CD27-Syk++ B cells (median±SD; Figure 
4-26). 
In summary, this data indicate, that increased availability of certain cytokines in 
patients with SLE especially the Th1 specific cytokines INF-γ and TNF-α in contrast to the 
typical Th2 cytokine IL-6 may be able to induce the generation of CD27-Syk++ B cells. In 
line with this, secondary vaccination studies with tetanus did not induce the generation of 
CD27-Syk++ B cells in vivo.  
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4.2.6 sCD27 does not correlate with the occurrence of CD27-Syk++ B cells 
The co-stimulatory molecule CD27 can be released or shed from the cell surface 
by metalloproteinases after lymphocyte activation (194). Increased levels of soluble CD27 
(sCD27) have been found in anti-CD3 stimulated T cells in vitro (195). In addition, sCD27 
has been found in serum, plasma and urine samples in HD but was especially increased 
in patients with SLE indicating that sCD27 reflects an increased immune activation in vivo 
(194). Therefore, to check if CD27-Syk++ B cells are generated by the shedding of CD27, 
the concentration of sCD27 was compared with the frequency of CD27-Syk++ B cells in 
the serum of SLE patients as well as in the supernatant of 2 days in vitro stimulated whole 
blood B cell cultures. Analyzing the soluble form of CD27 by an ELISA assay showed no 
correlation between the concentration of sCD27 (U/ml) in the serum and the frequency of 
CD27-Syk++ B cells in the periphery of SLE patients (Figure 4-27A).  
 
Figure 4-27: The occurrence of CD27-Syk++ B cells in patients with SLE do not correlate with the concentration 
of sCD27 in the serum or in cell culture supernatants. A, Pearson’s correlation analysis of the frequency of 
CD27-Syk++ B cells with the concentration (U/ml) of soluble CD27 (sCD27) in the serum of 27 SLE patients is shown. 
B, Total sCD27 secreted into supernatants was analyzed from stimulated whole blood in vitro cultures after 2 days of 
stimulation with IL-6, IFN-γ, LPS, TNF-α, CpG or RPMI (control). Each symbol represents an individual sample of 5 
SLE patients; horizontal lines show the mean, Wilcoxon’s signed rank test.  
In addition, no differences between sCD27 has been observed between whole 
blood B cell culture supernatants unstimulated (RPMI) or stimulated with INF-γ, LPS, 
CpG, TNF-α or IL-6 even though the stimulation with INF-γ, LPS and TNF-α led to an 
enhanced frequency of CD27-Syk++ B cells in vitro (Figure 4-27B). 
 This observation permits the conclusion, that the lack of CD27 expression on 
CD27-Syk++ B cells is likely not related to an enhanced shedding of CD27 that would 
result in enhanced levels of sCD27. However, since B cells represent a minor fraction of 
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cells within whole blood, the detection sensitivity could be insufficient to detect minor 
changes of B cell specific sCD27. 
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4.3 Summary 
In summary, the comprehensive analysis of the BCR complex and the downstream 
signaling cascade in B cells of patients with SLE compared to HD revealed fundamentally 
and hitherto unknown molecular differences which could play an essential role in the 
development and maintenance of autoimmunity.  
First, the analysis of the expression profile of the BCR co-receptors CD19 and CD22 
revealed an enhanced expression and activation of the inhibitory co-receptor CD22 on 
CD27- B cells of SLE patients. Furthermore, CD27- B cells from SLE patients showed an 
imbalanced expression of CD19/CD22 which strongly correlated with the ratio of 
p-Syk/p-Akt after BCR activation in CD27- but also CD27+ B cells. This indicates a striking 
interrelation between the surface expression of CD22 and CD19 and the balance of the 
p-Syk/p-Akt signaling pathways. 
In addition, SLE patients in comparison to HD showed a hyporesponsive BCR 
reactivity regarding the phosphorylation of Syk, PLC-γ2 and, finally intracellular Ca2+ 
release upon anti-IgM/IgG stimulation which was independent of the BCR isotype. 
Simultaneously, hyperactive Akt activation was observed in patients with SLE leading to 
a shifted balance of p-Syk/p-Akt towards the pro-survival kinase Akt. 
This dysbalance of p-Syk/p-Akt appeared to be likely related to an enhanced tyrosine 
phosphatase activity in these patients. The disturbed CD22 expression and imbalanced 
equilibrium of kinases and phosphatases possibly led to a dysbalance of p-Syk and p-Akt 
resulting in an enhanced survival of SLE B cells. These observations were independent 
of in vivo pre-activation or environmental conditions. 
Furthermore, a reduced basal expression of Syk and p-Syk expression was found 
in SLE B cells that could influence the BCR response in SLE patients. However, SLE 
patients expressed an enhanced frequency of a unique memory like CD27-Syk++ 
population, which showed a heterogeneous recently activated memory-like phenotype. 
Besides the lack of CD38 and an enhanced level of p-Syk, CD19, CD20 expression, 
memory characteristics like mutated V(D)JH gene rearrangements and largely absent 
ABC-B1 transporter activity was found. While in vivo immune activation by a secondary 
tetanus toxoid vaccination as well as follow-up studies in SLE patients did not find a 
relation with immune or disease activation, respectively. In vitro stimulation studies 
showed an INF-γ and TNF-α dependent generation of CD27-Syk++ B cells in patients 
with SLE. Further, a memory-like p-Syk and p-Akt phosphorylation kinetic after BCR 
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activation and the ability to differentiate in (auto)-Ab producing plasma cells were 
observed. 
Noteworthy, CD27+, CD27-Syk+ and the novel memory-like CD27-Syk++ B cell 
population showed no differences in the ratio of p-Syk/p-Akt upon BCR engagement 
indicating a general B cell activation abnormality in patients with SLE. Further studies are 
needed to delineate if the p-Syk/p-Akt dysbalance is rather intrinsic or in response to an 
overly activated immune system in SLE. 
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5. Discussion 
The current study analyzed in detail BCR related intracellular signaling pathways 
in patients with SLE compared to HD. In more detail, potential disturbances in the BCR 
signaling leading to the development and maintenance of autoreactive B and plasma cells 
were investigated in this prototypic systemic autoimmune disease.  
The current findings provide evidence that SLE patients display an increased 
tyrosine phosphatase activity and an imbalanced CD19/CD22 expression ratio that lead 
to a diminished Syk and PLC-γ2 activation and further downstream to a decreased Ca2+ 
influx. Otherwise, a hyperactive Akt phosphorylation after BCR stimulation in these 
patients was found and excluded the possibility that there is a globally reduced 
intracellular kinase activity in lupus B cells. The disturbed balance between p-Syk and p-
Akt towards the pro-survival kinase Akt may be involved in the circumvention of BCR 
induced negative selection together with enhanced survival of B cells and increased 
differentiation into plasma cells in patients with SLE. 
Additionally, whole blood analysis of SLE patients revealed a diminished Syk and 
p-Syk(Y352) expression in CD27+ and CD27- B cells and unfolded a hitherto unknown 
Syk++ B cell subset lacking the conventional memory marker CD27. This study could 
demonstrate that the use of this intracellular marker is able to detect also other previously 
described CD27- memory B cell subsets but appear to be superior compared to previous 
cell surface phenotyping. CD27-Syk++ B cells showed an activated memory-like 
phenotype with the ability to differentiate into auto-Ab secreting B cells and displayed an 
increased tonic BCR signaling represented by enhanced basal expression of Syk and 
p-Syk. This data provide evidence, that certain intracellular mechanisms are not 
sufficiently in place or able to control these cells which could also play a key role in the 
maintenance of autoreactivity. 
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5.1 Intrinsic molecular defects in SLE patients lead to the development 
and maintenance of autoimmunity 
5.1.1 Enhanced expression and activation of CD22 could lead to the reduced 
Syk and PLC-γ2 phosphorylation observed in SLE B cells 
This study was set out to address whether BCR signaling events of SLE B cells 
are abnormal and may explain the importance of B cell effector mechanisms in SLE, as 
a disease with abundant autoimmune findings, including ANA induction.  
First, analyzing the expression and activation of the inhibitory co-receptor CD22 
as well as the balance between CD19/CD22 revealed enhanced CD22 expression on 
CD27- compared to CD27+ B cells in SLE and HD. Interestingly, CD27- B cells of SLE 
patients showed increased CD22 expression and phosphorylation kinetics after BCR 
stimulation as well as a disturbed CD19/CD22 balance compared to HD. However, no 
differences between SLE and HD B cells have been observed comparing the recruitment 
of SHP-1 to CD22 or CD22 to the activated BCR complex indicating that there are no 
defects in the signalosome formation but rather signaling disturbances.  
Consistent with the publication of Daridon et al. (106) we could show, that naïve 
CD27- B cells have elevated expression levels of CD22 compared to CD27+ memory HD 
B cells. Contrary to our findings, Liossin, Suzuki and colleges found similar expression 
levels of CD22 and CD19 in SLE compared to HD B cells (85, 163). However, they did 
not differentiate between CD27+ and CD27- B cells and may have overlooked the 
reduction on CD27- SLE B cells especially since the frequency of CD27+ B cells is 
significantly enhanced in these patients (134).  
An increased expression and activation of CD22 on B cells would induce an 
enhanced activation of the CD22 associated phosphatase SHP-1 which in turn would 
lead to a reduced activation of Syk and PLC-γ2 after BCR activation as it has been 
described by Sieger et al. (111). Confirming these findings, SLE B cells displayed a 
diminished B cell response after BCR stimulation as shown by a decreased Syk and PLC-
γ2 phosphorylation, including reduced Syk phosphorylation efficiency as well as a 
diminished Ca2+ mobilization.  
In accordance with our findings, a decreased expression level of the positively 
regulating BCR co-receptor phosphatase CD45 has been reported (5, 196) which could 
lead to a diminished B cell response in patients with SLE. Additionally, a decreased p-
Syk and p-PLC-γ2 response in IgM+ and transitional B cells (197) as well as reduced 
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levels of p-BLNK were observed after IgM stimulation in patients with SLE (198). 
Furthermore, reduced BLK expression in mouse and humans due to genetic defects were 
detected leading to a diminished BCR response and enhanced frequency of autoreactive 
naïve B cells, increased expression of pro-inflammatory cytokines and enhanced 
susceptibility for autoimmune kidney disease (174, 199). In mice models carrying the 
lupus-associated Ly108.1 allele, a rather diminished BCR response with a reduced 
proliferation capacity and apoptosis have been predicted to be involved in SLE. Ly108 
(CD352) is a member of the signaling lymphocytic activation molecule (SLAM) family 
receptors and is important during B cell tolerance (175). This polymorphism led to a 
disturbed GC response, auto-Ab production, reduced Ca2+ influx after IgM stimulation and 
breakdown of tolerance (175, 200). Especially the reduced Syk activation and further the 
decreased Ca2+ influx could favor the development of self-reactive B cells since Cappione 
et al. could show a reduced Ca2+ response in autoreactive B cells (156). 
Interestingly, challenging SLE patients with standard immunizations or stimulating 
lupus B cells with polyclonal activators in vitro resulted in substantially decreased 
amounts of specific Ab and a reduced immune response (201). In this context, Sieber et 
al. could recently show a rather hyporesponsive SLE B cell phenotype indicated by a 
decreased cytokine production of IL-6 and IL-10 after TLR9 stimulation (202). These 
results appear to be contradictory to the widely accepted B cell hyperactivity based on 
the induction of various auto-Abs (203), detection of increased plasmablasts in the 
circulation of SLE patients (134, 140, 204) and spontaneous development of Ig secreting 
cells in vitro (141, 142, 205, 206). 
Contradictory and implicating a rather hyperactive B cell phenotype, a number of 
studies described an enhanced tyrosine phosphorylation and Ca2+ influx as well as an 
increased p-Syk response in CD19high (136, 137), CD27+ and CD27- SLE B cells due to 
a reduced Lyn expression (163) and lipid raft localization (164), reduced expression of 
the FcγRIIb receptor (168) or enhanced occurrence of INF-α (6). The results suggest so 
far a globally enhanced tyrosine phosphorylation in SLE B cells that includes all kinases 
and does not dissect single ones like Syk or PLC-γ2. However, this hypothesis needs to 
be proven. Therefore, a detailed analysis of BCR downstream kinases is needed to 
differentiate between a hyper- and/or hyporesponsive B cell phenotype in SLE. The 
differences concerning the Ca2+ influx could be due to the fact that PBMCs were 
stimulated with IgM only or enriched B cells were stained against CD20 prior to IgM 
stimulation whereas untouched negative selected B cells were used in this experimental 
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setup. Since CD20 is known to be involved in Ca2+ signaling as a potential Ca2+ channel 
(207, 208) using an anti-CD20 antibody to label B cells could pre-activate these cells and 
influence the Ca2+ response. The variations regarding p-Syk in CD27+ (137) and CD27-
CD38++ transitional B cells (6) could be explained by the fact that the percentage of 
responding cells (% of p-Syk) after IgG or IgM stimulation was analyzed in SLE in contrast 
to the MFI values used in this study.  
Collectively, our results provide evidence that the enhanced expression and 
activation of CD22 as well as the disturbed balance of CD19/CD22 on CD27- SLE B cells 
could potentially lead to an enhanced activation of the CD22 associated tyrosine 
phosphatase SHP-1 and thereafter to an enhanced dephosphorylation of Syk and 
diminished BCR response in SLE B cells. Interestingly, this diminished BCR response 
was observed in CD27- but also CD27+ SLE B cells even though CD27+ B cells did not 
show any abnormalities with regard to CD22. One explanation could be that CD27+ SLE 
B cells display an enhanced tyrosine phosphatase activity either directly related to SHP-
1 or to other phosphatases leading to an enhanced dephosphorylation of Syk 
independent of the expression level or activation of CD22.  
Overall the data shed new light in the role of B cell autoimmunity and put forward 
the hypothesis that an intracellular signaling dysbalance may account for autoimmune 
B cell emergence and maintenance in SLE.  
 
5.1.2 Similar BCR response of CD27- and CD27+ B cells and isotype 
independent diminished Syk activation in SLE patients 
Comparison of the BCR response between CD27+ and CD27- B cells showed in 
HD but not in SLE patients an enhanced activation capacity of CD27+ compared to CD27- 
B cells. In line with our findings, other groups described a more responsive phenotype in 
HD CD27+ memory compared to CD27- B cells indicated by a stronger formation of BCR 
oligomers, microcluster formation, higher phosphorylation kinetics and a more effective 
recruitment of kinases (75). Intrinsic differences, such as the expression of genes 
involved in activation, co-stimulation and survival as well as the decreased expression of 
the inhibitory BCR co-receptor CD22 are responsible for the more efficient BCR response 
in CD27+ B cells (77, 106). However, the phosphorylation of Syk and PLC-γ2 in CD27+ 
versus CD27- B cells in SLE patients has not been analyzed in greater detail so far. Thus, 
the same BCR response of CD27+ and CD27- SLE B cells leave room for various 
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speculations. On the one hand, the chronic immune activation observed in patients with 
SLE (1) could lead to a less responsive phenotype of CD27+ SLE B cells. On the other 
hand, aberration in co-receptor expression like CD19, CD21 or CD81 which positively 
regulate BCR signaling (113, 138, 176, 209) could result in a disturbed BCR response. 
Therefore, further analyses are needed to reveal which signaling abnormalities especially 
related to CD27+ memory SLE B cell are effective in SLE. 
Additionally, analysis of the frequency of CD27+IgM+ and CD27+IgG+ memory B cells 
in SLE and HD showed no differences, precluding, that the differences regarding the BCR 
response between SLE and HD B cells is not due to an enhanced occurrence of less 
responsive CD27+IgM+ memory B cells (76) or related to Ig-switched B cells in patients 
with SLE. This suggests that these abnormalities are rather of intrinsic nature and also 
isotype independent.  
We can conclude, that the diminished Syk response observed in SLE B cells is found 
in CD27-, CD27+IgM+ as well as CD27+IgG+ B cells with a more pronounced amplitude 
in CD27+ memory B cells and suggest an intrinsic SLE associated disturbance. 
 
5.1.3 In vivo pre-activation does not correlate with the diminished Syk 
response in SLE B cells 
A chronic in vivo immune activation can lead to an exhausted and non-responsive 
phenotype as it has been described for T cells (210, 211). Especially CD27- naïve B cells 
in SLE patients have been shown to be antigen engaged and as a consequence 
pre-activated in vivo (180). Therefore, the occurrence of CD80+ and CD86+ B cells in 
SLE patients were analyzed. Indeed, an increased frequency of CD80+ and CD86+ 
B cells in SLE patients was observed indicating an in vivo pre-activation of circulating B 
cells in these patients as it has been observed already by other groups (180, 181, 212). 
However, correlation analysis between the frequency of these cells and Syk 
phosphorylation after BCR activation showed no interrelation. This observation makes it 
unlikely, that the in vivo pre-activation is responsible for the diminished Syk response in 
SLE B cells. Confirming this data, an in vitro resting phase for 24 or 48 h and the removal 
of the pro-inflammatory environment including SLE-related enhanced INF-α  levels and 
other inflammatory cytokines/mediators (120, 149, 182-184, 213), did not restore the BCR 
response or the missing differences between CD27- and CD27+ B cells in SLE patients.  
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This data, together with the absence of a correlation between remission, disease 
activity or therapeutic interventions suggest that intrinsic isotype independent defects 
induce the disturbed BCR response observed in SLE B cells. 
 
5.1.4 Hyperactivation of the serine kinase Akt after BCR stimulation in SLE 
Analyzing the activation of the pro-survival kinase Akt after BCR stimulation 
showed increased phosphorylation kinetics in CD27+ and CD27- SLE B cells compared 
to HD. Thus, it is unlikely that there is a global diminished kinase phosphorylation capacity 
or a non-responsive phenotype in SLE B cells due to chronic antigen stimulation or 
therapeutic interventions. In line with our findings, multi-signaling analysis in lupus mice 
revealed enhanced activation of the PI3K/Akt signaling pathway (162). Additionally, Taher 
et al. showed enhanced levels of PI3K and phosphorylated Akt in B cells of SLE patients 
(214). Moreover, Wu and colleges described an enhanced expression of PTEN in CD27- 
SLE B cells leading to hyperactivation of Akt (165). Of particular note, enhanced PI3K 
and therefore Akt activation in B cells led to an increased plasma cell formation and 
reduced class-switch recombination reflecting the hyperactive B cell phenotype as 
described in the literature, including auto-Ab production, enhanced frequencies of 
circulating plasmablasts and spontaneous secretion of Ab in vitro (105, 141, 142, 205, 
206, 215).  
We conclude that the increased Akt phosphorylation in CD27- and CD27+ SLE 
B cells after BCR activation could lead to the elevated generation of 
plasmablasts/plasma cells observed in SLE (36, 135, 140). Furthermore, the enhanced 
differentiation into plasma cells due to elevated Akt activation could be responsible for 
the reduced frequency of periphery B cells in SLE patients (lymphopenia) (216).  
5.1.5 Disturbed balance of p-Syk/p-Akt in B cells of patients with SLE could 
lead to the breakdown of self-tolerance 
As discussed earlier, hypo- as well as hyperactive B cell responses were found in 
SLE dependent on the kinase analyzed. Similar results were obtained in this study. While 
the BCR response regarding Syk and PLC-γ2 was diminished, the activation of Akt was 
increased in SLE B cells. Therefore, a general prediction whether B cells of SLE patients 
suffer from an enhanced or a diminished B cell signaling response cannot be concluded 
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at this time. It appears that the interactions and the balance of BCR related signaling 
kinases are important and determine the B cell fate and development of autoreactivity. 
In line with this, comparing the phosphorylation of Syk and Akt in CD27+ and 
CD27- SLE and HD B cells revealed an imbalanced signaling network which could lead 
to the survival of autoreactive B and plasma cells as described in the literature (36, 135, 
140, 165). In fact, the current study could show that SLE patients had a reduced p-Syk/p-
Akt ratio compared to HD B cells towards the pro-survival kinase Akt which was 
correlating with the expression of CD19/CD22 in CD27+ and CD27- SLE B cells. In line 
with this, the balance between CD19/CD22 has been already associated to the 
development of autoimmune diseases (84, 115, 116). However, the direct impact on the 
signaling outcome after BCR activation in SLE versus HD B cells has not been 
investigated so far. Our data indicate that the balance between CD19 and CD22 has a 
direct effect on the activation strength and therefore ratio of p-Syk and p-Akt. This could 
be an explanation for the reduced Syk phosphorylation in CD27+ B cells even without 
showing enhanced expression or activation of CD22.  
Furthermore, Syk-/- mice fail to enter the re-circulating follicular B cell pool 
indicating that Syk plays a crucial role during positive selection processes within the GC 
reaction (59). Together with the findings, that the strength of the BCR response 
determines the B cell fate (16, 56, 217), the disturbed balance of p-Syk/p-Akt in CD27- 
as well as CD27+ SLE B cells could be responsible for the lack of sufficient central and 
peripheral selection of autoreactive B cell clones and could contribute to the emergence 
of autoimmunity and breakdown of self-tolerance. 
 
5.1.6 Enhanced tyrosine phosphatase activity leads to the dysbalanced 
activation of Syk and Akt in SLE B cells 
The activation of kinases is counterbalanced by phosphatases and is important for 
the BCR signaling strength as it has been shown for the Syk/SHP-1 (90) and Btk/SHIP-1 
equilibrium (218). In the study of Alsadeq et al. Syk and SHP-1 single deficient compared 
to double knockout mice were analyzed. Syk single knockout mice showed a 
developmental block during the early B cell phase, whereas SHP-1-/- mice had enhanced 
frequencies of B1 transitional B cells and developed an autoimmune phenotype. The 
double knockout phenotype (Syk-/- SHP-1-/-) could partially rescue the maturation of 
B cells but displayed defects in BCR but not TLR or CD40L induced signaling. Thus, the 
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equilibrium between Syk and SHP-1 might be crucial for normal B cell development and 
BCR signaling (90). A similar conclusion was made by Liu and colleges; Btk deficient 
mice showed a reduced BCR aggregation and actin remodeling compared to wild-type 
B cells leading to a reduced B cell activation. In SHP-1-/- B cells a normal BCR 
aggregation compared to wild-type B cells was observed. However, the BCR aggregation 
persists over a longer time period inducing higher levels of BCR signals. Regarding the 
opposing effect of Btk and SHIP-1 deficiency, an important balance between these two 
molecules needs to be taken into consideration (218). 
Therefore, the tyrosine as well as serine/threonine phosphatase activities were 
analyzed in SLE B cells. Interestingly, SLE B cells showed an enhanced tyrosine but 
similar serine/threonine phosphatase activity compared to HD. Furthermore, inhibition of 
the tyrosine phosphatase activity was efficient to overcome this effect and increases Syk 
phosphorylation with an impact on the p-Syk/p-Akt ratio after BCR activation in CD27+ 
and CD27- SLE B cells. 
In line with our data, enhanced levels of the tyrosine phosphate PTPN22 was 
observed in SLE T and B cells (169, 171, 219). In contrast, an increased expression of 
the serine/threonine proteinphosphatase 2A (PP2A) in SLE mouse T cells was reported 
leading to increased IL-17 production and higher occurrence of lupus nephritis (220). 
Since we analyzed the global phosphatase activity, it cannot be excluded that specific 
serine/threonine phosphatases are also reduced in SLE B cells. Additionally, a reduced 
expression level of the tyrosine phosphatase SHP-1 in SLE B cells has been reported (5). 
Due to the fact, that only the expression and not the phosphatase activity of SHP-1 was 
analyzed, the reduced SHP-1 level in SLE B cells does not preclude that SLE patients 
show a higher phosphatase activity which would lead to an enhanced dephosphorylation 
of Syk. 
Of note, it has been published that GC B cells have a diminished signaling strength 
compared to naïve and non-GC B cells which was due to an enhanced phosphatase 
activity. Interestingly, GC B cells showed hyperphosphorylation of the tyrosine 
phosphatase SHP-1 (177). For CLL B cells, a reduced activation of Syk, BLNK and 
PLC-γ2 after IgM stimulation dependent on increased phosphatase activity was observed 
(221).  
Our data lead to the conclusion that the phosphatase activity directly regulates the 
BCR response and reinforces the hypothesis that the enhanced tyrosine phosphatase 
activity observed in SLE B cells led to the shifted balance between the tyrosine kinase 
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Syk and the serine kinase Akt. However, it has to be further investigated which specific 
phosphatase or a certain group of phosphatases are involved in this process. 
 
5.1.7 Dysbalanced activation of Syk and Akt led to enhanced survival of SLE 
B cells 
Analyzing the viability of HD and SLE B cells after BCR activation revealed an 
enhanced survival of SLE B cells. Furthermore, the frequency of viable cells strongly 
correlated with the ratio of p-Syk/p-Akt in SLE B cells indicating that an enhanced 
activation of Akt led to increased survival of these cells. 
In line with our data, overexpression of the tyrosine phosphatase PTPN22 in CLL 
B cells led to the blockade of IgM induced apoptosis but positively regulated the 
anti-apoptotic kinase Akt showing the same imbalance of signaling pathways observed 
for SLE in this study (95, 170). Accordingly, it was published that enhanced activation of 
PI3K contributes to enhanced survival of memory T cells in SLE. However, contradictory 
results were published regarding the survival of lymphocytes in SLE patients. Some found 
less survival of lymphocytes or increased expression of the death receptor CD95 (Fas) 
on B cells in SLE patients (222, 223). Others found increased T cell but not B cell 
apoptosis in SLE (224) and an enhanced survival of transitional B1 cells in mice after IgM 
stimulation due to an enhanced expression of the anti-apoptotic transcription factor Bcl-2 
(225). Furthermore, the occurrence of elevated levels of BAFF (57, 89, 128), known to be 
anti-apoptotic, indicates a rather enhanced survival of SLE B cells. In line with this, the 
reduced expression of the PLC-γ2 downstream kinase PKCδ in patients with SLE led to 
a resistance against apoptosis after BCR activation (226, 227). Interestingly and in 
accordance with a reduced Lyn expression in SLE patients, a targeted deletion of Lyn 
induces increased Akt activation in antigen stimulated B cells and further downstream to 
an enhanced B cell survival (228). The differences between the reduced survival found 
in the literature and the enhanced survival observed in this study could be explained by 
the fact that mainly lymphocytes (222, 223) and the spontaneous BCR independent 
apoptosis was analyzed (224).  
Taking together, the dysbalanced activation of Syk and Akt in SLE B cells appears 
to be related to an enhanced tyrosine phosphatase activity and a disturbed CD19/CD22 
expression that could lead to the circumvention of selection checkpoints at certain stages, 
including the BM as well as in the periphery. As consequence, a preferential differentiation 
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of autoreactive B cells which would have been normally negative selected and may result 
into an increased survival of (autoreactive) plasma cells. 
 
5.1.8 Reduced expression of Syk and p-Syk in SLE B cells 
Analysis of the baseline expression of Syk and p-Syk(Y352) in untouched whole 
blood B cells from SLE patients and HD revealed a significant reduced expression of Syk 
in CD27+ and p-Syk(Y352) in CD27+ and CD27- SLE B cells. 
In contrast with this data, Iwata and colleges found increased Syk and p-Syk(Y348) 
levels in unstimulated CD19+ B cells of SLE patients (102). This variation could be 
explained by the fact, that CD19+ SLE B cells were not separated by their CD27 
expression. Furthermore, they analyzed the frequency of p-Syk positive B cells purified 
by Ficoll on tyrosine 348 (102). However, we determined the MFI values of p-Syk on the 
tyrosine phosphorylation site 352 using untouched whole blood CD27+ and CD27- 
B cells. 
Together, the enhanced tyrosine phosphatase activity, the dysbalanced 
CD19/CD22 expression and the reduced expression of Syk and p-Syk observed in this 
study could be responsible for the reduced Syk phosphorylation efficiency and overall 
reduced Syk and PLC-γ2 activation in SLE B cells. 
5.2 Enhanced frequency of a novel CD27-Syk++ B cell subset in patients 
with SLE could contribute to the maintenance of autoreactivity 
Besides detailed signaling abnormalities in SLE B cells, a new CD27- population 
expressing high levels of Syk and p-Syk was identified in these patients. Interestingly, no 
correlation between the SLEDAI, the ANA-titer or therapeutic interventions was found. 
Furthermore, the occurrence of CD27-Syk++ was stable over time. In contrast, 
abnormalities in SLE associated B cell subsets were found to correlate with the SLEDAI 
as it has been shown for CD27++ plasma cells (140) or CD27-IgD-CD95+ memory B cells 
(36). Our data indicate, that the generation of CD27-Syk++ is due to intrinsic defects as 
it has been shown for CD27+ and CD27- SLE B cells in this study or environmental 
abnormalities related to SLE which are not necessarily dependent on the activity status. 
Disturbed cytokine production and signaling aberrations have also been found in SLE 
patients (5, 98, 99, 120, 122, 126, 129, 131, 153, 198, 229, 230) and could be – at least 
partially - responsible for the generation of SLE associated B cell subset abnormalities. 
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5.2.1 B cell subset independent BCR associated intrinsic defects  
To analyze if the enhanced expression of Syk would lead to a hyperactive BCR 
response, the Syk phosphorylation kinetic in CD27-Syk+, CD27-Syk++ and CD27+ SLE 
B cells in contrast to controls was analyzed. Interestingly, even though enhanced basal 
Syk and p-Syk levels were observed in CD27-Syk++ B cells, the BCR response regarding 
p-Syk was comparable to CD27+ SLE memory B cells but still diminished compared to 
CD27+ HD memory B cells.  
This observation indicates, that CD27-Syk++ might display the same enhanced 
tyrosine phosphatase activity which downregulates the BCR response as it has been 
observed for SLE B cells. Overall, the ratio of p-Syk and p-Akt was the same in 
CD27-Syk++, CD27-Syk+ and CD27+ B cells indicating a general and rather intrinsically 
and disease activity independent abnormality of Syk regulation in SLE B cells. 
 
5.2.2 CD27-Syk++ represent a unique memory-like B cell subset  
Comparison with previously published B cell abnormalities in SLE including 
CD27+/-CD21- (138), transitional CD19+CD24++CD38++ (231), CD27+/-CD19high (136), 
CD27-IgD- (33) and CD27-IgD-CD95+ (36) B cells showed similarities but no complete 
overlap. The lack of CD38 of CD27-Syk++ B cells excludes the conformity with 
CD27-CD24++CD38++ transitional B cells. Moreover, CD21- and CD19high B cells 
comprise CD27- as well as CD27+ B cells and CD27-IgD- are precluding CD27-
Syk++IgD+ B cells. Additionally, not all analyzed B cells subset aberrant in SLE were 
Syk++. Therefore, CD27-Syk++ reflect a B cell subset predominantly enhanced in SLE 
which has not been described so far. 
Phenotypic analysis of CD27-Syk++ revealed characteristics which were distinct 
from classical naïve and memory B cells, including a higher expression of CD19 and 
CD20, increased frequency of CD21- and diverse frequencies of IgM+ only and IgM-IgD- 
class-switched B cells. However, conventional memory characteristics were consistently 
observed for these cells, such as the lack of an active ABC-B1 transporter and the lack 
of expression of CD38, imprints of SHM within V(D)J regions and class-switch as well as 
similar frequencies of CD95+ B cells. Based on these findings, the overall data are 
consistent with the conclusion that CD27-Syk++ B cells represent a unique 
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heterogeneous pre-activated B cell subset with memory characteristics, including IgM+ 
but also class-switched IgG+ and IgA+ memory B cells. 
These results are consistent with the conclusion that intracellular Syk can serve 
for B cell abnormalities in SLE patients as well as a reliable marker for the identification 
of activated B cells with memory characteristics, including certain CD27- subsets.  
 
5.2.3 Accumulation of Syk in CD27-Syk++ B cells could be due to an aberrant 
degradation of Syk 
In the current study, confocal analysis showed an elevated cytoplasmic 
accumulation of Syk in CD27-Syk++ compared to CD27+ and CD27-Syk+ B cells. Defects 
in apoptosis and proteasomal degradation have been already described in SLE, which 
would influence the cellular distribution and accumulation of Syk within the cytoplasm. 
However, since neither CD27+ nor CD27-Syk+ B cells were similarly affected by 
proteasomal abnormalities, such an explanation appears to be less likely. The increased 
tyrosine phosphatase activity observed in SLE B cells could lead to an increased 
generation of Syk in CD27-Syk++ B cells and therefore reflects a mechanism to 
compensate the reduced Syk phosphorylation response observed in these patients. 
Furthermore, aberrations of the ubiquitin-protease system tightly controlled by the 
ubiquitin ligase Cbl could lead to the dysfunction of the homeostasis and defects in Syk 
degradation (91-93). Interestingly, studies in human myeloblastic leukemia and 
monocytic cells have shown that the activation of CD38 is important to activate Cbl which 
in turn would degrade Syk (232, 233). Since CD27-Syk++ B cells have been described 
as CD38-, lacking this receptor could lead to an inefficient activation of Cbl and 
degradation of Syk. To confirm such interrelation, further studies are necessary to clearly 
link the absence of CD38 with the accumulation of Syk in the cytoplasm. 
 
5.2.4 Heterogeneity of CD27-Syk++ B cells is due to the origin by different 
developmental pathways  
Since CD38 is downregulated on class-switched CD27+ memory B cells after GC 
reaction (234) one possibility could be, that CD27-Syk++ B cells undergo multiple rounds 
of GC reactions and downregulate or shed CD38 as well as CD27. Additionally, CD38 is 
necessary for the recruitment and development during GC reactions (235) indicating that 
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CD27-Syk++ B cells lacking CD38 would undergo less stringent extrafollicular immune 
reactions, give rise to IgM+ memory B cells and fail to upregulate CD27.  
 
5.2.4.1 GC dependent development 
Speaking in favor for a GC dependent generation of CD27-Syk++ B cells, IgG+ 
and especially IgA+ showed a high frequency of SHM within V(D)J regions indicating that 
they have undergone a striking GC reaction as it has been already described for SLE 
B cells (157, 236). In fact, 5 out of 7 analyzed CD27-Syk++IgA+ clones showed a mutation 
frequency of over 9% (range 9-20%). Therefore, the lack of CD27 could be explained by 
a strong GC reaction which would lead to the loss or downregulation of CD27. In fact, an 
intense GC activity led to the generation of recently activated CD27-IgD-CD95+ memory 
B cells (36). It is noteworthy that similar observations were reported for T and B cells in 
HIV patients, elderly people and after a chronic humoral immune activation where 
class-switched memory B cells do not express the memory marker CD27 (32, 37, 210, 
211, 237). In line with this, Jung et al. found that B cells acquire CD27 at the centroblast 
stage and lose it gradually upon further differentiation (31). Since no correlation between 
the concentration of sCD27 and the frequency of CD27-Syk++ B cells has been found in 
our study, an increased shedding of surface CD27 is rather unlikely and would suggest 
that CD27-Syk++ cells downregulated CD27 or do not upregulate this marker at the first 
place. However, since the frequency of B cells within the whole blood represents only a 
minor fraction, the detection sensitivity could be insufficient to identify minor changes of 
B cell specific sCD27. 
 
5.2.4.2 Extrafollicular development 
The highly mutated CD27-Syk++IgG+ and IgA+ clones, 3 of 5 CD27-Syk++IgM+ 
clones showed no SHM within V(D)J regions and 2 clones a mutation frequency of 2 and 
8% indicating that CD27-Syk++IgM+ developed during GC or even T cell independent 
and rather extrafollicular immune reactions. In line with this, approximately 70% of CD27-
Syk++ B cells express IgM and only 30% were class-switched. It is well established, that 
an extrafollicular response would lead to the generation of low mutated IgM+ memory 
B cells which have not yet upregulate CD27 (51, 52, 238). Indeed, extrafollicular 
structures were often found in autoimmunity and may contribute to local production of 
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auto-Ab (238) as it has been observed for CD27-Syk++ B cells by the differentiation into 
(auto)-ASCs. 
Therefore, CD27-Syk++ B cells might develop during GC dependent and 
independent as well as T cell independent and dependent immune reactions and could 
develop into short-lived and less mutated IgM as well as long-lived highly mutated 
class-switched memory B and plasma cells.  
 
5.2.4.3 Progeny or progenitor of CD27+ memory B cells 
An alternative possibility is that CD27-Syk++ cells represent  not only progenitor 
of CD27+ memory B cell which have not yet acquired CD27. These cells could also 
represent progeny of CD27+ memory B cells due to the loss of CD27 after GC reaction 
and immune activation. Confirming the assumption that CD27-Syk++ B cells would 
represent progeny of CD27+ memory B cells, 70% of these cells to not express CD21. 
The lack of the complement receptor CD21 has been associated to chronic immune 
activation leading to a status called “exhaustion” (210). Together with the reduced 
generation of CD27++ B cells after 5 days in vitro culture compared to conventional 
CD27+ memory B cells it can be assumed that a persistent immune activation could lead 
to the emergence of CD27-Syk++ B cells lacking CD21. Interestingly, INF-α has been 
found to be a ligand for CD21 (209). Therefore, enhanced levels of INF-α in patients with 
SLE (149, 213) would continuously stimulate SLE B cells via CD21 and other 
conventional receptor pathways leading to the downregulation of this receptor on CD27-
Syk++ B cells. In line with this, analyzing the phosphorylation of Akt and Syk after BCR 
engagement showed memory-like phosphorylation kinetics similar to CD27+ B cells even 
though CD27-Syk++ B cells expressed significantly more Syk. This data indicate, that 
CD27-Syk++ B cells show a reduced Syk phosphorylation efficiency which would speak 
in favor for an “exhausted” phenotype. However, the balance between p-Syk and p-Akt 
was similar to the balance observed for CD27+ and CD27-Syk++ B cells and is 
contradictory to this assumption. Additionally, no correlation between age and the 
frequency of CD27-Syk++ B cell in HD was observed which would argues against an 
“exhausted” or better post-activated phenotype. 
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5.2.5 Increased basal expression of Syk and p-Syk, the lack of CD27 and 
imbalanced p-Syk/p-Akt ratio could lead to an enhanced survival of 
CD27-Syk++ B cells 
CD27-Syk++ B cells display an enhanced accumulation in the cytoplasm and basal 
phosphorylation of Syk reflecting an increased tonic signaling in these cells. The tonic 
signaling of B cells is essential during B cell development, selection processes and 
survival (17, 78). Therefore, CD27-Syk++ B cells could display increased survival 
capacity and therefore playing a key role in the maintenance of autoreactivity in SLE. 
Accordingly, co-ligation of CD27 at the same time with the BCR induces CD27- mediated 
apoptosis (28) and could implicate together with the enhanced activation of the pro-
survival kinase Akt, that Syk++ cells lacking CD27 represent a B cell subset increased in 
SLE which is more resistant against cell death. In line with this, defects in apoptosis are 
widely known in SLE (222-224) and appear to be consistent with this hypothesis. 
 
5.2.6 CD27-Syk++ could represent a tissue resident B cell subset 
Of importance, a current report described that CD27-IgG+FcRH4+ memory B cells 
reside within tonsil and possibly other secondary lymphoid organs (39) suggesting that 
the appearance of CD27-Syk++ B cells in the circulation of SLE patients may reflect a 
GC spillover of this population into the periphery due to an increased GC activity and 
memory B cell induction or processing. Alternatively, homing or entrance of this 
population within secondary lymphoid organs may be altered in SLE leading to their 
persistence in the blood. Therefore, further analysis regarding the expression of homing 
receptors like integrin ß7 (239), CXCR5 (240, 241) or CXCR4 (241) on CD27-Syk++ 
B cells are needed to further delineate the origin of these cells. Further characterization 
of the underlying mechanisms involved may direct or redirect therapeutic interventions. 
 
5.2.7 Microenvironmental conditions induce the generation of CD27-Syk++ 
B cells 
However, not only intrinsic B cell abnormalities may require considerations, since 
dysfunction of other immune cells, like T cells, DCs and macrophages have been 
associated with SLE (4, 99, 153, 242-244) and might have an impact on secondary B cell 
abnormalities. Especially disturbances in cytokine expression by these cells were noted 
(120, 126, 131, 229, 245) and could influence the development and activation of aberrant 
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B cell populations in SLE patients. Accordingly, in vitro analysis showed that the 
dysregulated cytokine environment in SLE patients could play an essential role during the 
development and maintenance of CD27-Syk++ B cells. In vitro stimulation with the 
anti-inflammatory cytokines INF-γ, TNF-α as well as the stimulation with LPS but not INF-
α, IL-6, IL-21 or BAFF led to an increased frequency of Syk++ B cells. Confirming these 
observations, studies have shown, that TNF-α regulates the expression and activation of 
Syk (246). Interestingly, immunization with the tetanus toxoid did not induce the 
generation of CD27-Syk++ cells indicating a cytokine involvement which is rather Th1 
(e.g. INF-γ and IL4) dependent (41). It is not clear if the vaccination with tetanus toxoid 
induces exclusively or predominantly a Th2 response (247-249). Therefore, an exact 
conclusion if the development of CD27-Syk++ B cells is Th1 or Th2 (e.g. INF-α, IL-6) 
driven cannot be drawn at this time. Interestingly, Akahoshi et al revealed a disturbed 
balance of Th1/Th2 towards Th1 cytokines in SLE patients (250). Additionally, increased 
levels of serum INF-γ in human SLE patients (251) as well as in MRL-Faslpr mice have 
been reported (252). Of note, analysis of HD with different inflammatory diseases 
revealed that healthy controls with dental root inflammation can also carry an enhanced 
frequency of CD27-Syk++ B cells. If this dental roots infection induces a Th1 response 
rather than a Th2 response has to be further investigated. However, this findings should 
not be taken as evidence that Th2 cytokines do not influence or regulate the occurrence 
of CD27-Syk++ B cells in SLE patients.  
No correlation between CD80+ and CD86+ B cells with the frequency of 
CD27-Syk++ B cells in SLE was found. Therefore, a general immune activation seems to 
be unlikely related with the generation of CD27-Syk++ B cells. Therefore, a combination 
of intrinsic abnormalities as well as environmental factors including a disturbed cytokine 
milieu are probably involved or responsible for the emergence of CD27-Syk++ B cells. 
Together, CD27-Syk++ B cells reflect an activated B cell subset with memory 
characteristics which can be generated by different maturation pathways and could reflect 
progenitor as well as progeny of CD27+ memory cells in patients with SLE. Furthermore, 
the disturbed cytokine environment and the lack of CD38 expression in SLE patients 
could favor the accumulation of Syk in these cells, which would potentially lead to an 
enhanced tonic BCR signaling and bypass of conventional differentiation pathways as 
well as survival and emergence of autoreactive B and plasma cells. Alternatively, the 
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increased Syk expression could reflect a compensation mechanism for accelerated 
phosphatase activity observed in this study for SLE B cells.  
However, further studies are needed to reveal the nature of the 
emergence/induction and maintenance of these cells and how they are involved in lupus 
autoimmunity. 
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5.3 Conclusion and outlook 
The initial question of this thesis was to analyze how B cell tolerance in SLE patients 
is disturbed and how autoreactive B cell clones survive and maintain in the repertoire of 
this disease. To which extent abnormalities of B cell subsets, intracellular BCR signaling 
pathways and BCR complex organization are involved in this process could be partially 
answered in this study. 
The current thesis provide evidence that SLE B cells display a dysbalanced BCR 
signaling (p-Syk/p-Akt) and abnormalities in the BCR complex organization (CD19/CD22) 
together with the occurrence of CD27-Syk++ B cells with BCR signaling comparable to 
conventional CD27+ lupus memory B cells. These abnormalities appear to be consistent 
with an enhanced capacity to differentiate into (auto)-ASC in SLE patients and could 
represent a possible mechanism to circumvent negative selection checkpoints in the BM 
and the periphery since CD27- and CD27+ SLE B cells are equally affected. 
Simultaneously, the data suggest that these abnormalities can lead to an enhanced 
survival and therefore persistence of (auto)-reactive B and plasma cells.  
This assumption can be solidified by the observation that SLE B cells have a reduced 
Syk but enhanced Akt response after BCR activation due to an enhanced tyrosine 
phosphatase activity, reduced basal Syk and p-Syk expression and dysbalance of the 
BCR co-receptor complex CD19/CD22. This altered balance could lead to the activation 
of a different transcription factor- and gene expression profile which would shift the B cell 
fate decision to an increased survival of autoreactive B cell clones and potential elevated 
plasma cell formation (
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Figure 5-1). 
Figure 5-1: Proposed scheme of the dysregulated BCR signaling pathways in patients with SLE compared to 
HD. Schematic diagrams show the BCR signaling in HD (A) versus SLE patients (B). (Auto)-antigen binding to the BCR 
induces the activation of Lyn which leads to an activation of several signaling pathways including Syk and CD19. On 
the one hand SLE B cells showed an enhanced CD22 phosphorylation that could lead to a reduced Syk activation as 
well as a reduced Ca2+ influx partially dependent on the balance between CD19 and CD22 expression as well as a 
global enhanced tyrosine phosphatase activity. On the other hand an enhanced activation of the PI3K/Akt signaling 
pathway in these patients was observed. This imbalance of the signaling strength of different BCR related signaling 
pathways could result in a disturbed relation between BCR dependent negative selection processes and impact of 
apoptosis that may permit a preferential survival of (auto)-reactive B and plasma cells under the conditions of SLE. 
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So far, a myriad on molecular aberrations in B cells of SLE patients including 
genetic defects, signaling abnormalities or aberrant expression profiles of receptors have 
been described (102, 152, 163, 167-169, 171, 175, 196, 199, 225, 226) but the balance 
between different signaling pathways have not been investigated in greater detail. In this 
regard, the observation of an imbalanced activation of Syk and Akt after BCR stimulation 
in SLE B cells reflects a hitherto unknown abnormality and could also be a novel 
therapeutic target. Therefore, specific inhibitors against PI3K or Akt have to be 
investigated regarding their ability to restore the balance between Syk and Akt. Also B cell 
specific Ab against BCR co-receptors, like the monoclonal Ab epratuzumab targeting 
CD22, need to be tested concerning its capacity to regulate this equilibrium. A modulatory 
effect of epratuzumab on Syk and PLC-γ2 is already known (111) but to which extent the 
PI3K/Akt pathway and therefore cell survival is influenced has not been investigated yet. 
The role of Lyn and its phosphorylation status after BCR activation in SLE versus HD 
B cells are needed to complete the study regarding BCR downstream signaling 
disturbances in this disease. Further, it has to be analyzed in more detail which 
phosphatases (e.g. SHP-1) or other signaling pathways (e.g. TLR9, CD40, BAFF, CD19) 
and BCR co-receptors (CD21, CD81) are involved.  
Moreover, the unique CD27-Syk++ B cells enhanced in SLE represent a 
heterogeneous memory-like B cell subset containing activated IgM+, IgM+IgD+ and 
IgM-IgD- class-switched B cells. CD27-Syk++ B cells are probably generated through 
different maturation pathways and containing B cells of different developmental stages 
including progenitor as well as progeny of classical CD27+ memory B cells. CD27-Syk++ 
B cells could represent a tissue resident memory B cell subset which re-circulates in 
higher frequencies in the periphery of patients with SLE. Therefore it would be interesting 
to investigate the expression of surface markers like CD40, CD80 or MHC class II which 
are important during B-T cell interaction and antigen presentation as well as the 
expression of the homing receptors, CXCR4, CXCR5 or adhesion molecules, such as 
integrin beta 7. Other lymphoid organs like the spleen, tonsil or the BM needs to be 
analyzed regarding their occurrence of CD27-Syk++ B cells to understand more in detail 
the origin of these cells. However, since these B cells have been only found in humans 
so far, analysis regarding their tissue localization in human SLE patients is challenging.  
In conclusion, the current study provides evidence that regulating the balance of 
BCR related signaling pathways might be a promising therapeutic target to modulate the 
development and persistent of autoreactive B cells in SLE. Additionally, the use of 
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intracellular markers, such as Syk, permits a more precise delineation of activated CD27- 
memory B cell subsets to understand the causes of memory in autoimmunity. 
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